var title_f8_23_8560="Eval lymphadenopathy child";
var content_f8_23_8560=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F52688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F52688&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 581px\">",
"   <div class=\"ttl\">",
"    Evaluation of localized adenopathy in pediatric patients",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 561px; height: 580px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Malogolowkin MH, Steuber CP. Clinical Assessment and Differential Diagnosis of the Child with Suspected Cancer. In: Principles and Practice of Pediatric Oncology, 5th ed, Pizzo PA, Poplack DG (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2005.&nbsp;Copyright &copy; 2005 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8560=[""].join("\n");
var outline_f8_23_8560=null;
var title_f8_23_8561="Eye anatomy";
var content_f8_23_8561=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RHEUM%2F62615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RHEUM%2F62615&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 555px\">",
"   <div class=\"ttl\">",
"    Anatomy of the episclera and sclera",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 535px; height: 312px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the location of the cornea, conjunctiva, episclera, and sclera.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8561=[""].join("\n");
var outline_f8_23_8561=null;
var title_f8_23_8562="Sequestration CXR I";
var content_f8_23_8562=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F55015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F55015&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intralobar sequestration left lower lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 315px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph demonstrates a left lower lobe mass.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8562=[""].join("\n");
var outline_f8_23_8562=null;
var title_f8_23_8563="Pivot shift test";
var content_f8_23_8563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pivot shift test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 374px; height: 481px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pivot shift test assesses the presence of an anterior cruciate ligament injury.",
"    <br/>",
"    (A) The 45 degrees of the flexed knee is reduced with external tibial rotation.",
"    <br/>",
"    (B) Knee is allowed to extend with strong valgus pressure. A positive test is a definite \"thud\" as the tibia becomes subluxated and internally rotates between 20 and 10 degrees.",
"    <br/>",
"    (C) Complete extension reduces the knee as the posterior capsule tightens.This test may be more sensitive than the anterior drawer or Lachman test but is difficult to perform in the acutely injured athlete because of guarding and apprehension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Reid DC. Sports Injury Assessment and Rehabilitation. Churchill Livingstone, New York 1992. p.471. Copyright &copy; 1992 Elsevier Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8563=[""].join("\n");
var outline_f8_23_8563=null;
var title_f8_23_8564="Chlorzoxazone: Patient drug information";
var content_f8_23_8564=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Chlorzoxazone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40532?source=see_link\">",
"     see \"Chlorzoxazone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/19/4404?source=see_link\">",
"     see \"Chlorzoxazone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F150751\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Lorzone&trade;;",
"     </li>",
"     <li>",
"      Parafon Forte&reg; DSC",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030524\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691274",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to calm muscles.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030523\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701791",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to chlorzoxazone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030528\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696611",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, mixed drinks, or other drugs and natural products that slow your actions.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698060",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling lightheaded, sleepy, having blurred eyesight, or a change in thinking clearly. Avoid driving and doing other tasks or actions that call for you to be alert or have clear eyesight until you see how this drug affects you.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling dizzy. Rise slowly over a few minutes when sitting or lying down. Be careful climbing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030531\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030526\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695723",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tablet can be crushed and mixed with food or liquid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696051",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug is used with rest, PT (physical therapy), pain drugs, and other therapies.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030527\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030532\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030533\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12091 Version 35.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8564=[""].join("\n");
var outline_f8_23_8564=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F150751\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030524\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030523\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030528\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030529\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030531\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030526\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030527\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030532\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030533\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?39/37/40532?source=related_link\">",
"      Chlorzoxazone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/19/4404?source=related_link\">",
"      Chlorzoxazone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8565="Diethylpropion: Drug information";
var content_f8_23_8565=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Diethylpropion: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?37/16/38148?source=see_link\">",
"    see \"Diethylpropion: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F159808\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Tenuate&reg;;",
"     </li>",
"     <li>",
"      Tenuate&reg; Dospan&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F159836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Anorexiant;",
"     </li>",
"     <li>",
"      Central Nervous System Stimulant;",
"     </li>",
"     <li>",
"      Sympathomimetic",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F159812\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Obesity (short-term adjunct): Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet: 25 mg 3 times/day before meals or food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release: 75 mg at midmorning",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F4092484\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &gt;16 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F159813\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15796058\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling; use with caution.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15796059\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F159794\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as hydrochloride: 25 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, controlled release, oral, as hydrochloride: 75 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F159778\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block csi drugH1Div\" id=\"F159838\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Controlled Substance",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C-IV",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F803124\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dose should not be administered in evening or at bedtime.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: Administer 1 hour before meals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, controlled release: Do not crush tablet; administer at midmorning.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F159795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term (few weeks) adjunct in the management of exogenous obesity",
"    </p>",
"    <p style=\"text-indent:0em;margin-top:2em;\">",
"     Pharmacotherapy for weight loss is recommended only for obese patients with a body mass index &ge;30 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , or &ge;27 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     in the presence of other risk factors such as hypertension, diabetes, and/or dyslipidemia or a high waist circumference; therapy should be used in conjunction with a comprehensive weight management program.",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F159834\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Arrhythmia, ECG changes, hypertension, palpitation, precordial pain, pulmonary hypertension, tachycardia, valvulopathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Anxiety, CVA, depression, dizziness, drowsiness, dysphoria, euphoria, headache, insomnia, jitteriness, malaise, nervousness, overstimulation, psychosis, restlessness, seizure",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Alopecia, ecchymosis, erythema, rash, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Libido changes, gynecomastia, menstrual irregularities",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal discomfort, constipation, diarrhea, nausea, unpleasant taste, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Dysuria, impotence, polyuria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Bone marrow depression, agranulocytosis, leukopenia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dyskinesia, muscle pain, tremor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, mydriasis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Dyspnea",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis, tachyphylaxis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F159799\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity or idiosyncrasy to diethylpropion or other sympathomimetic amines; advanced arteriosclerosis, severe hypertension; pulmonary hypertension; hyperthyroidism; glaucoma; agitated states, history of drug abuse; during or within 14 days following MAO inhibitor therapy, concurrent use with other anorectic agents",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F159782\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS effects: Amphetamines may impair the ability to engage in potentially hazardous activities.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Primary pulmonary hypertension (PPH): A rare, frequently fatal disease of the lungs, PPH has been found to occur with increased frequency in patients receiving some anorexigens.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Valvular heart disease: The use of some anorexigens, including diethylpropion, has been associated with the development of valvular heart disease. Avoid stimulants in patients with known serious structural cardiac abnormalities, cardiomyopathy, serious heart rhythm abnormalities, or other serious cardiac problems that could increase the risk of sudden death that these conditions alone carry.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Diabetes: Use with caution in patients with diabetes mellitus; antidiabetic agent requirements may be altered with anorexigens and concomitant dietary restrictions.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hypertension: Use with caution in patients with hypertension and other cardiovascular conditions that might be exacerbated by increases in blood pressure or heart rate.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorders; seizures have been reported with use.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Tourette's syndrome: Use with caution in patients with Tourette's syndrome; stimulants may unmask tics.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Anorexigens: Safety and efficacy have not been established for use with other weight loss medications, including over-the-counter or herbal products. Not recommended for use in patients who have used other anorectic agents within the past year.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Use caution in this age group due to the risk for causing dependence, hypertension, angina, and myocardial infarction.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Pediatrics: Safety and efficacy have not been established in children &le;16 years of age.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Abuse potential: Diethylpropion is pharmacologically related to the amphetamines, which have a high abuse potential; prolonged use may lead to dependency. Prescriptions should be written for the smallest quantity consistent with good patient care to minimize possibility of overdose.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull;	Discontinuation of therapy: Discontinue if satisfactory weight loss has not occurred within the first 4 weeks of treatment, or if tolerance develops.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299190\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F159787\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Diethylpropion.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F159805\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F159788\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4092279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Teratogenic effects have not been observed in animal studies. Crosses the human placenta; spontaneous reports of congenital malformations have been reported, but an association with diethylpropion has not been established. Withdrawal symptoms may occur in the neonate following maternal use of diethylpropion.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F159816\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk/use caution",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F4092286\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Most effective when combined with a low calorie diet and behavior modification counseling.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F159800\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 24-hour",
"     </b>",
"     (Diethylpropion HCl ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     75 mg (100): $130.17",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Diethylpropion HCl Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     25 mg (100): $51.85",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F159791\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Baseline cardiac evaluation (for preexisting valvular heart disease, pulmonary hypertension); echocardiogram during therapy; weight, waist circumference, blood pressure; renal function in elderly patients",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F4092281\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Adult classification of weight by BMI (kg/m",
"     <sup>",
"      2",
"     </sup>",
"     ):",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Underweight: &lt;18.5",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Normal: 18.5-24.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Overweight: 25-29.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class I: 30-34.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Obese, class II: 35-39.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Extreme obesity (class III): &ge;40",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Waist circumference: In adults with a BMI of 25-34.9 kg/m",
"     <sup>",
"      2",
"     </sup>",
"     , high-risk waist circumference is defined as:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Men &gt;102 cm (&gt;40 in)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Women &gt;88 cm (&gt;35 in)",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F159801\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Anorex (FR);",
"     </li>",
"     <li>",
"      Apisate (IE);",
"     </li>",
"     <li>",
"      Atractil (LU);",
"     </li>",
"     <li>",
"      Bonumin (FI);",
"     </li>",
"     <li>",
"      Delgamer (ES);",
"     </li>",
"     <li>",
"      Dietil Retard (BE);",
"     </li>",
"     <li>",
"      Dietil-retard (LU);",
"     </li>",
"     <li>",
"      Dipion (KP);",
"     </li>",
"     <li>",
"      Dobesin (DK);",
"     </li>",
"     <li>",
"      Linea (GR, IT);",
"     </li>",
"     <li>",
"      Lipomin (ES);",
"     </li>",
"     <li>",
"      Moderatan (FR);",
"     </li>",
"     <li>",
"      Neobes (CR, DO, GT, HN, PA, SV);",
"     </li>",
"     <li>",
"      Nulobes (AR);",
"     </li>",
"     <li>",
"      Prefamone (CH, FR, LU);",
"     </li>",
"     <li>",
"      Prefamone Chronule (BE);",
"     </li>",
"     <li>",
"      Prothin (HK);",
"     </li>",
"     <li>",
"      Regenon (AT, BE, DK, LU);",
"     </li>",
"     <li>",
"      Regenon Retard (DE);",
"     </li>",
"     <li>",
"      Sacin (CN);",
"     </li>",
"     <li>",
"      Tenuate (AU, FR, KP);",
"     </li>",
"     <li>",
"      Tenuate Dospan (AE, BH, CY, EG, IL, IQ, IR, JO, KW, LB, LY, NZ, OM, PE, QA, SA, SY, YE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F159781\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diethylpropion s a sympathomimetic amine with pharmacologic properties similar to the amphetamines. It is also structurally similar to bupropion. The mechanism of action in reducing appetite appears to be secondary to CNS effects, including stimulation of the hypothalamus to release norepinephrine",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F159798\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Forms active metabolites via N-dealkylation and reduction",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: Aminoketone metabolites: &sim;4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Abenhaim L, Moride Y, Brenot F, et al, &ldquo;Appetite-Suppressant Drugs and the Risk of Primary Pulmonary Hypertension. International Primary Pulmonary Hypertension Study Group,&rdquo;",
"      <i>",
"       N Engl J Med",
"      </i>",
"      , 1996, 335(9):609-16.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/23/8565/abstract-text/8692238/pubmed\" id=\"8692238\" target=\"_blank\">",
"        8692238",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: Executive Summary. Expert Panel on the Identification, Evaluation, and Treatment of Overweight in Adults,&rdquo;",
"      <i>",
"       Am J Clin Nutr",
"      </i>",
"      , 1998, 68(4):899-917.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/23/8565/abstract-text/9771869/pubmed\" id=\"9771869\" target=\"_blank\">",
"        9771869",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Mokhlesi B, Leikin JB, Murray P, et al, &ldquo;Adult Toxicology in Critical Care: Part II: Specific Poisonings,&rdquo;",
"      <i>",
"       Chest",
"      </i>",
"      , 2003, 123(3):897-922.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/23/8565/abstract-text/12628894/pubmed\" id=\"12628894\" target=\"_blank\">",
"        12628894",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Snow V, Barry P, Fitterman N, et al, &ldquo;Pharmacologic and Surgical Management of Obesity in Primary Care: A Clinical Practice Guideline from the American College of Physicians,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2005, 142(7):525-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/23/8565/abstract-text/15809464/pubmed\" id=\"15809464\" target=\"_blank\">",
"        15809464",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;U.S. Preventative Services Task Force. Screening for Obesity in Adults: Recommendations and Rationale,&rdquo;",
"      <i>",
"       Ann Intern Med",
"      </i>",
"      , 2003, 139(11):933-49",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?8/23/8565/abstract-text/14644896/pubmed\" id=\"14644896\" target=\"_blank\">",
"        14644896",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9354 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-122.72.76.133-52D7E7C181-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8565=[""].join("\n");
var outline_f8_23_8565=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159808\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159836\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159812\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092484\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159813\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796058\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15796059\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159794\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159778\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159838\">",
"      Controlled Substance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F803124\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159795\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159834\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159799\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159782\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299190\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159787\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159805\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159788\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092279\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159816\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092286\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159800\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159791\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4092281\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159801\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159781\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F159798\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9354\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9354|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?37/16/38148?source=related_link\">",
"      Diethylpropion: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8566="Myxedema coma";
var content_f8_23_8566=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Myxedema coma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8566/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8566/contributors\">",
"     Douglas S Ross, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8566/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8566/contributors\">",
"     David S Cooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8566/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8566/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/23/8566/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxedema coma is defined as severe hypothyroidism leading to decreased mental status, hypothermia, and other symptoms related to slowing of function in multiple organs. It is a medical emergency with a high mortality rate. Fortunately, it is now a rare presentation of hypothyroidism, likely due to earlier diagnosis as a result of the widespread availability of thyrotropin (TSH) assays.",
"   </p>",
"   <p>",
"    Early recognition and therapy of myxedema coma are essential. Treatment should be begun on the basis of clinical suspicion without waiting for laboratory results. Important clues to the possible presence of myxedema coma in a poorly responsive patient are the presence of a thyroidectomy scar or a history of I-131 therapy or hypothyroidism. A history obtained from family members often reveals antecedent symptoms of thyroid dysfunction followed by progressive lethargy, stupor, and coma.",
"   </p>",
"   <p>",
"    The clinical presentation, diagnosis, and treatment of myxedema coma will be reviewed here. The diagnosis and treatment of hypothyroidism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=see_link\">",
"     \"Clinical manifestations of hypothyroidism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxedema coma can occur as the culmination of severe, long-standing hypothyroidism or be precipitated by an acute event such as infection, myocardial infarction, cold exposure, or the administration of sedative drugs, especially opioids.",
"   </p>",
"   <p>",
"    The demographics of patients who develop myxedema coma are those of hypothyroidism in general, with older women being most often affected. Myxedema coma can result from any of the usual causes of hypothyroidism, particularly chronic autoimmune thyroiditis, because of its often insidious course compared with post-surgical or -ablative hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .) It can occur in patients with secondary hypothyroidism, and there are case reports of its occurrence in patients with lithium- or amiodarone-induced hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The function of virtually every organ system and the activity of many metabolic pathways are slowed in severe hypothyroidism. The hallmarks of myxedema coma are decreased mental status and hypothermia, but hypotension, bradycardia, hyponatremia, hypoglycemia, and hypoventilation are often present as well. Puffiness of the hands and face, a thickened nose, swollen lips, and an enlarged tongue may occur secondary to nonpitting edema with abnormal deposits of mucin in the skin and other tissues (myxedema).",
"   </p>",
"   <p>",
"    The possibility of a precipitating infection or other acute illness should always be considered; it is important to appreciate, however, that the patient may not have a febrile response to infection (",
"    <a class=\"graphic graphic_table graphicRef54836 \" href=\"UTD.htm?0/9/153\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neurologic manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the name, myxedema coma, patients frequently do not present in coma, but do manifest lesser degrees of altered consciousness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/4\">",
"     4",
"    </a>",
"    ]. This usually takes the form of confusion with lethargy and obtundation. Alternatively, a more activated presentation may occur with prominent psychotic features, so-called myxedema madness [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/5\">",
"     5",
"    </a>",
"    ]. Untreated, patients will progress to coma.",
"   </p>",
"   <p>",
"    Focal or generalized seizures may occur, sometimes due to concomitant hyponatremia, and status epilepticus has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. In the absence of seizures, electroencephalogram (EEG) findings are nonspecific with slowing and decreased amplitude, rarely with triphasic waves [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/8\">",
"     8",
"    </a>",
"    ]. When cerebrospinal fluid is obtained (usually to rule out infection), modest elevation of protein levels (&lt;100",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    may be seen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Hyponatremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is present in approximately one-half of patients with myxedema coma. It can be severe and may contribute to the decrease in mental status. Most, but not all, patients have an impairment in free water excretion due to inappropriate excess vasopressin secretion or impaired renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/9\">",
"     9",
"    </a>",
"    ]. The low serum sodium concentration is reversible after treatment of the hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H88313973#H88313973\">",
"     \"Causes of hyponatremia\", section on 'Hypothyroidism'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Hypothermia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypothermia is present in many patients with myxedema coma. It is due to the decrease in thermogenesis that accompanies the decrease in metabolism.",
"   </p>",
"   <p>",
"    The low body temperature may not be recognized initially because many automatic thermometers do not register frankly hypothermic body temperatures. If a low temperature is found, the thermometer itself should be checked to avoid an incorrect measurement. The severity of the hypothermia is related to mortality in severe hypothyroidism; the lower the temperature, the more likely a patient is to die.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Hypoventilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoventilation with respiratory acidosis results primarily from central depression of ventilatory drive with decreased responsiveness to hypoxia and hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/10\">",
"     10",
"    </a>",
"    ]. Other contributing factors include respiratory muscle weakness, mechanical obstruction by a large tongue, and sleep apnea. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=see_link\">",
"     \"Clinical manifestations and diagnosis of obesity hypoventilation syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some patients require mechanical ventilation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=see_link\">",
"     \"Control of ventilation\"",
"    </a>",
"    .) Airway management may be complicated by myxedematous infiltration of the pharynx [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/11\">",
"     11",
"    </a>",
"    ]. Recovery from ventilatory depression may take as long as three to six months after treatment of hypothyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Hypoglycemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypoglycemia may be caused by hypothyroidism alone or, more often, by concurrent adrenal insufficiency due to autoimmune adrenal disease or hypothalamic-pituitary disease. The presumed mechanism is decreased gluconeogenesis, but starvation and infection can contribute. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=see_link\">",
"     \"Clinical manifestations of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Cardiovascular abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thyroid hormone plays a role in blood pressure homeostasis. Hypothyroid patients have diastolic hypertension, even though cardiac output is reduced, and a narrowed pulse pressure. Severe hypothyroidism is associated with bradycardia, decreased myocardial contractility, a low cardiac output, and sometimes hypotension [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/12\">",
"     12",
"    </a>",
"    ]. Overt congestive heart failure is quite rare in the absence of preexisting cardiac disease. This is probably due to the lower tissue demands for oxygenation and cardiac output in hypothyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=see_link\">",
"     \"Cardiovascular effects of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pericardial effusion may be present. Its clinical manifestations include diminished heart sounds, low voltage on electrocardiogram, and a large cardiac silhouette on chest x-ray; however, ventricular function is rarely compromised. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=see_link\">",
"     \"Constrictive pericarditis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the cardiac abnormalities are reversible with thyroid hormone therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of myxedema coma is initially based upon the history, physical examination, and exclusion of other causes of coma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=see_link\">",
"     \"Stupor and coma in adults\"",
"    </a>",
"    .) The diagnosis should be considered in any patient with coma or depressed mental status who also has hypothermia, hyponatremia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypercapnia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/4\">",
"     4",
"    </a>",
"    ]. Additional clues to the possible presence of myxedema coma in a poorly responsive patient are the presence of a thyroidectomy scar or a history of I-131 therapy or hypothyroidism.",
"   </p>",
"   <p>",
"    Before therapy with thyroid hormone and a glucocorticoid is given, blood should be drawn for measurements of serum thyrotropin (TSH), free T4, and cortisol. Ideally, cortisol should be measured before and after ACTH administration because of the possibility of associated adrenal insufficiency or hypopituitarism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Most patients with myxedema coma have primary hypothyroidism, with high serum TSH and low free T4 values. On the other hand, a normal or low serum TSH value in a patient with a low free T4 value indicates that the hypothyroidism is secondary to hypothalamic or pituitary dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=see_link\">",
"     \"Disorders that cause hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although in many clinical settings, the results of serum TSH measurements are rapidly available, in circumstances where laboratory confirmation of hypothyroidism is delayed, treatment should be instituted in patients with presumed myxedema coma without waiting for laboratory confirmation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Myxedema coma is an endocrine emergency and should be treated aggressively. The mortality rate remains high at 30 to 40 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], with elderly patients and those with cardiac complications, reduced consciousness, persistent hypothermia, and sepsis being at greatest risk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/15,17\">",
"     15,17",
"    </a>",
"    ]. Treatment consists of thyroid hormone, supportive measures, and appropriate management of coexisting problems such as infection (",
"    <a class=\"graphic graphic_table graphicRef61507 \" href=\"UTD.htm?14/0/14347\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition, until the possibility of coexisting adrenal insufficiency has been excluded, the patient must be treated with glucocorticoids in stress doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    given intravenously, 100 mg every eight hours). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thyroid hormone",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal mode of thyroid hormone therapy in patients with myxedema coma is controversial, largely because the condition is so rare that there are no clinical trials comparing the efficacy of different treatment regimens. While increasing serum thyroid hormone concentrations rapidly carries some risk of precipitating myocardial infarction or atrial arrhythmias, this risk must be accepted because of the high mortality of untreated myxedema coma.",
"   </p>",
"   <p>",
"    In one randomized trial of 11 patients, those who received a 500 mcg loading dose of T4, followed by 100 mcg daily, had a lower mortality than those treated with 100 mcg daily without a loading dose (one of six died compared with three of five who did not receive the loading dose); however, the difference did not reach statistical significance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is disagreement about the preferred thyroid hormone regimen, but both very high (T4 &gt;500 mcg, T3 &ge;75 mcg) and very low doses seem less effective than intermediate doses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/17\">",
"     17",
"    </a>",
"    ]. Whether patients with myxedema coma should be treated with T4, T3, or both, is controversial [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/4\">",
"     4",
"    </a>",
"    ]. Some experts favor administration of T3, while others favor T4, preferring that T3 production be governed by the activity of 5'-deiodinase in the patient, while others prefer a combination of T4 and T3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/4,19-22\">",
"     4,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    We prefer to give both hormones because the biologic activity of triiodothyronine (T3) is greater, and its onset of action is more rapid, than T4. An additional consideration is that the conversion of T4 to T3 is impaired due to both hypothyroidism and any concurrent nonthyroidal illness. The decrease in T4 to T3 conversion may be a protective adaptation in the face of severe illness. Therefore, proper dosing of T3 is important. High serum T3 concentrations during treatment have been correlated with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    T4 should be given intravenously, when available, because gastrointestinal absorption may be impaired [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8566/abstract/20\">",
"     20",
"    </a>",
"    ]. We typically administer T4 in a loading dose of 200 to 400 mcg followed by a daily dose of 1.6",
"    <span class=\"nowrap\">",
"     mcg/kg",
"    </span>",
"    thereafter, initially intravenously and, when feasible, orally (",
"    <a class=\"graphic graphic_table graphicRef61507 \" href=\"UTD.htm?14/0/14347\">",
"     table 2",
"    </a>",
"    ). Given the 10 L volume of distribution for T4, this will raise the total serum T4 level by 2 to 4",
"    <span class=\"nowrap\">",
"     mcg/dL.",
"    </span>",
"    The lower end of the dosing range is preferred in lighter and older patients and those at risk for cardiac complications (myocardial infarction, arrhythmia). T3 may be given simultaneously in a dose of 5 to 20 mcg, followed by 2.5 to 10 mcg every eight hours, depending upon the patient's age and coexistent cardiac risk factors. T3 is continued until there is clinical improvement and the patient is stable. Chronic therapy is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=see_link\">",
"     \"Treatment of hypothyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with secondary hypothyroidism may have associated hypopituitarism and secondary adrenal insufficiency. In addition, patients with autoimmune-mediated primary hypothyroidism may have concomitant primary adrenal insufficiency. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=see_link\">",
"     \"Diagnosis of hypopituitarism\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=see_link&amp;anchor=H2#H2\">",
"     \"Causes of primary adrenal insufficiency (Addison's disease)\", section on 'Autoimmune adrenalitis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Until the possibility of coexisting adrenal insufficiency has been excluded, the patient must be treated with glucocorticoids in stress doses (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    given intravenously, 100 mg every eight hours). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=see_link\">",
"     \"Treatment of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Supportive measures",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supportive measures are extremely important in the treatment of patients with myxedema coma and, in the first day or so, may make the difference between survival and death. These measures include treatment in an intensive care unit, mechanical ventilation if necessary, judicious administration of intravenous fluids including electrolytes and glucose, correction of hypothermia, and treatment of any underlying infection.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dilute fluids should be avoided in hyponatremic patients to prevent a further reduction in the plasma sodium concentration.",
"     </li>",
"     <li>",
"      Hypotension, if present and not caused by volume depletion, will be corrected by thyroid hormone therapy over a period of hours to days. Severe hypotension that does not respond to fluids should be treated with a vasopressor drug until the T4 has had time to act.",
"     </li>",
"     <li>",
"      Passive rewarming with a blanket is preferred for correction of hypothermia. Active rewarming carries a risk of vasodilatation and worsening hypotension.",
"     </li>",
"     <li>",
"      As with any critically ill, comatose patient, empiric administration of antibiotics should be considered until appropriate cultures are proven negative.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The hallmarks of myxedema coma are decreased mental status and hypothermia, but hypotension, bradycardia, hyponatremia, hypoglycemia, and hypoventilation are often present as well. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If the diagnosis of myxedema coma is suspected, a blood sample should be drawn for measurement of serum T4, TSH, and cortisol (ideally before and after ACTH administration) before therapy with a glucocorticoid and thyroid hormone are initiated. The serum T4 concentration is usually very low. The serum TSH concentration may be high, indicating primary hypothyroidism, or low, normal, or slightly high, indicating central hypothyroidism. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=see_link\">",
"       \"Diagnosis of and screening for hypothyroidism\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=see_link\">",
"       \"Central hypothyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with myxedema coma should be treated aggressively, because the mortality rate approaches 40 percent. In circumstances where laboratory confirmation of hypothyroidism is delayed, treatment with thyroid hormone and glucocorticoids should be instituted without waiting for laboratory confirmation. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with myxedema coma, we suggest combined therapy with T4 and T3 rather than T4 alone (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest an initial dose of 200 to 400 mcg T4 intravenously, followed by daily intravenous doses of 50 to 100 mcg until the patient can take T4 orally. T3 is given intravenously at the same time; the initial dose is 5 to 20 mcg, followed by 2.5 to 10 mcg every eight hours depending upon the patient's age and coexisting cardiovascular disease. T3 is continued until there is clinical improvement and the patient is stable. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Until coexisting adrenal insufficiency can be excluded, the patient should be given high-dose glucocorticoid therapy (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/49/32528?source=see_link\">",
"       hydrocortisone",
"      </a>",
"      100 mg intravenously every eight to twelve hours for two days, then lower doses). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Supportive measures are extremely important, including mechanical ventilation, appropriate fluid replacement, and correction of hyponatremia and hypothermia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link&amp;anchor=H88313973#H88313973\">",
"       \"Causes of hyponatremia\", section on 'Hypothyroidism'",
"      </a>",
"      .) In addition, there is often an associated illness that must be treated, such as infection, or gastrointestinal bleeding.",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/1\">",
"      Santiago R, Rashkin MC. Lithium toxicity and myxedema coma in an elderly woman. J Emerg Med 1990; 8:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/2\">",
"      Waldman SA, Park D. Myxedema coma associated with lithium therapy. Am J Med 1989; 87:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/3\">",
"      Mazonson PD, Williams ML, Cantley LK, et al. Myxedema coma during long-term amiodarone therapy. Am J Med 1984; 77:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/4\">",
"      Kwaku MP, Burman KD. Myxedema coma. J Intensive Care Med 2007; 22:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/5\">",
"      Westphal SA. Unusual presentations of hypothyroidism. Am J Med Sci 1997; 314:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/6\">",
"      Jansen HJ, Doeb&eacute; SR, Louwerse ES, et al. Status epilepticus caused by a myxoedema coma. Neth J Med 2006; 64:202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/7\">",
"      Woods KL, Holmes GK. Myxoedema coma presenting in status epilepticus. Postgrad Med J 1977; 53:46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/8\">",
"      Haupt M, Kurz A. Reversibility of dementia in hypothyroidism. J Neurol 1993; 240:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/9\">",
"      Iwasaki Y, Oiso Y, Yamauchi K, et al. Osmoregulation of plasma vasopressin in myxedema. J Clin Endocrinol Metab 1990; 70:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/10\">",
"      Zwillich CW, Pierson DJ, Hofeldt FD, et al. Ventilatory control in myxedema and hypothyroidism. N Engl J Med 1975; 292:662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/11\">",
"      Lee, CH, Wira, CR. Am J Emerg Med 2009; 27:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/12\">",
"      Klein I. Thyroid hormone and the cardiovascular system. Am J Med 1990; 88:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/13\">",
"      Shenoy MM, Goldman JM. Hypothyroid cardiomyopathy: echocardiographic documentation of reversibility. Am J Med Sci 1987; 294:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/14\">",
"      Hylander B, Rosenqvist U. Treatment of myxoedema coma--factors associated with fatal outcome. Acta Endocrinol (Copenh) 1985; 108:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/15\">",
"      Dutta P, Bhansali A, Masoodi SR, et al. Predictors of outcome in myxoedema coma: a study from a tertiary care centre. Crit Care 2008; 12:R1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/16\">",
"      Beynon J, Akhtar S, Kearney T. Predictors of outcome in myxoedema coma. Crit Care 2008; 12:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/17\">",
"      Yamamoto T, Fukuyama J, Fujiyoshi A. Factors associated with mortality of myxedema coma: report of eight cases and literature survey. Thyroid 1999; 9:1167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/18\">",
"      Rodr&iacute;guez I, Fluiters E, P&eacute;rez-M&eacute;ndez LF, et al. Factors associated with mortality of patients with myxoedema coma: prospective study in 11 cases treated in a single institution. J Endocrinol 2004; 180:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/19\">",
"      MacKerrow SD, Osborn LA, Levy H, et al. Myxedema-associated cardiogenic shock treated with intravenous triiodothyronine. Ann Intern Med 1992; 117:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/20\">",
"      HOLVEY DN, GOODNER CJ, NICOLOFF JT, DOWLING JT. TREATMENT OF MYXEDEMA COMA WITH INTRAVENOUS THYROXINE. Arch Intern Med 1964; 113:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8566/abstract/21\">",
"      Arlot S, Debussche X, Lalau JD, et al. Myxoedema coma: response of thyroid hormones with oral and intravenous high-dose L-thyroxine treatment. Intensive Care Med 1991; 17:16.",
"     </a>",
"    </li>",
"    <li>",
"     Wartofsky L. Myxedema coma. In: The Thyroid: A Fundamental and Clinical Text, Braverman LE, Utiger RD (Eds), Lippincott, Williams &amp; Wilkins, Philadelphia 2000. p.843.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7822 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-210.101.131.232-3CA5444EA1-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8566=[""].join("\n");
var outline_f8_23_8566=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neurologic manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Hypothermia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Hypoventilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Hypoglycemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Cardiovascular abnormalities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thyroid hormone",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Supportive measures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/7822\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/7822|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?0/9/153\" title=\"table 1\">",
"      Features of myxedema coma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/0/14347\" title=\"table 2\">",
"      Management of myxedema coma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/62/3046?source=related_link\">",
"      Cardiovascular effects of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/0/40969?source=related_link\">",
"      Causes of primary adrenal insufficiency (Addison's disease)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/6/18536?source=related_link\">",
"      Central hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/48/38661?source=related_link\">",
"      Clinical manifestations and diagnosis of obesity hypoventilation syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/0/33800?source=related_link\">",
"      Clinical manifestations of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/10/14503?source=related_link\">",
"      Clinical manifestations of hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/12/12490?source=related_link\">",
"      Constrictive pericarditis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/4/40008?source=related_link\">",
"      Control of ventilation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/7/26744?source=related_link\">",
"      Diagnosis of and screening for hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/28/41413?source=related_link\">",
"      Diagnosis of hypopituitarism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42744?source=related_link\">",
"      Disorders that cause hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28825?source=related_link\">",
"      Stupor and coma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/47/42745?source=related_link\">",
"      Treatment of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/53/43865?source=related_link\">",
"      Treatment of hypothyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8567="Cerebral salt-wasting";
var content_f8_23_8567=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Cerebral salt-wasting",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8567/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8567/contributors\">",
"     Biff F Palmer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8567/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8567/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8567/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8567/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/23/8567/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 2, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyponatremia is a common electrolyte disorder in the setting of central nervous system (CNS) disease. This is usually attributed to the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/1-4\">",
"     1-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Cerebral salt-wasting (CSW) is another potential cause of hyponatremia in those with CNS disease, particularly in patients with subarachnoid hemorrhage. CSW is characterized by hyponatremia and extracellular fluid depletion due to inappropriate sodium wasting in the urine [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/5\">",
"     5",
"    </a>",
"    ]. However, some authorities contend that CSW does not really exist and is only a misnomer for what is actually SIADH, with the putative salt wasting being due to unappreciated volume expansion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to CSW, including the differentiation from SIADH, will be reviewed here. The causes and diagnosis of hyponatremia, causes and treatment of SIADH, and the general management of patients with subarachnoid hemorrhage are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=see_link\">",
"     \"Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;With respect to pathophysiology, two issues need to be addressed: the mechanism of salt-wasting; and the mechanism of hyponatremia.",
"   </p>",
"   <p>",
"    The mechanism by which cerebral disease might lead to renal salt-wasting is poorly understood. Two putative mechanisms are disruption of neural input to the kidney and central elaboration of a circulating natriuretic factor [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The sympathetic nervous system promotes sodium, uric acid, and water reabsorption in the proximal tubule, as well as renin release. Thus, impaired sympathetic neural input could explain the reductions in proximal sodium and urate reabsorption and the impaired release of renin and aldosterone. The failure of serum aldosterone to rise in response to volume depletion would explain the absence of potassium wasting despite the increase in distal sodium delivery.",
"     </li>",
"     <li>",
"      The second theory is that a circulating factor that impairs renal tubular sodium reabsorption is released in patients with brain injury [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,10-13\">",
"       6,10-13",
"      </a>",
"      ]. The primary candidate is brain natriuretic peptide (BNP), which decreases sodium reabsorption and inhibits renin release [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/11,12,14\">",
"       11,12,14",
"      </a>",
"      ]. BNP may also decrease autonomic outflow via effects at the level of the brainstem [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. A discussion of the various actions of these hormones is available in a separate topic review. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=see_link\">",
"       \"Natriuretic peptide measurement in heart failure\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One report suggested that BNP might be the more probable candidate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/11\">",
"     11",
"    </a>",
"    ]. In this prospective observational study, 10 patients with subarachnoid hemorrhage were compared with a control group of 10 patients who underwent craniotomy for resection of cerebral tumors and 40 controls. The patients with subarachnoid hemorrhage had increases in urine volume and sodium excretion that correlated with a marked significant increase in mean plasma BNP (15.1 versus 1.6",
"    <span class=\"nowrap\">",
"     pmol/L",
"    </span>",
"    in the other two groups) and with the increase in intracranial pressure. The concentration of ANP was normal, while that of aldosterone was reduced, an effect that may be mediated in part by BNP.",
"   </p>",
"   <p>",
"    It was suggested that BNP was released from hormone-producing neurons in the brain in response to increased intracranial pressure. Some have speculated that renal salt-wasting and the resultant volume depletion is a protective measure, limiting extreme rises in intracranial pressure. In addition, the vasodilatory properties of BNP might decrease the tendency for vasospasm in subarachnoid hemorrhage.",
"   </p>",
"   <p>",
"    With respect to the mechanism of hyponatremia, renal salt wasting leads to volume depletion, which provides a baroreceptor stimulus for the release of ADH, thereby impairing the ability of the kidney to elaborate a dilute urine and leading to hyponatremia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=see_link\">",
"     \"General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Is cerebral salt-wasting real?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some authors have suggested that CSW may not exist [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. They contend that most patients given a diagnosis of CSW may be excreting excess sodium physiologically, either because of reduced venous capacitance caused by catecholamine-induced vasoconstriction or because of volume expansion with intravenous fluids. As an example, patients with subarachnoid hemorrhage are at risk for cerebral vasospasm thought to be precipitated by reduced cerebral blood flow. As a result, they are typically given large volumes of isotonic saline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If volume expansion were induced by saline administration, a high rate of sodium excretion would not be an indicator of salt-wasting. In a survey of patients admitted to a neurosurgical unit, a positive balance for sodium could be documented in over 90 percent of those believed to have CSW when calculations included all infusions from the time of first contact with medical or paramedical personnel [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, many authorities feel that CSW is a distinct entity. In the setting of CNS disease, patients with CSW meet the traditional laboratory criteria for SIADH but clearly have decreased extracellular volume due to excessive urinary sodium excretion [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/16-20\">",
"     16-20",
"    </a>",
"    ]. By comparison, SIADH is associated with a slightly increased or normal extracellular volume.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND CAUSES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of CSW is unclear, particularly given that its existence is disputed [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Among patients with CNS disease, cerebral salt-wasting is a much less common cause of hyponatremia than SIADH.",
"   </p>",
"   <p>",
"    Although CSW has been most often described in patients with subarachnoid hemorrhage, it accounts for only a small proportion of cases of hyponatremia in these patients (7 percent in one series compared to 69 percent due to SIADH) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/2\">",
"     2",
"    </a>",
"    ]. Furthermore, the frequency of CSW as a cause of hyponatremia in this setting may be diminishing, since the usual management of patients with subarachnoid hemorrhage consists of providing large volumes of isotonic saline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H13#H13\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Hyperdynamic therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    CSW has also been reported in patients with carcinomatous or infectious meningitis, encephalitis, poliomyelitis, and central nervous system tumors, as well as following CNS surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/5,21-25\">",
"     5,21-25",
"    </a>",
"    ]. Rare cases have been described in children [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/26-28\">",
"     26-28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The typical onset of hyponatremia due to CSW is within the first ten days following a neurosurgical procedure or event. However, case reports have described later onset (eg, one month after transsphenoidal surgery for treatment of a pituitary macroadenoma) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CSW is associated with extracellular fluid depletion. As a result, hypotension, decreased skin turgor,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    an elevated hematocrit may be observed.",
"   </p>",
"   <p>",
"    Theoretically, the volume depletion seen with CSW may worsen cerebral perfusion directly, and the associated hypotension may precipitate vasospasm in those subarachnoid hemorrhage [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Whether hyponatremia itself potentiates vasospasm is uncertain, but it may worsen cerebral edema and thus contribute to mental status decline. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\", section on 'Intracranial pressure and blood pressure'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=see_link&amp;anchor=H15#H15\">",
"     \"Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage\", section on 'Vasospasm'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;CSW should be considered in any patient with CNS disease and hyponatremia. A directed history and physical examination and appropriate laboratory tests are essential. The general approach to the diagnosis of hyponatremia is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the setting of CNS disease, CSW is diagnosed in the patient with clinical evidence of hypovolemia who have the following characteristics:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Hyponatremia (less than 135",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      with a low plasma osmolality",
"     </li>",
"     <li>",
"      An inappropriately elevated urine osmolality (above 100",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      and usually above 300",
"      <span class=\"nowrap\">",
"       mosmol/kg)",
"      </span>",
"     </li>",
"     <li>",
"      A urine sodium concentration usually above 40",
"      <span class=\"nowrap\">",
"       meq/L",
"      </span>",
"     </li>",
"     <li>",
"      A low serum uric acid concentration due to urate wasting in the urine",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical evidence of hypovolemia is crucial, since all of these laboratory findings are also seen in SIADH.",
"   </p>",
"   <p>",
"    Given the overlap and the frequent difficult in determining whether a patient has mild hypovolemia, the diagnosis of CSW should require that volume repletion leads to a dilute urine, which would be due to the removal of the hypovolemic stimulus to ADH release. Excretion of a dilute urine would lead to correction of the hyponatremia.",
"   </p>",
"   <p>",
"    Although difficult to perform accurately, evidence of net negative sodium balance prior to therapy is also consistent with the diagnosis of CSW [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,28\">",
"     6,28",
"    </a>",
"    ]. Calculation of the sodium intake includes that obtained via intravenous and oral routes (including sodium supplements and food), while sodium excretion involves frequent measurement of urine sodium concentrations combined with knowledge of urine volumes.",
"   </p>",
"   <p>",
"    Formation of a dilute urine with volume repletion has not been demonstrated and, in many if not most reported cases, clear evidence of hypovolemia has not been present [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of CNS injury, CSW must be distinguished from other causes of hyponatremia, principally SIADH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/5\">",
"     5",
"    </a>",
"    ]. General discussions concerning the causes and diagnosis of hyponatremia are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CSW versus SIADH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The distinction between CSW and SIADH is critically important since the two disorders are managed differently, with possible adverse consequences if the incorrect therapeutic strategy is administered [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/5,31\">",
"     5,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to hyponatremia, the two disorders share the following features:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The urine osmolality is inappropriately high in the presence of hyponatremia (which normally suppresses ADH release) due to increased release of ADH. This response is appropriate in cerebral salt-wasting, due to the volume depletion, but inappropriate in SIADH.",
"     </li>",
"     <li>",
"      The urine sodium is usually &gt;40",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      due to volume expansion in SIADH and putative salt-wasting in CSW.",
"     </li>",
"     <li>",
"      The serum uric acid concentration is typically reduced due to urinary losses, perhaps due to a putative hormone such as BNP in CSW and to volume expansion and a direct effect of ADH on the V1 receptor in SIADH [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is only the presence of clear evidence of volume depletion (eg, hypotension, decreased skin turgor, elevated hematocrit, possibly increased",
"    <span class=\"nowrap\">",
"     BUN/serum",
"    </span>",
"    creatinine ratio) despite a urine sodium concentration that is not low that suggests that CSW might be present rather than SIADH [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/6,8\">",
"     6,8",
"    </a>",
"    ]. By comparison, extracellular fluid volume is normal or slightly increased with SIADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=see_link\">",
"     \"Etiology, clinical manifestations, and diagnosis of volume depletion in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Evaluating the response to isotonic saline is also important in distinguishing between CSW and SIADH. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=see_link\">",
"     \"Evaluation of the patient with hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Restoration of euvolemia in CSW should remove the stimulus to ADH release, resulting in a dilute urine and correction of the hyponatremia. As mentioned above, this has not been documented in CSW. Lack of urinary dilution does not necessarily preclude CSW, since it might be expected that patients with subarachnoid hemorrhage would also have SIADH.",
"     </li>",
"     <li>",
"      In contrast, isotonic saline often worsens the hyponatremia in SIADH as the salt is excreted and some of the water is retained. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"       \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although unlikely, it is also possible that some patients have preexisting hyponatremia due to some other disorder that is associated with a urine sodium that is not low (eg, thiazide diuretics and hypoaldosteronism ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=see_link\">",
"     \"Causes of hyponatremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyponatremia and hyperkalemia are the two major manifestations of adrenal insufficiency. The hyponatremia is mediated by increased release of ADH, which can be due to any cause of cortisol deficiency or hypoaldosteronism, while hyperkalemia only occurs with primary adrenal disease. The diagnosis of adrenal insufficiency is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=see_link\">",
"     \"Hyponatremia and hyperkalemia in adrenal insufficiency\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of CNS disease, the distinction between CSW and SIADH is critically important since the two disorders are managed differently, with possible adverse consequences if the incorrect therapy is administered. As an example, fluid restriction, the usual first-line therapy for SIADH, may increase the risk of cerebral infarction among patients who actually have CSW since ongoing salt losses might worsen the volume depletion and lower the blood pressure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=see_link\">",
"     \"Treatment of aneurysmal subarachnoid hemorrhage\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Volume repletion with isotonic saline is the recommended therapy in CSW, since it will suppress the release of ADH, thereby permitting excretion of the excess water and correction of the hyponatremia. If CSW is the sole cause of the hyponatremia, volume repletion would result in the urine osmolality falling below 100",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    which, as noted above, has not been documented. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=see_link&amp;anchor=H6#H6\">",
"     \"Overview of the treatment of hyponatremia\", section on 'True volume depletion'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lack of urinary dilution does not necessarily preclude CSW, since it might be expected that patients with subarachnoid hemorrhage would also have SIADH. Volume repletion would have little effect on urine osmolality in SIADH, since ADH secretion in this disorder is not mediated by hypovolemia. [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/8,9,33\">",
"     8,9,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with documented CSW, salt tablets can be administered once they are able to take oral medications. Administration of a mineralocorticoid, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    , can also be used [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/28,34,35\">",
"     28,34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Long-term therapy of CSW is not necessary since CSW tends to be transient [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/9\">",
"     9",
"    </a>",
"    ]. Resolution usually occurs within three to four weeks.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     THERAPY OF SIADH ASSOCIATED WITH SAH",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal therapy for hyponatremia due to SIADH in patients with subarachnoid hemorrhage (SAH) is not clear since the standard initial therapy, fluid restriction, may increase the risk of cerebral infarction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Isotonic saline can be given initially, particularly if the serum sodium is normal. However, careful monitoring is required isotonic saline can lower the serum sodium in patients with SIADH. The administered sodium will be excreted (there is no defect in sodium handling in SIADH) but some of the water will be retained if the urine osmolality is substantially higher than that 300",
"    <span class=\"nowrap\">",
"     mosmol/kg",
"    </span>",
"    (the osmolality of isotonic saline). Such patients should be treated with hypertonic saline. How this occurs is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H7#H7\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Intravenous saline'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=see_link&amp;anchor=H6#H6\">",
"     \"Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat\", section on 'Subarachnoid hemorrhage'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with subarachnoid hemorrhage, a separate issue is the possible administration of a mineralocorticoid, such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    , to prevent volume depletion and delayed cerebral ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/28,37,38\">",
"     28,37,38",
"    </a>",
"    ]. The potential efficacy of this approach was examined in a trial of 91 patients with newly diagnosed subarachnoid hemorrhage, who were randomly assigned to fludrocortisone (0.2 mg twice daily) or control therapy for a maximum of 12 days [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8567/abstract/37\">",
"     37",
"    </a>",
"    ]. Plasma volume was measured by the isotope dilution technique during the first day, and days 6 and 12, and sodium balance was ascertained using estimates of intake and measurement of urinary sodium excretion. Significantly fewer patients in the treatment group developed negative sodium balance (38 versus 63 percent in the control group at six days, 29 versus 70 percent at 12 days). There was a suggestion that fludrocortisone might reduce cerebral ischemia (22 versus 31 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cerebral salt wasting (CSW) is characterized by hyponatremia and extracellular fluid depletion due to inappropriate sodium wasting in the urine, in the setting of acute disease in central nervous system (CNS), usually subarachnoid hemorrhage. CSW is a much less common cause of hyponatremia in patients with cerebral injury than the syndrome of inappropriate ADH secretion (SIADH). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Epidemiology and causes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathophysiology of CSW is related to impaired sodium reabsorption, possibly due to the release of brain natriuretic peptide",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diminished central sympathetic activity. Regardless of the mechanism, sodium-wasting can lead sequentially to volume depletion, increased ADH release, hyponatremia due to the associated water retention, and possibly increased neurologic injury. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathophysiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some authorities contend that CSW does not exist and that the laboratory findings are due to SIADH. However, we feel that CSW is a distinct entity. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Is cerebral salt-wasting real?'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Specific laboratory findings include hyponatremia with a low plasma osmolality, an inappropriately elevated urine osmolality (above 100",
"      <span class=\"nowrap\">",
"       mosmol/kg",
"      </span>",
"      and usually above 300",
"      <span class=\"nowrap\">",
"       mosmol/kg),",
"      </span>",
"      a urine sodium concentration above 40",
"      <span class=\"nowrap\">",
"       meq/L,",
"      </span>",
"      and a low serum uric acid concentration due to urate wasting in the urine. Since CSW is associated with extracellular fluid depletion, hypotension and decreased skin turgor may also be observed. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CSW mimics all of the laboratory findings in the SIADH. The only clue to the presence of CSW rather than SIADH is clinical evidence of extracellular volume depletion, such as hypotension and decreased skin turgor,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      increased hematocrit, in a patient with a urine sodium concentration above 40",
"      <span class=\"nowrap\">",
"       meq/L.",
"      </span>",
"      Unlike SIADH, volume repletion in CSW leads to a dilute urine, due to removal of the hypovolemic stimulus to ADH release, and subsequent correction of the hyponatremia. &nbsp;This finding has not been convincingly demonstrated which could reflect concurrent SIADH due to the CNS disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the setting of CNS disease, accurate distinction between CSW and SIADH is essential since the two disorders are managed differently, with possible adverse consequences if the incorrect therapeutic strategy is administered. In patients with a clinical picture compatible with CSW, we recommend initial therapy with isotonic saline to correct the volume depletion and possibly reverse the hyponatremia. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/1\">",
"      Hasan D, Wijdicks EF, Vermeulen M. Hyponatremia is associated with cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage. Ann Neurol 1990; 27:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/2\">",
"      Sherlock M, O'Sullivan E, Agha A, et al. The incidence and pathophysiology of hyponatraemia after subarachnoid haemorrhage. Clin Endocrinol (Oxf) 2006; 64:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/3\">",
"      Wartenberg KE, Schmidt JM, Claassen J, et al. Impact of medical complications on outcome after subarachnoid hemorrhage. Crit Care Med 2006; 34:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/4\">",
"      Qureshi AI, Suri MF, Sung GY, et al. Prognostic significance of hypernatremia and hyponatremia among patients with aneurysmal subarachnoid hemorrhage. Neurosurgery 2002; 50:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/5\">",
"      Gutierrez OM, Lin HY. Refractory hyponatremia. Kidney Int 2007; 71:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/6\">",
"      Singh S, Bohn D, Carlotti AP, et al. Cerebral salt wasting: truths, fallacies, theories, and challenges. Crit Care Med 2002; 30:2575.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/7\">",
"      Carlotti AP, Bohn D, Rutka JT, et al. A method to estimate urinary electrolyte excretion in patients at risk for developing cerebral salt wasting. J Neurosurg 2001; 95:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/8\">",
"      Palmer BF. Hyponatremia in patients with central nervous system disease: SIADH versus CSW. Trends Endocrinol Metab 2003; 14:182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/9\">",
"      Palmer BF. Hyponatraemia in a neurosurgical patient: syndrome of inappropriate antidiuretic hormone secretion versus cerebral salt wasting. Nephrol Dial Transplant 2000; 15:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/10\">",
"      Al-Mufti H, Arieff AI. Hyponatremia due to cerebral salt-wasting syndrome. Combined cerebral and distal tubular lesion. Am J Med 1984; 77:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/11\">",
"      Berendes E, Walter M, Cullen P, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet 1997; 349:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/12\">",
"      Berger TM, Kistler W, Berendes E, et al. Hyponatremia in a pediatric stroke patient: syndrome of inappropriate antidiuretic hormone secretion or cerebral salt wasting? Crit Care Med 2002; 30:792.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/13\">",
"      Harrigan MR. Cerebral salt wasting syndrome: a review. Neurosurgery 1996; 38:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/14\">",
"      Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/15\">",
"      Steele MK, Gardner DG, Xie PL, Schultz HD. Interactions between ANP and ANG II in regulating blood pressure and sympathetic outflow. Am J Physiol 1991; 260:R1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/16\">",
"      Nelson PB, Seif SM, Maroon JC, Robinson AG. Hyponatremia in intracranial disease: perhaps not the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). J Neurosurg 1981; 55:938.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/17\">",
"      Wijdicks EF, Vermeulen M, ten Haaf JA, et al. Volume depletion and natriuresis in patients with a ruptured intracranial aneurysm. Ann Neurol 1985; 18:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/18\">",
"      Levine JP, Stelnicki E, Weiner HL, et al. Hyponatremia in the postoperative craniofacial pediatric patient population: a connection to cerebral salt wasting syndrome and management of the disorder. Plast Reconstr Surg 2001; 108:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/19\">",
"      Sivakumar V, Rajshekhar V, Chandy MJ. Management of neurosurgical patients with hyponatremia and natriuresis. Neurosurgery 1994; 34:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/20\">",
"      Lenhard T, K&uuml;lkens S, Schwab S. Cerebral salt-wasting syndrome in a patient with neuroleptic malignant syndrome. Arch Neurol 2007; 64:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/21\">",
"      Filippella M, Cappabianca P, Cavallo LM, et al. Very delayed hyponatremia after surgery and radiotherapy for a pituitary macroadenoma. J Endocrinol Invest 2002; 25:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/22\">",
"      Sengupta K, Ali U, Andankar P. Cerebral salt wasting. Indian Pediatr 2002; 39:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/23\">",
"      Ti LK, Kang SC, Cheong KF. Acute hyponatraemia secondary to cerebral salt wasting syndrome in a patient with tuberculous meningitis. Anaesth Intensive Care 1998; 26:420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/24\">",
"      Erduran E, Mocan H, Aslan Y. Another cause of hyponatraemia in patients with bacterial meningitis: cerebral salt wasting. Acta Paediatr 1997; 86:1150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/25\">",
"      Oster JR, Perez GO, Larios O, et al. Cerebral salt wasting in a man with carcinomatous meningitis. Arch Intern Med 1983; 143:2187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/26\">",
"      Ganong CA, Kappy MS. Cerebral salt wasting in children. The need for recognition and treatment. Am J Dis Child 1993; 147:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/27\">",
"      Jim&eacute;nez R, Casado-Flores J, Nieto M, Garc&iacute;a-Teresa MA. Cerebral salt wasting syndrome in children with acute central nervous system injury. Pediatr Neurol 2006; 35:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/28\">",
"      Taplin CE, Cowell CT, Silink M, Ambler GR. Fludrocortisone therapy in cerebral salt wasting. Pediatrics 2006; 118:e1904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/29\">",
"      Naval NS, Stevens RD, Mirski MA, Bhardwaj A. Controversies in the management of aneurysmal subarachnoid hemorrhage. Crit Care Med 2006; 34:511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/30\">",
"      Wijdicks EF, Vermeulen M, Murray GD, et al. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. Clin Neurol Neurosurg 1990; 92:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/31\">",
"      Maesaka JK, Imbriano LJ, Ali NM, Ilamathi E. Is it cerebral or renal salt wasting? Kidney Int 2009; 76:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/32\">",
"      Maesaka JK, Venkatesan J, Piccione JM, et al. Abnormal urate transport in patients with intracranial disease. Am J Kidney Dis 1992; 19:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/33\">",
"      Diringer MN, Wu KC, Verbalis JG, Hanley DF. Hypervolemic therapy prevents volume contraction but not hyponatremia following subarachnoid hemorrhage. Ann Neurol 1992; 31:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/34\">",
"      Albanese A, Hindmarsh P, Stanhope R. Management of hyponatraemia in patients with acute cerebral insults. Arch Dis Child 2001; 85:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/35\">",
"      Kinik ST, Kandemir N, Baykan A, et al. Fludrocortisone treatment in a child with severe cerebral salt wasting. Pediatr Neurosurg 2001; 35:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/36\">",
"      Wijdicks EF, Vermeulen M, Hijdra A, van Gijn J. Hyponatremia and cerebral infarction in patients with ruptured intracranial aneurysms: is fluid restriction harmful? Ann Neurol 1985; 17:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/37\">",
"      Hasan D, Lindsay KW, Wijdicks EF, et al. Effect of fludrocortisone acetate in patients with subarachnoid hemorrhage. Stroke 1989; 20:1156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8567/abstract/38\">",
"      Ishikawa SE, Saito T, Kaneko K, et al. Hyponatremia responsive to fludrocortisone acetate in elderly patients after head injury. Ann Intern Med 1987; 106:187.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2367 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-61.234.146.186-239B17CE44-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8567=[""].join("\n");
var outline_f8_23_8567=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Is cerebral salt-wasting real?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      EPIDEMIOLOGY AND CAUSES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CSW versus SIADH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      THERAPY OF SIADH ASSOCIATED WITH SAH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/30/3562?source=related_link\">",
"      Causes of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/46/44777?source=related_link\">",
"      Diagnosis of adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/39/38522?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24457?source=related_link\">",
"      Etiology, clinical manifestations, and diagnosis of volume depletion in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/20/21832?source=related_link\">",
"      Evaluation of the patient with hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/48/11018?source=related_link\">",
"      General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/17/25876?source=related_link\">",
"      Hyponatremia and hyperkalemia in adrenal insufficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/22/19818?source=related_link\">",
"      Natriuretic peptide measurement in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18986?source=related_link\">",
"      Overview of the treatment of hyponatremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/46/7913?source=related_link\">",
"      Pathophysiology and etiology of the syndrome of inappropriate antidiuretic hormone secretion (SIADH)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/54/37738?source=related_link\">",
"      Treatment of aneurysmal subarachnoid hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/57/17306?source=related_link\">",
"      Treatment of hyponatremia: Syndrome of inappropriate antidiuretic hormone secretion (SIADH) and reset osmostat",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8568="The anti-Ro/SSA and anti-La/SSB antigen-antibody systems";
var content_f8_23_8568=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   The anti-Ro/SSA and anti-La/SSB antigen-antibody systems",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8568/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8568/contributors\">",
"     Donald B Bloch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8568/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8568/contributors\">",
"     Robert H Shmerling, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8568/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8568/contributors\">",
"     Paul L Romain, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/23/8568/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 25, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H11717191\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies directed against",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    autoantigens were originally identified in patients with Sj&ouml;gren&rsquo;s syndrome and systemic lupus erythematosus (SLE). Subsequent studies showed that",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibodies may be present in patients with other autoimmune diseases, including systemic sclerosis, idiopathic inflammatory myopathies (IIM), primary biliary cirrhosis (PBC), and rheumatoid arthritis (RA). Additionally,",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    antibodies (with or without",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibodies) identify pregnant women who are at increased risk of having a child with neonatal lupus syndrome.",
"    <span class=\"nowrap\">",
"     Anti-Ro/SSA",
"    </span>",
"    antibodies may also be the only autoantibodies present in a subset of patients with &ldquo;ANA-negative&rdquo; SLE. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The",
"    <span class=\"nowrap\">",
"     anti-Ro/SSA",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     anti-La/SSB",
"    </span>",
"    antibody system and the clinical significance of these antibodies are reviewed here. An overview of the antinuclear antibodies important in SLE and in related autoimmune diseases and the clinical significance of autoantibodies directed against double-stranded deoxyribonucleic acid (dsDNA), U1 ribonucleoprotein (RNP), Sm, and ribosomal P proteins are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=see_link\">",
"     \"Measurement and clinical significance of antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=see_link\">",
"     \"Miscellaneous antinuclear antibodies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=see_link\">",
"     \"Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=see_link\">",
"     \"Antiribosomal P protein antibodies\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717198\">",
"    <span class=\"h1\">",
"     Ro/SSA ANTIGENS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum containing autoantibodies directed against the",
"    <span class=\"nowrap\">",
"     Ro/SSA",
"    </span>",
"    antigens may recognize one or both of two cellular proteins with molecular weights of approximately 52 and 60 kD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. These autoantigens are referred to as &ldquo;Ro52&rdquo; and &ldquo;Ro60,&rdquo; respectively. The two autoantigens were originally thought to interact with each other, but subsequent studies have shown that the two proteins reside in distinct cellular compartments, with Ro60 localized to the nucleus and nucleolus and with Ro52 localized to the cytoplasm.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717213\">",
"    <span class=\"h2\">",
"     Ro60",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amino acid sequence of the Ro60 autoantigen was described in the late 1980s [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]; Ro60 was shown to bind small, non-coding ribonucleic acids (RNAs) termed &ldquo;Y RNAs.&rdquo; Although the function of Y RNAs is unknown, one report suggests that Y RNAs may be a source of micro (mi)RNA molecules, which have a role in the regulation of messenger (m)RNA stability and translation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/5\">",
"     5",
"    </a>",
"    ]. The crystal structure of Ro60 suggests that the protein can bind to both single- and double-stranded RNA. The protein may function as a &ldquo;RNA chaperone&rdquo; that binds to misfolded pre-5S ribosomal RNA and may hasten the degradation of the defective molecule. Ro60 may also bind to other cellular and viral RNAs in the cell, including Epstein-Barr virus (EBV) early RNA 1 (EBER1) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/6\">",
"     6",
"    </a>",
"    ]. Mice that lack the functional gene encoding Ro60 develop an autoimmune syndrome characterized by antiribosome and antichromatin antibodies, as well as glomerulonephritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/7\">",
"     7",
"    </a>",
"    ], suggesting that Ro60 may have an important role in preventing systemic autoimmune disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717220\">",
"    <span class=\"h2\">",
"     Ro52",
"    </span>",
"    &nbsp;&mdash;&nbsp;The amino acid sequence of the Ro52 autoantigen was reported in 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/3\">",
"     3",
"    </a>",
"    ]. Ro52 is an interferon-inducible protein that belongs to the &ldquo;tripartite motif&rdquo; family of proteins. Ro52 contains an amino (N)-terminal RING finger domain, followed by B-box and coiled-coil domains and by a carboxy (C)-terminal B30.2 or &ldquo;PRYPRY&rdquo; domain. The protein localizes to the cytoplasm and functions as an E3 ubiquitin ligase, an enzyme that adds ubiquitin molecules to target proteins [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ro52 interacts with a broad range of substrates and may either enhance or inhibit the function of target proteins. It interacts with the Fc portion of immunoglobulin G (IgG) molecules, via its C-terminal B30.2 domain, and catalyzes the poly-ubiquitinization of misfolded IgG, thereby hastening its degradation in proteasomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Ro52, like Ro60 and La (see below), may also have a role in the regulation of messenger RNA (mRNA) stability. Ro52 interacts with and enhances the activity of decapping protein (DCP) 2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/10\">",
"     10",
"    </a>",
"    ], a protein that removes the 5&rsquo; cap from mRNA molecules. Removal of the 5&rsquo; cap exposes mRNA molecules to degradation by exoribonuclease I.",
"   </p>",
"   <p>",
"    Ro52 may also have important roles in the regulation of inflammation. Ro52 adds an ubiquitin molecule to activated inhibitor of nuclear factor kappa-B kinase subunit beta (IKKB) and, thereby, down-regulates proinflammatory nuclear factor kappa-B (NFKB) signaling [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/11\">",
"     11",
"    </a>",
"    ]. Ro52 also inhibits inflammation by targeting interferon regulatory factors (IRF) 3 and 7 for ubiquitin-mediated degradation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Consistent with the effects of Ro52 on NFKB signaling and IRF stability, mice that lack Ro52 develop an autoimmune disease, which is characterized by hypergammaglobulinemia and renal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717236\">",
"    <span class=\"h1\">",
"     La/SSB ANTIGEN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies directed against the",
"    <span class=\"nowrap\">",
"     La/SSB",
"    </span>",
"    autoantigen (La) interact with a 47-kD protein, which shuttles between the nucleus and cytoplasm but which is predominantly found in the nucleus [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/16\">",
"     16",
"    </a>",
"    ]. A complementary DNA (cDNA) encoding La was identified in 1988 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/17\">",
"     17",
"    </a>",
"    ]. The N-terminus of the protein contains a &ldquo;La&rdquo; RNA-binding domain and an adjacent RNA recognition motif (RRM), which cooperate to bind RNA. The C-terminus of the protein contains a second RRM followed by a short basic motif (&ldquo;SBF&rdquo; domain) and a nuclear localization sequence [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/18\">",
"     18",
"    </a>",
"    ]. The N-terminal portion of La mediates the interaction with the 3&rsquo; end of RNA polymerase III transcripts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/19\">",
"     19",
"    </a>",
"    ]. La participates in the processing of small, noncoding RNAs such as ribosomal 5S RNA.",
"   </p>",
"   <p>",
"    La also binds cellular transfer RNAs (tRNAs), as well as viral RNA molecules, including those produced by EBV, by Hepatitis A and C, by respiratory syncytial virus, by adenovirus, and by human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/16,20-24\">",
"     16,20-24",
"    </a>",
"    ]. La may regulate the translation of viral RNAs by enhancing internal ribosomal entry site function. A report suggests that La has a critical role in regulating RNA interference (RNAi) by enhancing RNAi turnover in the RNA-induced silencing complex (RISC) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/25\">",
"     25",
"    </a>",
"    ]. If confirmed, this result would suggest that La has a role in the regulation of mRNA stability and translation. A mouse model that lacks the La protein has not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H349797881\">",
"    <span class=\"h1\">",
"     DETECTION OF ANTI-Ro AND ANTI-La ANTIBODIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H795098207\">",
"    <span class=\"h2\">",
"     Solid phase assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, antibodies directed against the Ro and La antigens were detected by immunodiffusion or by counter-immunoelectrophoresis. Most laboratories have subsequently adopted solid phase assays, including enzyme linked immunosorbent assays (ELISA) or antigen-coated fluorescent microsphere and flow cytometry-based assays. Solid phase assays use either native or recombinant protein as substrate. These assays have advantages over other techniques including decreased cost, increased sensitivity for the detection of the corresponding autoantibodies, and the ability to quantify the amount of antibody. The increased sensitivity of solid phase assays comes at the cost of decreased specificity for the diagnosis of autoimmune diseases. The reported prevalence of anti-Ro and anti-La autoantibodies in patients with autoimmune diseases depends upon the method used to detect the autoantibodies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29645360\">",
"    <span class=\"h2\">",
"     Immunofluorescence staining on HEp-2 substrates",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients in whom the only autoantibodies present are anti-Ro antibodies may have a falsely negative ANA test using the traditional human epithelial cell line-2 (HEp-2) cell substrate, because Ro60 immunoreactivity may be lost during the preparation of the cells and because Ro52 is a cytoplasmic, rather than nuclear, autoantigen.",
"   </p>",
"   <p>",
"    The ability to detect anti-Ro60 antibodies by indirect immunofluorescence has been enhanced by use of a modified HEp-2 cell substrate (&ldquo;HEp-2000&rdquo;), in which transfection of a cDNA encoding Ro-60 was used to over-express the protein in 10 to 20 percent of the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Anti-Ro60 antibodies produce nucleolar and nuclear speckled staining patterns in transfected cells on the Hep-2000 substrate. Only 10 to 20 percent of the cells will produce this staining pattern if anti-Ro60 antibodies are the only autoantibodies present in a patient&rsquo;s serum (",
"    <a class=\"graphic graphic_picture graphicRef86981 \" href=\"UTD.htm?16/54/17249\">",
"     picture 1",
"    </a>",
"    ). However, only about 25 percent of clinical and commercial laboratories in the United States use the HEp-2000 substrate, while, in Europe and Australia, Hep-2000 is used as the ANA substrate in about 75 percent of such laboratories. In laboratories using the traditional HEp-2 cell substrate, solid phase assays are the most reliable approach to detecting anti-Ro60 antibodies.",
"   </p>",
"   <p>",
"    In contrast to anti-Ro60, anti-Ro52 antibodies can be detected by indirect immunofluorescence using the traditional HEp-2 cell substrate. Under normal tissue culture conditions, Ro52 localizes to the cell cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef86982 \" href=\"UTD.htm?18/46/19183\">",
"     picture 2",
"    </a>",
"    ). Because Ro52 is not a nuclear autoantigen, autoantibodies directed against this antigen may not be reported by those commercial laboratories that only report the presence of antinuclear (but not anticytoplasmic) antibodies using the HEp-2 cell substrate.",
"   </p>",
"   <p>",
"    Although La has been shown to shuttle between the nucleus and cytoplasm, the protein is predominantly found in the nucleus of HEp-2 cells. Autoantibodies directed against La produce a speckled nuclear staining pattern (",
"    <a class=\"graphic graphic_picture graphicRef86983 \" href=\"UTD.htm?34/34/35361\">",
"     picture 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717265\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Ro, detected by solid phase immunoassays, which have traditionally detected both Ro60 and Ro52, have been found in patients with a range of autoimmune disorders, including SLE (32 percent), Sj&ouml;gren&rsquo;s syndrome (59 percent), IIM (19 percent), systemic sclerosis (21 percent), and RA (15 percent), as well as PBC and undefined connective tissue disease (UCTD) (infrequently) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/28\">",
"     28",
"    </a>",
"    ]. Women with anti-Ro antibodies (with or without anti-La and with or without autoimmune disease) are at increased risk for having a child with neonatal lupus syndrome. Anti-Ro antibodies may be the only autoantibodies present in more than half of the patients with &ldquo;ANA-negative&rdquo; SLE. Anti-Ro antibodies may also be the first detectable autoantibodies that precede the development of SLE in asymptomatic individuals. (See",
"    <a class=\"local\" href=\"#H11717369\">",
"     'Sj&ouml;gren&rsquo;s syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11717383\">",
"     'Anti-Ro and &ldquo;ANA-negative&rdquo; SLE'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11717418\">",
"     'Neonatal lupus syndrome'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H11717440\">",
"     'Anti-Ro and other autoimmune diseases'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In contrast to anti-Ro antibodies, anti-La antibodies are relatively specific for the diagnosis of SLE and Sj&ouml;gren&rsquo;s syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/29\">",
"     29",
"    </a>",
"    ]. In addition, as with anti-Ro antibodies, anti-La antibodies may be detected in the mothers of children who are born with neonatal lupus syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These women may or may not have evidence of systemic autoimmune disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717369\">",
"    <span class=\"h2\">",
"     Sj&ouml;gren&rsquo;s syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Ro antibodies detected by a solid phase immunoassay that includes mixture of Ro60 and Ro52 (with or without anti-La antibodies) are frequently detected in the serum of patients with Sj&ouml;gren&rsquo;s syndrome. Because these autoantibodies are relatively specific for Sj&ouml;gren&rsquo;s syndrome, an American-European Consensus Group included the presence of anti-Ro with or without anti-La antibodies as one of six classification criteria for this disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H21#H21\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Antibodies to Ro/SSA and La/SSB'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link&amp;anchor=H23#H23\">",
"     \"Classification and diagnosis of Sj&ouml;gren's syndrome\", section on 'Classification criteria'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717376\">",
"    <span class=\"h2\">",
"     Anti-Ro60 versus anti-Ro52",
"    </span>",
"    &nbsp;&mdash;&nbsp;With recognition that Ro consists of both a 60 kD protein and 52 kD protein, solid phase immunoassays have been developed for each [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/33\">",
"     33",
"    </a>",
"    ]. The prevalence of anti-Ro60 and anti-Ro52 antibodies in patients with SLE was reported to be 49 and 43 percent, respectively. In patients with Sj&ouml;gren&rsquo;s syndrome, these antibodies were detected in 67 and 75 percent of affected individuals. The prevalence of the two types of anti-Ro antibodies diverged in patient with other autoimmune diseases [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/33\">",
"     33",
"    </a>",
"    ]. Anti-Ro52 antibodies but not anti-Ro60 antibodies were detected in patients with IIM (35 versus 0 percent), and anti-Ro52 was more common than anti-Ro60 in patients with systemic sclerosis (19 versus 6 percent).",
"   </p>",
"   <p>",
"    In a study of anti-Jo-1 antibody-positive patients with idiopathic inflammatory myopathy (IIM), 36 of 89 consecutive patients (40 percent) had coexisting anti-Ro52 antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/34\">",
"     34",
"    </a>",
"    ]. The presence of anti-Ro52 antibodies appeared to identify a subset of anti-Jo-1 antibody-positive patients with more severe muscle and joint disease.",
"   </p>",
"   <p>",
"    Most commercial laboratories use a single &ldquo;anti-Ro&rdquo; antibody test for both anti-Ro60 and anti-Ro52 antibodies using a combination of the two antigens, despite the different clinical information provided by the individual detection of anti-Ro60 and anti-Ro52 autoantibodies, respectively. The common practice of combining Ro60 and Ro52 in solid phase immunoassays provides less useful clinical information than do separately performed assays for Ro60 and Ro52 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/35-37\">",
"     35-37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717383\">",
"    <span class=\"h2\">",
"     Anti-Ro and &ldquo;ANA-negative&rdquo; SLE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As described above, sera that have only anti-Ro60",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-Ro52 autoantibodies may be reported to be &ldquo;ANA-negative.&rdquo; When evaluating patients who are thought to have SLE or Sj&ouml;gren&rsquo;s syndrome but who are ANA-negative by indirect immunofluorescence, it is important to request testing for anti-Ro antibodies using a solid phase assay [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H29645360\">",
"     'Immunofluorescence staining on HEp-2 substrates'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=see_link&amp;anchor=H49403701#H49403701\">",
"     \"Diagnosis and differential diagnosis of systemic lupus erythematosus in adults\", section on 'ANA-negative lupus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717418\">",
"    <span class=\"h2\">",
"     Neonatal lupus syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neonatal lupus is a passively transferred autoimmune disease that occurs in some babies born to mothers with anti-Ro",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    anti-La antibodies. The most serious complication in the neonate is complete heart block, which occurs in approximately 1 to 2 percent of such pregnancies and in 15 percent of subsequent pregnancies in a mother who has given birth to a child with congenital heart block [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/39\">",
"     39",
"    </a>",
"    ]. Neonatal lupus accounts for 90 to 95 percent of cases of congenital heart block occurring in utero or in the neonatal period. Most mothers of babies with neonatal lupus do not have SLE or another autoimmune disease, although they may develop such a disorder over time. The pathogenesis and clinical features of the neonatal lupus syndrome, as well as the management of congenital complete heart block, are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=see_link\">",
"     \"Neonatal lupus\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=see_link\">",
"     \"Congenital third degree (complete) atrioventricular block\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717425\">",
"    <span class=\"h2\">",
"     Anti-Ro preceding autoimmune disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Autoantibodies may precede the diagnosis of SLE by years, if not decades. A study using serum samples of 130 patients with known SLE from the Department of Defense Serum Repository to test for the presence of autoantibodies (by ELISA) prior to the diagnosis detected anti-Ro antibodies in 48 percent of the patients [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/40\">",
"     40",
"    </a>",
"    ]. The mean interval between the dates of the stored serum sample in which anti-Ro antibodies were present and of the diagnosis of SLE was longer than 3.6 years. Relative to all other autoantibodies tested, anti-Ro antibodies were the first to develop in patients who eventually were diagnosed with SLE. The number of normal individuals who are anti-Ro antibody positive but who never develop an autoimmune disease is unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8189318\">",
"    <span class=\"h2\">",
"     Anti-Ro in patients with cutaneous lupus erythematosus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Ro antibodies are frequently detected in patients with dermatologic manifestations of lupus erythematosus. In one study, anti-Ro antibodies were detected in 173 of 235 (74 percent) of patients with subacute cutaneous lupus erythematosus (SCLE) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/41\">",
"     41",
"    </a>",
"    ]. The relationship between anti-Ro antibodies and cutaneous photosensitivity is uncertain. One report suggests that the presence of anti-Sm antibodies, rather than anti-Ro antibodies, is associated with photosensitivity in patients with SLE [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11717440\">",
"    <span class=\"h2\">",
"     Anti-Ro and other autoimmune diseases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-Ro antibodies may be present in conditions other than SLE and Sj&ouml;gren&rsquo;s syndrome, including primary biliary cirrhosis (PBC), IIM, and RA. Anti-Ro52 antibodies were detected in 28 to 32 percent of patients with PBC, in whom their presence may provide an important clue to the diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Anti-Ro antibodies have also been detected in 6 to 12 percent of patients with rheumatoid arthritis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. No difference was seen between the clinical presentations of anti-Ro antibody-positive versus anti-Ro antibody-negative patients. However, one study suggests that RA patients with anti-Ro antibodies may have a poorer clinical response to treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    , a tumor necrosis factor (TNF) inhibitor, compared with patients lacking such autoantibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8189358\">",
"    <span class=\"h2\">",
"     Anti-Ro antibody-negative, anti-La antibody-positive patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anti-La antibodies are rarely detected in the absence of anti-Ro antibodies. In a study of 201 mothers of children with neonatal lupus syndrome, 113 had antibodies directed against both Ro and La, and 85 had antibodies directed against Ro alone. Only three patients were found to have anti-La antibodies in the absence of anti-Ro antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/30\">",
"     30",
"    </a>",
"    ]. Among 335 patients with Sj&ouml;gren&rsquo;s syndrome, 74 had both anti-Ro and anti-La antibodies, and 85 had only anti-Ro antibodies. Only four patients were anti-Ro antibody-negative and anti-La antibody-positive [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/49\">",
"     49",
"    </a>",
"    ]. Among 165 PBC patients who had ANA, 58 were anti-Ro and anti-La antibody positive, and 61 had only anti-Ro antibodies. Two patients had only anti-La antibodies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8568/abstract/50\">",
"     50",
"    </a>",
"    ]. These studies demonstrate that anti-Ro antibody-negative, anti-La antibody-positive patients are uncommon; the clinical significance of this combination of serological results is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR ANTI-RO AND ANTI-LA TESTING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision to obtain testing for anti-Ro and anti-La antibodies, using solid phase assays, depends upon the clinical setting. Patients in whom testing for anti-Ro and anti-La antibodies is indicated include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptoms that suggest Sj&ouml;gren&rsquo;s syndrome, such as xerostomia, keratoconjunctivitis sicca,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      salivary and lacrimal gland enlargement, regardless of ANA testing (see",
"      <a class=\"local\" href=\"#H11717369\">",
"       'Sj&ouml;gren&rsquo;s syndrome'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=see_link\">",
"       \"Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=see_link\">",
"       \"Classification and diagnosis of Sj&ouml;gren's syndrome\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Women with SLE or Sj&ouml;gren&rsquo;s syndrome who wish to become pregnant",
"     </li>",
"     <li>",
"      Women (with or without a systemic autoimmune disease) who have a history of giving birth to a child with congenital heart block (see",
"      <a class=\"local\" href=\"#H11717418\">",
"       'Neonatal lupus syndrome'",
"      </a>",
"      above)",
"     </li>",
"     <li>",
"      Women planning to become pregnant who are known to be ANA-positive. The utility of such testing is uncertain.",
"     </li>",
"     <li>",
"      Patients suspected of having SLE in whom the screening indirect immunofluorescence test for ANA is negative. Such testing should employ a solid phase assay because anti-Ro antibodies may not be detected by indirect immunofluorescence using a traditional Hep-2 cell substrate. (See",
"      <a class=\"local\" href=\"#H11717383\">",
"       'Anti-Ro and &ldquo;ANA-negative&rdquo; SLE'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H107571872\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum containing autoantibodies directed against the",
"      <span class=\"nowrap\">",
"       Ro/SSA",
"      </span>",
"      autoantigens may recognize one or both of two cellular proteins with molecular weights of approximately 52 and 60 kD; the autoantigens are referred to as &ldquo;Ro52&rdquo; and &ldquo;Ro60,&rdquo; respectively. Ro60 is localized to the nucleus and nucleolus, and Ro52 is localized to the cytoplasm. (See",
"      <a class=\"local\" href=\"#H11717198\">",
"       'Ro/SSA antigens'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Autoantibodies directed against the",
"      <span class=\"nowrap\">",
"       La/SSB",
"      </span>",
"      autoantigen (La) interact with a 47-kD protein, which shuttles between the nucleus and cytoplasm but which is predominantly found in the nucleus. (See",
"      <a class=\"local\" href=\"#H11717236\">",
"       'La/SSB antigen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Solid phase assays, including enzyme linked immunosorbent assays (ELISA) and flow cytometry-based assays, with either native or recombinant protein as substrate, are generally used to detect antibodies directed against the Ro and La antigens. Anti-Ro antibodies may not be detected by indirect immunofluorescence using a traditional Hep-2 cell substrate. (See",
"      <a class=\"local\" href=\"#H29645360\">",
"       'Immunofluorescence staining on HEp-2 substrates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H349797881\">",
"       'Detection of anti-Ro and anti-La antibodies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anti-Ro antibodies may be present in patients with a range of autoimmune disorders, including systemic lupus erythematosus (SLE), Sj&ouml;gren&rsquo;s syndrome, dermatomyositis or polymyositis, systemic sclerosis, primary biliary cirrhosis, and rheumatoid arthritis. Women with anti-Ro (with or without co-occurring anti-La) autoantibodies are at increased risk for having a child with neonatal lupus syndrome. Anti-Ro antibodies may be the only autoantibodies present in more than half of the patients with &ldquo;antinuclear antibody (ANA)-negative&rdquo; SLE. The combination of anti-Ro and anti-La antibodies is relatively specific for the diagnoses of SLE and Sj&ouml;gren&rsquo;s syndrome. (See",
"      <a class=\"local\" href=\"#H11717265\">",
"       'Clinical significance'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients in whom testing for anti-Ro and anti-La antibodies is indicated include (see",
"      <a class=\"local\" href=\"#H11\">",
"       'Indications for anti-Ro and anti-La testing'",
"      </a>",
"      above):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patients with findings that suggest Sj&ouml;gren&rsquo;s syndrome",
"     </li>",
"     <li>",
"      Women with SLE or Sj&ouml;gren&rsquo;s syndrome who wish to become pregnant",
"     </li>",
"     <li>",
"      Women with a history of giving birth to a child with congenital heart block",
"     </li>",
"     <li>",
"      Women planning to become pregnant who are known to be ANA-positive, although the utility of such testing is uncertain",
"     </li>",
"     <li>",
"      Patients with symptoms and findings that suggest the diagnosis of SLE in whom the indirect immunofluorescence test for ANA is negative",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3790491\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editors of UpToDate, Inc. would like to acknowledge Morris Reichlin, MD, who contributed to earlier versions of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/1\">",
"      Deutscher SL, Harley JB, Keene JD. Molecular analysis of the 60-kDa human Ro ribonucleoprotein. Proc Natl Acad Sci U S A 1988; 85:9479.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/2\">",
"      Ben-Chetrit E, Gandy BJ, Tan EM, Sullivan KF. Isolation and characterization of a cDNA clone encoding the 60-kD component of the human SS-A/Ro ribonucleoprotein autoantigen. J Clin Invest 1989; 83:1284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/3\">",
"      Chan EK, Hamel JC, Buyon JP, Tan EM. Molecular definition and sequence motifs of the 52-kD component of human SS-A/Ro autoantigen. J Clin Invest 1991; 87:68.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/4\">",
"      Wada K, Kamitani T. Autoantigen Ro52 is an E3 ubiquitin ligase. Biochem Biophys Res Commun 2006; 339:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/5\">",
"      Verhagen AP, Pruijn GJ. Are the Ro RNP-associated Y RNAs concealing microRNAs? Y RNA-derived miRNAs may be involved in autoimmunity. Bioessays 2011; 33:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/6\">",
"      Fuchs G, Stein AJ, Fu C, et al. Structural and biochemical basis for misfolded RNA recognition by the Ro autoantigen. Nat Struct Mol Biol 2006; 13:1002.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/7\">",
"      Xue D, Shi H, Smith JD, et al. A lupus-like syndrome develops in mice lacking the Ro 60-kDa protein, a major lupus autoantigen. Proc Natl Acad Sci U S A 2003; 100:7503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/8\">",
"      Keeble AH, Khan Z, Forster A, James LC. TRIM21 is an IgG receptor that is structurally, thermodynamically, and kinetically conserved. Proc Natl Acad Sci U S A 2008; 105:6045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/9\">",
"      Takahata M, Bohgaki M, Tsukiyama T, et al. Ro52 functionally interacts with IgG1 and regulates its quality control via the ERAD system. Mol Immunol 2008; 45:2045.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/10\">",
"      Yamochi T, Ohnuma K, Hosono O, et al. SSA/Ro52 autoantigen interacts with Dcp2 to enhance its decapping activity. Biochem Biophys Res Commun 2008; 370:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/11\">",
"      Wada K, Niida M, Tanaka M, Kamitani T. Ro52-mediated monoubiquitination of IKK{beta} down-regulates NF-{kappa}B signalling. J Biochem 2009; 146:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/12\">",
"      Higgs R, N&iacute; Gabhann J, Ben Larbi N, et al. The E3 ubiquitin ligase Ro52 negatively regulates IFN-beta production post-pathogen recognition by polyubiquitin-mediated degradation of IRF3. J Immunol 2008; 181:1780.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/13\">",
"      Higgs R, Lazzari E, Wynne C, et al. Self protection from anti-viral responses--Ro52 promotes degradation of the transcription factor IRF7 downstream of the viral Toll-Like receptors. PLoS One 2010; 5:e11776.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/14\">",
"      Espinosa A, Dardalhon V, Brauner S, et al. Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway. J Exp Med 2009; 206:1661.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/15\">",
"      Bolland S, Garcia-Sastre A. Vicious circle: systemic autoreactivity in Ro52/TRIM21-deficient mice. J Exp Med 2009; 206:1647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/16\">",
"      Fok V, Friend K, Steitz JA. Epstein-Barr virus noncoding RNAs are confined to the nucleus, whereas their partner, the human La protein, undergoes nucleocytoplasmic shuttling. J Cell Biol 2006; 173:319.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/17\">",
"      Chambers JC, Kenan D, Martin BJ, Keene JD. Genomic structure and amino acid sequence domains of the human La autoantigen. J Biol Chem 1988; 263:18043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/18\">",
"      Alfano C, Sanfelice D, Babon J, et al. Structural analysis of cooperative RNA binding by the La motif and central RRM domain of human La protein. Nat Struct Mol Biol 2004; 11:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/19\">",
"      Teplova M, Yuan YR, Phan AT, et al. Structural basis for recognition and sequestration of UUU(OH) 3' temini of nascent RNA polymerase III transcripts by La, a rheumatic disease autoantigen. Mol Cell 2006; 21:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/20\">",
"      Bitko V, Musiyenko A, Bayfield MA, et al. Cellular La protein shields nonsegmented negative-strand RNA viral leader RNA from RIG-I and enhances virus growth by diverse mechanisms. J Virol 2008; 82:7977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/21\">",
"      Honda M, Shimazaki T, Kaneko S. La protein is a potent regulator of replication of hepatitis C virus in patients with chronic hepatitis C through internal ribosomal entry site-directed translation. Gastroenterology 2005; 128:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/22\">",
"      Pudi R, Abhiman S, Srinivasan N, Das S. Hepatitis C virus internal ribosome entry site-mediated translation is stimulated by specific interaction of independent regions of human La autoantigen. J Biol Chem 2003; 278:12231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/23\">",
"      Cordes S, Kusov Y, Heise T, Gauss-M&uuml;ller V. La autoantigen suppresses IRES-dependent translation of the hepatitis A virus. Biochem Biophys Res Commun 2008; 368:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/24\">",
"      Inoue Y, Sato H, Fujita K, et al. Selective translation of the measles virus nucleocapsid mRNA by la protein. Front Microbiol 2011; 2:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/25\">",
"      Liu Y, Tan H, Tian H, et al. Autoantigen La promotes efficient RNAi, antiviral response, and transposon silencing by facilitating multiple-turnover RISC catalysis. Mol Cell 2011; 44:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/26\">",
"      Pollock W, Toh BH. Routine immunofluorescence detection of Ro/SS-A autoantibody using HEp-2 cells transfected with human 60 kDa Ro/SS-A. J Clin Pathol 1999; 52:684.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/27\">",
"      Fritzler MJ, Hanson C, Miller J, Eystathioy T. Specificity of autoantibodies to SS-A/Ro on a transfected and overexpressed human 60 kDa Ro autoantigen substrate. J Clin Lab Anal 2002; 16:103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/28\">",
"      Reveille JD, Solomon DH, Schur PH, Kavanaugh A. Evidence based guidelines for the use of immunologic laboratory tests: Anti-Ro (SS-A) and La (SS-B). Arthritis Care Res 2013; in press.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/29\">",
"      Franceschini F, Cavazzana I. Anti-Ro/SSA and La/SSB antibodies. Autoimmunity 2005; 38:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/30\">",
"      Izmirly PM, Kim MY, Llanos C, et al. Evaluation of the risk of anti-SSA/Ro-SSB/La antibody-associated cardiac manifestations of neonatal lupus in fetuses of mothers with systemic lupus erythematosus exposed to hydroxychloroquine. Ann Rheum Dis 2010; 69:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/31\">",
"      Llanos C, Izmirly PM, Katholi M, et al. Recurrence rates of cardiac manifestations associated with neonatal lupus and maternal/fetal risk factors. Arthritis Rheum 2009; 60:3091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/32\">",
"      Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria for Sj&ouml;gren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002; 61:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/33\">",
"      Schulte-Pelkum J, Fritzler M, Mahler M. Latest update on the Ro/SS-A autoantibody system. Autoimmun Rev 2009; 8:632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/34\">",
"      Marie I, Hatron PY, Dominique S, et al. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Semin Arthritis Rheum 2012; 41:890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/35\">",
"      Peene I, Meheus L, De Keyser S, et al. Anti-Ro52 reactivity is an independent and additional serum marker in connective tissue disease. Ann Rheum Dis 2002; 61:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/36\">",
"      Dugar M, Cox S, Limaye V, et al. Diagnostic utility of anti-Ro52 detection in systemic autoimmunity. Postgrad Med J 2010; 86:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/37\">",
"      Langguth DM, Morris S, Clifford L, et al. Specific testing for \"isolated\" anti-52 kDa SSA/Ro antibodies during standard anti-extractable nuclear antigen testing is of limited clinical value. J Clin Pathol 2007; 60:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/38\">",
"      Pourmand N, Blomberg S, R&ouml;nnblom L, et al. Ro 52kD autoantibodies are detected in a subset of ANA-negative sera. Scand J Rheumatol 2000; 29:116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/39\">",
"      Friedman DM, Rupel A, Buyon JP. Epidemiology, etiology, detection, and treatment of autoantibody-associated congenital heart block in neonatal lupus. Curr Rheumatol Rep 2007; 9:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/40\">",
"      Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/41\">",
"      Biazar C, Sigges J, Patsinakidis N, et al. Cutaneous lupus erythematosus: first multicenter database analysis of 1002 patients from the European Society of Cutaneous Lupus Erythematosus (EUSCLE). Autoimmun Rev 2013; 12:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/42\">",
"      Paz ML, Gonz&aacute;lez Maglio DH, Pino M, et al. Anti-ribonucleoproteins autoantibodies in patients with systemic autoimmune diseases. Relation with cutaneous photosensitivity. Clin Rheumatol 2011; 30:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/43\">",
"      Muratori L, Granito A, Muratori P, et al. Antimitochondrial antibodies and other antibodies in primary biliary cirrhosis: diagnostic and prognostic value. Clin Liver Dis 2008; 12:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/44\">",
"      Stinton LM, Swain M, Myers RP, et al. Autoantibodies to GW bodies and other autoantigens in primary biliary cirrhosis. Clin Exp Immunol 2011; 163:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/45\">",
"      Granito A, Muratori P, Muratori L, et al. Antibodies to SS-A/Ro-52kD and centromere in autoimmune liver disease: a clue to diagnosis and prognosis of primary biliary cirrhosis. Aliment Pharmacol Ther 2007; 26:831.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/46\">",
"      Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-Ro/SSA antibodies in rheumatoid arthritis: clinical and immunologic associations. Clin Exp Rheumatol 2006; 24:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/47\">",
"      Schneeberger E, Citera G, Heredia M, Maldonado Cocco J. Clinical significance of anti-Ro antibodies in rheumatoid arthritis. Clin Rheumatol 2008; 27:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/48\">",
"      Matsudaira R, Tamura N, Sekiya F, et al. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis. J Rheumatol 2011; 38:2346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/49\">",
"      Nardi N, Brito-Zer&oacute;n P, Ramos-Casals M, et al. Circulating auto-antibodies against nuclear and non-nuclear antigens in primary Sj&ouml;gren's syndrome: prevalence and clinical significance in 335 patients. Clin Rheumatol 2006; 25:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8568/abstract/50\">",
"      Takada K, Suzuki K, Matsumoto M, et al. Primary biliary cirrhosis in female subjects with sicca-associated antibodies. Mod Rheumatol 2007; 17:486.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1818 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-61.234.146.186-AFBC45AB80-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8568=[""].join("\n");
var outline_f8_23_8568=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H107571872\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11717191\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11717198\">",
"      Ro/SSA ANTIGENS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717213\">",
"      Ro60",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717220\">",
"      Ro52",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11717236\">",
"      La/SSB ANTIGEN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H349797881\">",
"      DETECTION OF ANTI-Ro AND ANTI-La ANTIBODIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H795098207\">",
"      Solid phase assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29645360\">",
"      Immunofluorescence staining on HEp-2 substrates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11717265\">",
"      CLINICAL SIGNIFICANCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717369\">",
"      Sj&ouml;gren&rsquo;s syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717376\">",
"      Anti-Ro60 versus anti-Ro52",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717383\">",
"      Anti-Ro and &ldquo;ANA-negative&rdquo; SLE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717418\">",
"      Neonatal lupus syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717425\">",
"      Anti-Ro preceding autoimmune disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8189318\">",
"      Anti-Ro in patients with cutaneous lupus erythematosus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11717440\">",
"      Anti-Ro and other autoimmune diseases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8189358\">",
"      Anti-Ro antibody-negative, anti-La antibody-positive patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      INDICATIONS FOR ANTI-RO AND ANTI-LA TESTING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H107571872\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3790491\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"RHEUM/1818\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"RHEUM/1818|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/54/17249\" title=\"picture 1\">",
"      Anti-Ro60 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/46/19183\" title=\"picture 2\">",
"      Anti-Ro52 staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?34/34/35361\" title=\"picture 3\">",
"      Anti-La staining",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/10/1192?source=related_link\">",
"      Antibodies to double-stranded (ds)DNA, Sm, and U1 RNP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/4/27718?source=related_link\">",
"      Antiribosomal P protein antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18794?source=related_link\">",
"      Classification and diagnosis of Sj&ouml;gren's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/1/11287?source=related_link\">",
"      Clinical manifestations of Sj&ouml;gren's syndrome: Exocrine gland disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41641?source=related_link\">",
"      Clinical manifestations, diagnosis, and natural history of primary biliary cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/8/10376?source=related_link\">",
"      Congenital third degree (complete) atrioventricular block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/16/3338?source=related_link\">",
"      Diagnosis and differential diagnosis of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/54/28520?source=related_link\">",
"      Measurement and clinical significance of antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/44/42695?source=related_link\">",
"      Miscellaneous antinuclear antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/57/24474?source=related_link\">",
"      Neonatal lupus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8569="Immunizations for patients with chronic liver disease";
var content_f8_23_8569=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunizations for patients with chronic liver disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Raymond S Koff, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8569/contributors\">",
"     Anne C Travis, MD, MSc, FACG",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/23/8569/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of patients with liver disease has changed dramatically in the last 25 years, leading to improved outcomes and survival. Prevention of liver disease also has improved; hepatitis A and B vaccines have reduced the incidence of acute viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/1\">",
"     1",
"    </a>",
"    ]. Furthermore, HepB vaccines have resulted in a decline in the sequelae of chronic hepatitis B and, despite the absence of a specific hepatitis D vaccine, a marked decrease in hepatitis D infections in the United States. Although not yet FDA approved, a hepatitis E vaccine may become available in the future [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/2\">",
"     2",
"    </a>",
"    ]. This is important since acute hepatitis E is associated with high case fatality rates in pregnant women and chronic hepatitis E has been reported in liver, kidney, and pancreas transplant recipients in France [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/3\">",
"     3",
"    </a>",
"    ]. Despite these advances, a hepatitis C vaccine has still not been achieved and chronic liver disease from multiple etiologies continues to be a prevalent health problem in the United States.",
"   </p>",
"   <p>",
"    In one sense, patients with chronic liver disease are no different from the general population. Both groups require appropriate immunizations in order to maintain their general health status. However, for some individuals with chronic liver disease due to the bloodborne pathogens, shared risk factors may result in dual infections with hepatitis B and C or exposure to hepatitis A. Data suggest that the prevalence of hepatitis A infection is higher in patients with chronic liver disease than in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/4\">",
"     4",
"    </a>",
"    ]. Furthermore, in patients with chronic liver disease or in recipients of liver transplants, the superimposition of another acute disease (hepatitis virus superinfection, influenza, and pneumococcal infection) may result in higher morbidity and mortality than in individuals without pre-existing liver disease.",
"   </p>",
"   <p>",
"    The impact of hepatitis viruses, pneumococcal disease, and influenza infection in the patient with chronic liver disease will be discussed here. Efficacy of preventive vaccines will also be discussed. For further information regarding general safety and efficacy issues related to these vaccines, please see appropriate topics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     IMPACT OF VACCINE-PREVENTABLE INFECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies of the impact of vaccine-preventable infections (hepatitis A and B, influenza, and pneumococcal disease) in chronic liver disease have been largely restricted to patients with chronic hepatitis B and C, alcoholic liver disease, compensated and decompensated cirrhosis, and liver transplant recipients. Immunization recommendations and strategies to eliminate transmission of hepatitis B infection in the United States have been developed by the Advisory Committee on Immunization Practices (ACIP) of Centers for Disease Control and Prevention (CDC) (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Data on the impact of acute viral hepatitis A and B, influenza, and pneumococcal infection on other liver diseases are sparse. Fatty liver and non-alcoholic steatohepatitis, hereditary hemochromatosis, primary biliary cirrhosis, autoimmune hepatitis, primary sclerosing cholangitis, alpha-1 antitrypsin deficiency, Wilson's disease, and granulomatous liver disease have received little attention. In one study of 225 patients with autoimmune liver diseases, all achieved seroconversion followed hepatitis A vaccination while 76 percent developed seroprotective levels of surface antibodies (anti-HBs) following",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/6\">",
"     6",
"    </a>",
"    ]. Both immunosuppressive therapy and advanced liver disease were common in nonresponders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/6\">",
"     6",
"    </a>",
"    ]. Other systemic disorders that may involve the liver (eg, celiac disease and cystic fibrosis) also have not been extensively studied. Nonetheless, HAV and HBV vaccinations have been recommended by one European group for individuals with cystic fibrosis, either at the time of diagnosis of cystic fibrosis or when liver involvement is recognized [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Acute viral hepatitis, regardless of etiology, may have deleterious consequences when occurring as a superinfection in patients with pre-existing chronic viral hepatitis or the HBV carrier state. This phenomenon was demonstrated decades ago when acute hepatitis D (HDV or delta) superinfection of patients with chronic hepatitis B was shown to result in severe and progressive disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/8\">",
"     8",
"    </a>",
"    ]. In a subsequent study of acute hepatitis in Taiwan, acute liver failure was observed in only 3.2 percent of 157 patients with acute viral hepatitis of varying etiologies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/9\">",
"     9",
"    </a>",
"    ]. In contrast, acute liver failure was seen in 20.3 percent of 177 acute hepatitis patients among HBsAg carriers. This increased risk was independent of the etiology of the acute hepatitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Acute hepatitis A",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal evidence that acute HAV superinfection could be a clinically important entity received modest attention until the publication of a longitudinal study in 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/10\">",
"     10",
"    </a>",
"    ]. Both the course and outcome of acute hepatitis A superinfection in 17 (3.9 percent) of 432 patients with pre-existing chronic HCV who were monitored for 86 months were described. In 10 of the 17 patients the course of acute HAV infection was uncomplicated and all recovered. In contrast, seven patients developed acute hepatic failure after superinfection with HAV, and six of these died. Severe hepatocyte necrosis with lymphocytic and plasma cell infiltration of the liver was evident in all patients. Outcome was probably unrelated to chronic hepatitis C disease severity, since none of the fatal cases had cirrhosis. Since HCV replication was reduced during infection with HAV, suggesting viral interference, it seemed unlikely that HCV per se was directly responsible for the severity of HAV superinfection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=see_link\">",
"     \"Overview of hepatitis A virus infection in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although the study was initially controversial due to the high fatality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/11-14\">",
"     11-14",
"    </a>",
"    ], subsequent studies have confirmed these observations in diverse regions. For example, in Thailand, 100 patients with acute hepatitis A without underlying chronic liver disease recovered fully, whereas 11 of 20 of patients with acute hepatitis A superimposed on the HBsAg carrier state and four of twelve patients with chronic hepatitis B or C developed fulminant or submassive liver necrosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/15\">",
"     15",
"    </a>",
"    ]. The average age of the patients who died was significantly older than those who survived their severe hepatitis (59 versus 40 years of age). These observations confirm the notion that HBsAg carriers, in whom liver disease is often mild, also are an increased risk of severe disease when superinfected.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Acute hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anecdotal reports of acute hepatitis B superinfection of patients with chronic hepatitis C resulting in acute liver failure have supported the notion that superinfection may be devastating [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/16\">",
"     16",
"    </a>",
"    ]. In a study of 21 patients with chronic HCV infection who developed acute hepatitis B, 28.6 percent had severe disease (encephalopathy, ascites, or hypoprothrombinemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/17\">",
"     17",
"    </a>",
"    ]. In contrast, among 20 patients with acute hepatitis B in the absence of HCV infection, none had evidence of severe disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=see_link\">",
"     \"Clinical manifestations and natural history of hepatitis B virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Acute hepatitis C",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute hepatitis C superimposed on chronic hepatitis B also appears to be a clinically severe infection. Furthermore, those patients who develop chronic hepatitis C may have a worse long-term prognosis due to an increased risk of cirrhosis and hepatocellular carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/18\">",
"     18",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=see_link\">",
"     \"Clinical manifestations and natural history of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Pneumococcal disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to individuals over 65 years of age, pneumococcal infections may be more prevalent and may elicit more severe disease and life-threatening complications in those with underlying medical conditions, regardless of age. In patients with chronic liver disease, and particularly in liver disease as a consequence of alcohol abuse, the incidence of pneumococcal disease is increased [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/19-21\">",
"     19-21",
"    </a>",
"    ]. Patients with alcoholism also are likely to have an increased risk of dying from pneumococcal disease, including pneumonia, meningitis, and septicemia.",
"   </p>",
"   <p>",
"    Some of these observations may be related to defective antibody formation, poor functioning of polymorphonuclear cells, malnutrition and general debilitation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=see_link\">",
"     \"Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Influenza",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited anecdotal reports indicate that influenza virus infection has been associated with hepatic decompensation in patients with advanced chronic liver disease and in recipients of liver transplants [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     VACCINES IN CHRONIC LIVER DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Hepatitis A vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP) has recommended the immunization of all patients with chronic liver disease against hepatitis A [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=see_link\">",
"     \"Hepatitis A virus vaccination and postexposure prophylaxis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a large US multicenter evaluation of the immunogenicity of the two-dose inactivated HepA vaccine in 475 adult patients with compensated chronic liver disease and 188 healthy control subjects, 95 percent of the liver disease patients seroconverted versus 98 percent of controls [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/26\">",
"     26",
"    </a>",
"    ]. However, post-vaccination titers of anti-HAV were lower in the patients with liver disease than in controls. A similar reduction in anti-HAV titers was seen in 65 HBV-infected patients from Hong Kong when compared to 28 healthy controls [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/27\">",
"     27",
"    </a>",
"    ]. Whether this will have any impact on the duration of immunity remains uncertain.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     Hepatitis A vaccine",
"    </a>",
"    has been demonstrated to be effective in children with chronic liver disease as well, although the titers of protective antibody were significantly lower in those with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/28,29\">",
"     28,29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The immunogenicity of the HepA vaccine in patients with more advanced liver disease or decompensated disease is reduced. In three separate studies of patients with hepatic decompensation, seroconversion rates varied from 49 percent to 66 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/30-32\">",
"     30-32",
"    </a>",
"    ]. In liver transplant recipients, immunogenicity of the HepA vaccine is also compromised [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/33\">",
"     33",
"    </a>",
"    ] and antibody titers may wane over time [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/34,35\">",
"     34,35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The American College of Immunization Practices does not recommend routine post-immunization testing of vaccination titers. The efficacy of repeat HAV immunization has not been studied.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inactivated HepA vaccines are well tolerated with minimal side effects. No special precautions or monitoring are necessary following vaccination of patients with chronic liver disease. No serious adverse events have been identified in recipients of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/30/44518?source=see_link\">",
"     hepatitis A vaccine",
"    </a>",
"    and because the vaccine is inactivated there are no concerns about immunizing immunocompromised individuals other than the possibility of a reduced immune response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Hepatitis B vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP recommends that chronic liver disease patients with risk factors for hepatitis B should be immunized with the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5,36\">",
"     5,36",
"    </a>",
"    ]. Since about 33 percent of patients with acute hepatitis B fail to report identifiable risk factors, we recommend immunization of all chronic liver disease patients, regardless of risk factor history. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Available information suggests that the immunogenicity of the HepB vaccine is unimpaired in patients with fatty liver [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/37\">",
"     37",
"    </a>",
"    ], but is reduced in patients with other chronic liver diseases and in liver transplant recipients. In one small study, utilizing recombinant HepB vaccine given at 0, 1, and 2 months, seroconversion rates measured three months after the first dose were 94 percent in 16 patients with fatty liver versus 39 percent in 13 patients with cirrhosis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a prospective study of 85 patients with chronic hepatitis C and 46 healthy adults, non-response to the three-dose regimen of the recombinant HepB vaccine was reported in 45 percent of patients and 2 percent in the control group [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/38\">",
"     38",
"    </a>",
"    ]. No difference in vaccine response was found when patients with cirrhosis were compared to those without cirrhosis. Earlier studies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/39-41\">",
"     39-41",
"    </a>",
"    ] showed response rates in hepatitis C patients varying between 69 to 100 percent. Impaired immunogenicity has been described in patients with alcoholic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/42-44\">",
"     42-44",
"    </a>",
"    ], liver transplant recipients, and in those awaiting liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/45-47\">",
"     45-47",
"    </a>",
"    ]. In contrast, a success rate of 90 percent was observed among 19 Korean pediatric patients after liver transplantation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/48\">",
"     48",
"    </a>",
"    ], suggesting that age is an important determinant of response.",
"   </p>",
"   <p>",
"    HepB vaccine immunogenicity in patients with chronic hepatitis C, vaccinated while receiving treatment with pegylated-interferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/25/27033?source=see_link\">",
"     ribavirin",
"    </a>",
"    , remains ill defined. In a small study in Greece, HepB vaccine was given concomitantly with pegylated-interferon and ribavirin to 15 patients with chronic hepatitis C and to 15 patients with chronic hepatitis C without treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/49\">",
"     49",
"    </a>",
"    ]. Seroconversion rates one month after the third dose were lower in the group receiving treatment when compared to the untreated group (87 versus 93 percent), but this difference was not statistically significant. A larger study will be required to determine the impact of HBV and HAV vaccination during treatment for hepatitis C.",
"   </p>",
"   <p>",
"    Strategies to improve the immunogenicity of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"     hepatitis B vaccine",
"    </a>",
"    in this patient population have been studied:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A randomized, double-blind trial in 110 alcoholic patients was conducted to assess whether the use of high-dose versus standard-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      would be more effective [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/44\">",
"       44",
"      </a>",
"      ]. Patients were randomly assigned to 20 micrograms at baseline, one, and six months versus 40 micrograms at baseline, one, two, and six months. Seroconversion rates were improved in the high-dose arm (75 versus 46 percent).",
"     </li>",
"     <li>",
"      Accelerated high-dose regimens have also been studied in transplant candidates and in transplant recipients without a control group [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/46,47\">",
"       46,47",
"      </a>",
"      ]; although overall seroconversion rates were low in both studies, there was some suggestion that the patients with a double dose of vaccine had modest improvement in seroconversion rates.",
"     </li>",
"     <li>",
"      The use of anti-HBs immunoglobulins to enhance the immunogenicity of the three-dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      schedule in alcoholic patients was unsuccessful in one small study of 25 patients [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Testing for post-immunization antibody titers is not recommended; exceptions include patients at increased risk for recurrent exposure. This includes healthcare workers, patients on chronic hemodialysis, and other individuals (such as gay or bisexual men, and sexual partners of carriers). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"     \"Hepatitis B virus vaccination\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some experts also test for post-immunization antibody titers in patients with chronic liver diseases, due to the risk of severe infection in this subgroup. If the patient has not achieved seroconversion, repeat immunization with a high-dose HBV immunization schedule may be considered, although this approach has not been studied among nonresponders with chronic liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1286917481\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The safety of the initial plasma-derived and the recombinant HepB vaccines has been well documented in patients with chronic liver disease. Adverse events do not differ from those seen in healthy individuals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hepatitis C vaccine",
"    </span>",
"    &nbsp;&mdash;&nbsp;No prophylactic or therapeutic vaccine for hepatitis C exists. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=see_link\">",
"     \"Investigational therapies for hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Pneumococcal vaccine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 23-valent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12422?source=see_link\">",
"     pneumococcal polysaccharide vaccine",
"    </a>",
"    (PPSV23) is recommended for use in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ]. Large studies of the immunogenicity of pneumococcal vaccine in patients with chronic liver disease are not available and the spectrum of liver disease evaluated has been narrow [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In one small study of 15 patients with alcohol-related cirrhosis, antibody titers after pneumococcal immunization were comparable to healthy volunteers [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/50\">",
"     50",
"    </a>",
"    ]. Despite the paucity of data, the Advisory Committee on Immunization Practices recommends immunization against pneumococcal infection in patients with chronic liver disease in view of the potential risks of invasive disease by this pathogen [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ]. The cost-effectiveness of this recommendation is uncertain. &nbsp;",
"   </p>",
"   <p>",
"    Patients who have already developed advanced disease have a diminished response to vaccination. In one study of 45 transplant candidates of whom 25 received a new liver, as well as 13 age-matched healthy controls, the immune response to pneumococcal vaccine was weaker in the transplant patients; by three months post-transplantation the antibody titers had fallen to or below pre-vaccination levels [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/51\">",
"     51",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=see_link\">",
"     \"Pneumococcal vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;No specific safety issues have been described.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Influenza vaccine",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h3\">",
"     Immunogenicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune response to influenza vaccine in patients with chronic liver disease has not been extensively studied [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=see_link\">",
"     \"Seasonal influenza vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a controlled prospective study from Korea, 198 patients with cirrhosis were vaccinated with a trivalent influenza vaccine and 113 were unvaccinated [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/55\">",
"       55",
"      </a>",
"      ]. Immunization was associated with decreased rates of influenza-like illness and complications and viral culture positivity [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/55\">",
"       55",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The immune response to an adjuvanted trivalent influenza vaccine was studied in 20 Italian patients with cirrhosis due to chronic hepatitis B or C and eight age-matched healthy controls [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/53\">",
"       53",
"      </a>",
"      ]. Seroconversion or a fourfold or greater rise in antibody titers to each antigen occurred in 75 to 85 percent of patients and 100 percent of controls, suggesting a mild impairment of immunogenicity in these patients with cirrhosis.",
"     </li>",
"     <li>",
"      Two studies of the effectiveness of influenza vaccine in transplant recipients demonstrated conflicting results [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/54,56\">",
"       54,56",
"      </a>",
"      ]. In a subsequent study of 51 liver transplant recipients, antibody responses developed in 14 percent of patients vaccinated within four months of transplantation and in 67 percent immunized between month 4 and 12, suggesting that efficacy may improve further out from the time of transplant [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/57\">",
"       57",
"      </a>",
"      ]. Whether a two-dose vaccination strategy would improve responsiveness has been suggested [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/58\">",
"       58",
"      </a>",
"      ] but has not been adequately studied.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Safety",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inactivated vaccines are generally well tolerated, with reactions seen in fewer than 5 percent of cases. There are no data about special safety concerns in patients with liver disease. Inactivated vaccine is recommended for use in patients with hepatic dysfunction by the Advisory Committee on Immunization Practices [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no specific data on the use of intranasal live-attenuated vaccine in patients with liver disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Routine immunizations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ACIP publishes vaccination schedules for measles, mumps and rubella; diphtheria and tetanus and acellular pertussis; zoster and other vaccines in persons with chronic medical conditions (",
"    <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no specific data on the use of these vaccines in patients with chronic liver disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A retrospective study demonstrated that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/4/5190?source=see_link\">",
"     herpes zoster vaccine",
"    </a>",
"    was associated with a significantly reduced risk of herpes zoster disease by more than 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/59\">",
"     59",
"    </a>",
"    ]. This vaccine benefit was also seen among persons with chronic medical conditions, including liver disease. Herpes zoster immunization is recommended in persons over the age of 60. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=see_link&amp;anchor=H5#H5\">",
"     \"Prevention of varicella-zoster virus infection: Herpes zoster\", section on 'Adults &ge;60 years of age'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Meningococcal and Haemophilus influenzae vaccines",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with advanced liver disease who may be undergoing splenectomy for other medical conditions (eg, idiopathic thrombocytopenia) should be considered for meningococcal and Haemophilus influenzae vaccines. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"     \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     VACCINE RECOMMENDATIONS AND COVERAGE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Guidelines recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Advisory Committee on Immunization Practices (ACIP) recommends hepatitis A and hepatitis B vaccines along with tetanus, diphtheria, and acellular pertussis, pneumococcal (",
"    <a class=\"graphic graphic_table graphicRef86782 \" href=\"UTD.htm?11/48/12046\">",
"     table 1",
"    </a>",
"    ), and yearly seasonal influenza vaccines for patients with chronic liver disease [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A one-time revaccination with pneumococcal vaccine is recommended by the ACIP after five years for persons with various medical conditions, including \"functional asplenia\" [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ]. For persons aged 65 years and older, a one-time revaccination is also recommended if they were vaccinated five or more years previously.",
"   </p>",
"   <p>",
"    Since persons with liver disease are at increased risk of pneumococcal infections, which may be due to acquired immunodeficiency and splenic dysfunction, we also routinely revaccinate our patients on a one-time basis according to the ACIP schedule [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Missed opportunities",
"    </span>",
"    &nbsp;&mdash;&nbsp;However, many missed opportunities for vaccine administration occur despite widespread recognition of the importance of immunizations in disease prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/60\">",
"     60",
"    </a>",
"    ]. As a consequence, immunization appears to be underutilized in patients with chronic liver disease.",
"   </p>",
"   <p>",
"    The US Department of Veterans Affairs has recommended the HepA vaccine for susceptible patients with chronic liver disease. A retrospective study was undertaken between 2000 and 2002 in two VA medical centers in New York to assess the frequency of testing for susceptibility to HAV and administration of the HepA vaccine to patients with chronic hepatitis C with the following results [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Despite multiple visits to their primary care practitioners or to the Gastroenterology Clinic, only 54 percent of the 1193 chronic hepatitis C patients identified had been tested for anti-HAV.",
"     </li>",
"     <li>",
"      Older patients and those with psychiatric disorders were less likely to be tested, while those with a history of an STD or those seen in the Gastroenterology Clinic were more likely to be tested.",
"     </li>",
"     <li>",
"      Slightly more than half the tested patients were immune and did not require HAV vaccination. Among the susceptible, only 27 percent received at least one dose of the HepA vaccine.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical importance of this study in these two centers takes on added significance with the observation that on follow-up 3 of the 1193 chronic hepatitis C patients in this study developed acute hepatitis A and one of these died of acute liver failure. All three patients were susceptible to HAV and none had received the HepA vaccine.",
"   </p>",
"   <p>",
"    In a separate retrospective cohort study of chronic hepatitis C patients receiving care at a large Veterans Administration Medical Center between 2002 and 2005, only 8 percent had documented receipt of hepatitis vaccines. Of those patients who had not been vaccinated, half had not been tested for susceptibility nor had negative serologies [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Variations in coverage rates between primary care and specialist centers, such as gastroenterology and hepatology practices, involved in the care of patients with chronic liver disease are receiving attention. In a retrospective analysis of vaccine coverage in almost 700 patients with chronic liver disease seen by 22 primary care offices (337 patients) and 15 gastroenterologists or hepatologists (356 patients), chronic hepatitis C was the most common diagnosis, followed by non-alcoholic liver disease, alcoholic liver disease, and chronic hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8569/abstract/62\">",
"     62",
"    </a>",
"    ]. The study was notable for the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients seen in primary care offices were more likely to receive seasonal influenza and pneumococcal vaccine than the patients who frequented specialty offices.",
"     </li>",
"     <li>",
"      Of patients who were susceptible to HAV and HBV, patients were much more likely to receive hepatitis A or B vaccines if they were seen in specialist offices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Better communication between primary care personnel and specialists, with explicit understanding of which office will assume responsibility for immunization and accurate record keeping of immunization history may reduce vaccine underutilization in patients with chronic liver disease and improve health outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=see_link\">",
"       \"Patient information: Vaccines for adults (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       \"Patient information: Vaccines (The Basics)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?1/45/1746?source=see_link\">",
"       \"Patient information: Vaccines when you have hepatitis C (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=see_link\">",
"       \"Patient information: Adult vaccines (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Acute viral hepatitis in patients with chronic liver disease and in liver transplant recipients can lead to significant morbidity and mortality. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Impact of vaccine-preventable infections'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest vaccination of all patients with chronic liver disease against hepatitis A and B unless they are already immune (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). However, there remains uncertainty about how chronic liver disease should be defined. It is possible, for example, that patients with non-alcoholic fatty liver disease alone may not be at the same risk for serious morbidity from acute viral hepatitis as those with underlying hepatitis C. Until further data are available to better define the risks with specific forms of liver disease and the cost-effectiveness of vaccination strategies, we suggest immunization for patients with all forms of liver disease regardless of its severity. The benefits of vaccination are expected to be greatest in those with relatively advanced disease or those at risk for progressive liver disease. This recommendation also considers the safety of the available vaccinations. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Vaccines in chronic liver disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest pneumococcal vaccination in all adult patients with chronic liver disease, regardless of age (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). We suggest a one-time revaccination in patients who are over 65 years of age and who had their prior immunization greater than five years previously (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). We suggest a one-time revaccination in patients who are subsequently diagnosed with invasive pneumococcal disease, although the benefit of this intervention is unknown (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Pneumococcal vaccine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with liver disease should receive standard immunizations that are applicable to an otherwise healthy population (",
"      <a class=\"graphic graphic_figure graphicRef62130 \" href=\"UTD.htm?41/17/42263\">",
"       figure 1",
"      </a>",
"      ). This includes routine diphtheria and tetanus booster immunizations every ten years. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"       \"Tetanus-diphtheria toxoid vaccination in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Haemophilus influenzae and meningococcal vaccines should be administered to those who require a splenectomy. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=see_link&amp;anchor=H4#H4\">",
"       \"Prevention of sepsis in the asplenic patient\", section on 'Immunizations'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      We suggest",
"      <strong>",
"       not",
"      </strong>",
"      routinely obtaining antibody titers after immunization to determine efficacy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). Exceptions may be testing for response to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?26/36/27207?source=see_link\">",
"       hepatitis B vaccine",
"      </a>",
"      in patients with advanced disease and those at increased risk for recurrent exposure. This includes healthcare workers, patients on chronic hemodialysis, and other individuals (such as gay or bisexual men, and spouses of carriers). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=see_link\">",
"       \"Hepatitis B virus vaccination\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Centers for Disease Control and Prevention. Hepatitis Surveillance Report No. 60. Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, 2005.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/2\">",
"      Shrestha MP, Scott RM, Joshi DM, et al. Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med 2007; 356:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/3\">",
"      Kamar N, Selves J, Mansuy JM, et al. Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 2008; 358:811.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/4\">",
"      Saab S, Lee C, Shpaner A, Ibrahim AB. Seroepidemiology of hepatitis A in patients with chronic liver disease. J Viral Hepat 2005; 12:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/5\">",
"      ACIP Adult Immunization Work Group, Bridges CB, Woods L, et al. Advisory Committee on Immunization Practices (ACIP) recommended immunization schedule for adults aged 19 years and older--United States, 2013. MMWR Surveill Summ 2013; 62 Suppl 1:9.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/6\">",
"      W&ouml;rns MA, Teufel A, Kanzler S, et al. Incidence of HAV and HBV infections and vaccination rates in patients with autoimmune liver diseases. Am J Gastroenterol 2008; 103:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/7\">",
"      Malfroot A, Adam G, Ciofu O, et al. Immunisation in the current management of cystic fibrosis patients. J Cyst Fibros 2005; 4:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/8\">",
"      Rizzetto M, Bonino F, Verme G. Hepatitis delta virus infection of the liver: progress in virology, pathobiology, and diagnosis. Semin Liver Dis 1988; 8:350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/9\">",
"      Chu CM, Liaw YF. Increased incidence of fulminant hepatic failure in previously unrecognized HBsAg carriers with acute hepatitis independent of etiology. Infection 2005; 33:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/10\">",
"      Vento S, Garofano T, Renzini C, et al. Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/11\">",
"      Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:1771; author reply 1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/12\">",
"      Hasle G, Hoel T, Jensenius M. Mortality of hepatitis A in adults with hepatitis C antibodies. Lancet 1998; 351:1888.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/13\">",
"      Martins EB. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:1772; author reply 1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/14\">",
"      Mele A, Tosti ME, Stroffolini T. Hepatitis associated with hepatitis A superinfection in patients with chronic hepatitis C. N Engl J Med 1998; 338:1771; author reply 1772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/15\">",
"      Pramoolsinsap C, Poovorawan Y, Hirsch P, et al. Acute, hepatitis-A super-infection in HBV carriers, or chronic liver disease related to HBV or HCV. Ann Trop Med Parasitol 1999; 93:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/16\">",
"      Liaw YF, Yeh CT, Tsai SL. Impact of acute hepatitis B virus superinfection on chronic hepatitis C virus infection. Am J Gastroenterol 2000; 95:2978.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/17\">",
"      Sagnelli E, Coppola N, Messina V, et al. HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. Hepatology 2002; 36:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/18\">",
"      Liaw YF, Chen YC, Sheen IS, et al. Impact of acute hepatitis C virus superinfection in patients with chronic hepatitis B virus infection. Gastroenterology 2004; 126:1024.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/19\">",
"      Burman LA, Norrby R, Trollfors B. Invasive pneumococcal infections: incidence, predisposing factors, and prognosis. Rev Infect Dis 1985; 7:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/20\">",
"      Lipsky BA, Boyko EJ, Inui TS, Koepsell TD. Risk factors for acquiring pneumococcal infections. Arch Intern Med 1986; 146:2179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/21\">",
"      Prevention of pneumococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 1997; 46(RR-8):1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/22\">",
"      Gluckman SJ, Dvorak VC, MacGregor RR. Host defenses during prolonged alcohol consumption in a controlled environment. Arch Intern Med 1977; 137:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/23\">",
"      Spinozzi F, Cimignoli E, Gerli R, et al. IgG subclass deficiency and sinopulmonary bacterial infections in patients with alcoholic liver disease. Arch Intern Med 1992; 152:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/24\">",
"      Duchini A, Viernes ME, Nyberg LM, et al. Hepatic decompensation in patients with cirrhosis during infection with influenza A. Arch Intern Med 2000; 160:113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/25\">",
"      Vilchez RA, Fung JJ, Kusne S. Influenza A myocarditis developing in an adult liver transplant recipient despite vaccination: a case report and review of the literature. Transplantation 2000; 70:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/26\">",
"      Keeffe EB, Iwarson S, McMahon BJ, et al. Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology 1998; 27:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/27\">",
"      Tsang SW, Sung JJ. Inactivated hepatitis A vaccine in Chinese patients with chronic hepatitis B infection. Aliment Pharmacol Ther 1999; 13:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/28\">",
"      Majda-Stanislawska E, Bednarek M, Kuydowicz J. Immunogenicity of inactivated hepatitis A vaccine in children with chronic liver disease. Pediatr Infect Dis J 2004; 23:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/29\">",
"      Ferreira CT, da Silveira TR, Vieira SM, et al. Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease. J Pediatr Gastroenterol Nutr 2003; 37:258.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/30\">",
"      Smallwood GA, Coloura CT, Martinez E, et al. Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine? Transplant Proc 2002; 34:3289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/31\">",
"      Dumot JA, Barnes DS, Younossi Z, et al. Immunogenicity of hepatitis A vaccine in decompensated liver disease. Am J Gastroenterol 1999; 94:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/32\">",
"      Arguedas MR, Johnson A, Eloubeidi MA, Fallon MB. Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients. Hepatology 2001; 34:28.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/33\">",
"      Arslan M, Wiesner RH, Poterucha JJ, Zein NN. Safety and efficacy of hepatitis A vaccination in liver transplantation recipients. Transplantation 2001; 72:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/34\">",
"      Stark K, G&uuml;nther M, Neuhaus R, et al. Immunogenicity and safety of hepatitis A vaccine in liver and renal transplant recipients. J Infect Dis 1999; 180:2014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/35\">",
"      G&uuml;nther M, Stark K, Neuhaus R, et al. Rapid decline of antibodies after hepatitis A immunization in liver and renal transplant recipients. Transplantation 2001; 71:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/36\">",
"      Sexually transmitted diseases treatment guidelines 2002. Centers for Disease Control and Prevention. MMWR Recomm Rep 2002; 51:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/37\">",
"      Ko��li��ska-Berkan E, Kuydowicz J. [The comparison of the humoral response among the patients with liver cirrhosis and steatosis of the liver after HBV vaccination]. Przegl Epidemiol 2006; 60:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/38\">",
"      Mattos AA, Gomes EB, Tovo CV, et al. Hepatitis B vaccine efficacy in patients with chronic liver disease by hepatitis C virus. Arq Gastroenterol 2004; 41:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/39\">",
"      Keeffe EB, Krause DS. Hepatitis B vaccination of patients with chronic liver disease. Liver Transpl Surg 1998; 4:437.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/40\">",
"      Lee SD, Chan CY, Yu MI, et al. Hepatitis B vaccination in patients with chronic hepatitis C. J Med Virol 1999; 59:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/41\">",
"      Wiedmann M, Liebert UG, Oesen U, et al. Decreased immunogenicity of recombinant hepatitis B vaccine in chronic hepatitis C. Hepatology 2000; 31:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/42\">",
"      Mendenhall C, Roselle GA, Lybecker LA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. Dig Dis Sci 1988; 33:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/43\">",
"      Bronowicki JP, Weber-Larivaille F, Gut JP, et al. [Comparison of immunogenicity of vaccination and serovaccination against hepatitis B virus in patients with alcoholic cirrhosis]. Gastroenterol Clin Biol 1997; 21:848.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/44\">",
"      Rosman AS, Basu P, Galvin K, Lieber CS. Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: a randomized clinical trial. Am J Med 1997; 103:217.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/45\">",
"      Villeneuve E, Vincelette J, Villeneuve JP. Ineffectiveness of hepatitis B vaccination in cirrhotic patients waiting for liver transplantation. Can J Gastroenterol 2000; 14 Suppl B:59B.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/46\">",
"      Arslan M, Wiesner RH, Sievers C, et al. Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease. Liver Transpl 2001; 7:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/47\">",
"      Dom&iacute;nguez M, B&aacute;rcena R, Garc&iacute;a M, et al. Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list. Liver Transpl 2000; 6:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/48\">",
"      Chang SH, Suh KS, Yi NJ, et al. Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation. Hepatology 2003; 37:1329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/49\">",
"      Elefsiniotis IS, Vezali E, Kamposioras K, et al. Immunogenicity of recombinant hepatitis B vaccine in treatment-naive and treatment-experienced chronic hepatitis C patients: the effect of pegylated interferon plus ribavirin treatment. World J Gastroenterol 2006; 12:4420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/50\">",
"      Pirovino M, Lydick E, Grob PJ, et al. Pneumococcal vaccination: the response of patients with alcoholic liver cirrhosis. Hepatology 1984; 4:946.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/51\">",
"      McCashland TM, Preheim LC, Gentry MJ. Pneumococcal vaccine response in cirrhosis and liver transplantation. J Infect Dis 2000; 181:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/52\">",
"      Heijtink RA, Masurel N, Weimar W, Schalm SW. Influenza vaccination in HBsAg positive chronic active hepatitis patients treated with interferon. Med Microbiol Immunol 1980; 169:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/53\">",
"      Gaeta GB, Stornaiuolo G, Precone DF, et al. Immunogenicity and safety of an adjuvanted influenza vaccine in patients with decompensated cirrhosis. Vaccine 2002; 20 Suppl 5:B33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/54\">",
"      Duchini A, Hendry RM, Nyberg LM, et al. Immune response to influenza vaccine in adult liver transplant recipients. Liver Transpl 2001; 7:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/55\">",
"      Song JY, Cheong HJ, Ha SH, et al. Clinical impact of influenza immunization in patients with liver cirrhosis. J Clin Virol 2007; 39:159.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/56\">",
"      Burbach G, Bienzle U, Stark K, et al. Influenza vaccination in liver transplant recipients. Transplantation 1999; 67:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/57\">",
"      Lawal A, Basler C, Branch A, et al. Influenza vaccination in orthotopic liver transplant recipients: absence of post administration ALT elevation. Am J Transplant 2004; 4:1805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/58\">",
"      Soesman NM, Rimmelzwaan GF, Nieuwkoop NJ, et al. Efficacy of influenza vaccination in adult liver transplant recipients. J Med Virol 2000; 61:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/59\">",
"      Tseng HF, Smith N, Harpaz R, et al. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA 2011; 305:160.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/60\">",
"      Shim M, Khaykis I, Park J, Bini EJ. Susceptibility to hepatitis A in patients with chronic liver disease due to hepatitis C virus infection: missed opportunities for vaccination. Hepatology 2005; 42:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/61\">",
"      Hachem CY, Kramer JR, Kanwal F, El-Serag HB. Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Veterans Administration Medical Centre. Aliment Pharmacol Ther 2008; 28:1078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8569/abstract/62\">",
"      Jacobs RJ, Meyerhoff AS, Saab S. Immunization needs of chronic liver disease patients seen in primary care versus specialist settings. Dig Dis Sci 2005; 50:1525.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3891 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-1.234.2.38-C3DAD56939-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8569=[""].join("\n");
var outline_f8_23_8569=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H27\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      IMPACT OF VACCINE-PREVENTABLE INFECTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Acute hepatitis A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Acute hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Acute hepatitis C",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Pneumococcal disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Influenza",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      VACCINES IN CHRONIC LIVER DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Hepatitis A vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Hepatitis B vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1286917481\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hepatitis C vaccine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Pneumococcal vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Influenza vaccine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      - Immunogenicity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Safety",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Routine immunizations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Meningococcal and Haemophilus influenzae vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      VACCINE RECOMMENDATIONS AND COVERAGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Guidelines recommendations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Missed opportunities",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3891\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3891|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/17/42263\" title=\"figure 1\">",
"      Vaccine schedule based on medical conditions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3891|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/48/12046\" title=\"table 1\">",
"      Pneumococcal vaccination indications for adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/50/31530?source=related_link\">",
"      Clinical manifestations and natural history of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/26/30122?source=related_link\">",
"      Clinical manifestations and natural history of hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/38/1641?source=related_link\">",
"      Hepatitis A virus vaccination and postexposure prophylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/60/31690?source=related_link\">",
"      Hepatitis B virus vaccination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7642?source=related_link\">",
"      Invasive pneumococcal (Streptococcus pneumoniae) infections and bacteremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/30/38378?source=related_link\">",
"      Investigational therapies for hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/26/7591?source=related_link\">",
"      Overview of hepatitis A virus infection in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?38/25/39318?source=related_link\">",
"      Patient information: Adult vaccines (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?23/4/23619?source=related_link\">",
"      Patient information: Vaccines for adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?1/45/1746?source=related_link\">",
"      Patient information: Vaccines when you have hepatitis C (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/12/21705?source=related_link\">",
"      Pneumococcal vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/9/1177?source=related_link\">",
"      Prevention of sepsis in the asplenic patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/22/36200?source=related_link\">",
"      Prevention of varicella-zoster virus infection: Herpes zoster",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/8/37002?source=related_link\">",
"      Seasonal influenza vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8570="Peroxisomal disorders";
var content_f8_23_8570=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Peroxisomal disorders",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Alan K Percy, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Ronald JA Wanders, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Marc C Patterson, MD, FRACP",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Helen V Firth, DM, FRCP, DCH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?8/23/8570/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?8/23/8570/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 16, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peroxisomes are subcellular organelles with a variable diameter ranging from 0.05 to 0.5 micron in diameter, and are present in all cells except erythrocytes. The highest concentration of peroxisomes is in the liver and kidney [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/1\">",
"     1",
"    </a>",
"    ]. Although they are not present in mature erythrocytes, they are present during the early stages of erythrocyte development when membranes are formed.",
"   </p>",
"   <p>",
"    Peroxisomes catalyze numerous catabolic and anabolic functions in cellular metabolism [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Catalytic functions include beta-oxidation of very long chain fatty acids (VLCFA); oxidation of pipecolic, phytanic, pristanic, and many dicarboxylic acids; and degradation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    by catalase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Anabolic functions include synthesis of bile acids and plasmalogens, which are important components of cell membranes and myelin.",
"   </p>",
"   <p>",
"    Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism that result in impairment of peroxisome function. In most cases, this results in neurologic dysfunction of varying extent. The major peroxisomal disorders will be reviewed here. The pathophysiology, clinical manifestations, and management of adrenoleukodystrophy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peroxisomal disorders are divided into two major categories [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2,5-8\">",
"     2,5-8",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Disorders of peroxisome biogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;This group includes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Zellweger syndrome (ZWS)",
"     </li>",
"     <li>",
"      Neonatal adrenoleukodystrophy (NALD)",
"     </li>",
"     <li>",
"      Infantile Refsum disease (IRD)",
"     </li>",
"     <li>",
"      Rhizomelic chondrodysplasia punctata type 1 (RCDP1)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The first three disorders are thought to represent a clinical continuum, referred to as Zellweger spectrum disorders (ZSD), with Zellweger syndrome the most severe, infantile Refsum disease the mildest, and neonatal adrenoleukodystrophy intermediate in severity. In ZSD patients there is a generalized loss of peroxisomal functions, caused by molecular defects in genes coding for peroxins (Pex), proteins required for peroxisome biogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/9\">",
"     9",
"    </a>",
"    ]. These defects interfere with import of proteins into the peroxisome.",
"   </p>",
"   <p>",
"    In RCDP type 1, peroxisomes are present, but they lack a specific group of proteins due to mutations in the PEX7 gene. Two peroxisomal functions are impaired, including the synthesis of etherphospholipids and the alpha-oxidation of phytanic acid.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Deficiency of a single peroxisomal enzyme",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following disorders are characterized by deficiency of a single peroxisomal enzyme; peroxisome structure is intact:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      X-linked adrenoleukodystrophy (X-ALD), including adrenomyeloneuropathy (AMN) due to deficiency of adrenoleukodystrophy protein (ALDP), a peroxisomal membrane protein",
"     </li>",
"     <li>",
"      Refsum disease (phytanoyl CoA hydroxylase deficiency)",
"     </li>",
"     <li>",
"      Acyl CoA oxidase deficiency (pseudo-NALD)",
"     </li>",
"     <li>",
"      D-bifunctional protein deficiency (DBP deficiency)",
"     </li>",
"     <li>",
"      Rhizomelic chondrodysplasia punctata type 2 (RCDP2; dihydroxy-acetone phosphate acyltransferase deficiency)",
"     </li>",
"     <li>",
"      Rhizomelic chondrodysplasia punctata type 3 (RCDP3; alkyldihydroxyacetone phosphate synthase deficiency)",
"     </li>",
"     <li>",
"      Alpha-methylacyl-CoA racemase deficiency (AMACR deficiency)",
"     </li>",
"     <li>",
"      Peroxisomal sterol carrier protein-X deficiency (SCPx deficiency)",
"     </li>",
"     <li>",
"      Acatalasemia (catalase deficiency)",
"     </li>",
"     <li>",
"      Hyperoxaluria type 1 (alanine glyoxylate aminotransferase deficiency) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=see_link\">",
"       \"Primary hyperoxaluria\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peroxisomal disorders are thought to occur in at least 1 in 5 to 10,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/5\">",
"     5",
"    </a>",
"    ]. Among 1000 patients with inborn errors of metabolism seen between 1982 and 1997 at the hospital Necker&ndash;Enfants Malades in Paris, peroxisomal disorders accounted for 2.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    X-linked adrenoleukodystrophy (X-ALD) is the most common peroxisomal disorder, with an estimated frequency of 1:17,000 in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/11\">",
"     11",
"    </a>",
"    ]. No differences in frequency within ethnic groups have been demonstrated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    ZWS is the most common peroxisomal disorder to present in early infancy. The incidence is 1 in 50,000 to 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     PATHOPHYSIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peroxisomes catalyze numerous catabolic and anabolic functions in cellular metabolism. Catalytic functions include beta-oxidation of very long chain fatty acids (VLCFA); oxidation of pipecolic, phytanic, pristanic, and many dicarboxylic acids; and degradation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    by catalase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2,4\">",
"     2,4",
"    </a>",
"    ]. Anabolic functions include synthesis of bile acids and plasmalogens, which are important components of cell membranes and myelin.",
"   </p>",
"   <p>",
"    One of the hallmarks of most peroxisomal disorders is the abnormal elevation of VLCFA, especially those with 26 carbon atoms, and an increased ratio of C26 to C22 fatty acids in the plasma, as well as fibroblasts and amniocytes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/14\">",
"     14",
"    </a>",
"    ]. Accumulation of VLCFA in the membranes of neuronal cells contributes to neurologic injury [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/15\">",
"     15",
"    </a>",
"    ]. VLCFA accumulation impairs erythrocyte membrane structure and function and the capacity of cultured adrenal cells to respond to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/33/14871?source=see_link\">",
"     adrenocorticotropic hormone",
"    </a>",
"    (ACTH) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/16\">",
"     16",
"    </a>",
"    ] and impairs the stability of model membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Of note, VLCFA levels are normal in some of the peroxisomal disorders. This applies to RCDP (where deficiency of plasmalogens is the principal biochemical abnormality) and to Refsum disease (where accumulation of phytanic acid contributes to pathogenesis).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NEUROPATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The neuropathology of peroxisomal disorders is characterized by one or more of the following processes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neuronal migration defects (at least in the ZSDs and DBP deficiency)",
"     </li>",
"     <li>",
"      Abnormalities in cerebral and peripheral myelin",
"     </li>",
"     <li>",
"      Neuronal degeneration (although this is not true for all peroxisomal disorders)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The mechanism is thought to be accumulation of VLCFA in neuronal membranes, resulting in abnormal function, atrophy, and death of vulnerable cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/15\">",
"     15",
"    </a>",
"    ]. Studies in an animal model of ZWS provide evidence that the neuronal migration defect is due to N-methyl-D-aspartate receptor dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Migration and differentiation defects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disorders of neuronal migration and differentiation vary in severity among the different disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/19\">",
"     19",
"    </a>",
"    ]. Migration of all neuronal classes appears to be affected, especially those destined for the outer layers of cortex.",
"   </p>",
"   <p>",
"    The abnormalities are most prominent in ZWS and ZWS-like disorders, including DBP deficiency, which are characterized by a unique combination of centrosylvian pachygyria-polymicrogyria likely responsible for the seizure disorder and mental retardation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/20\">",
"     20",
"    </a>",
"    ]. Less severe defects in cerebral migration, usually polymicrogyria, occur in NALD as diffuse, focal or multifocal lesions that may be associated with subcortical heterotopias [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/21\">",
"     21",
"    </a>",
"    ]. These also occur in D-bifunctional enzyme deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. More subtle neuronal migration defects appear as heterotopic Purkinje cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. These are usually asymptomatic.",
"   </p>",
"   <p>",
"    Neuronal migration abnormalities do not occur in all peroxisomal disorders. None have been identified in IRD, classic Refsum disease, acyl-CoA oxidase deficiency (pseudo-NALD), X-ALD, or AMN. They occur rarely in RCDP [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Defects in neuronal differentiation or terminal migration are common and result in dysplasia and simplification of the affected structures in ZWS. In the brainstem, they usually involve the principal nuclei of the inferior medullary olives. Less frequently, the dentate nuclei and claustra are affected. Neuronal loss may be seen in NALD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/27\">",
"     27",
"    </a>",
"    ]. The type of neuronal degeneration varies among the disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Myelination abnormalities",
"    </span>",
"    &nbsp;&mdash;&nbsp;Abnormalities in the formation or maintenance of central white matter",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    peripheral nerve myelin are frequently found in patients affected by peroxisomal disorders with neurologic involvement. Peripheral nerve involvement is less well studied than central lesions. An exception is Refsum disease, which typically has a hypertrophic (onion bulb) demyelinating neuropathy.",
"   </p>",
"   <p>",
"    Degenerative central white matter lesions consist of myelin abnormalities that can be inflammatory [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/28,29\">",
"     28,29",
"    </a>",
"    ] or noninflammatory, and nonspecific decreases in myelin volume or staining [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/15\">",
"     15",
"    </a>",
"    ]. The latter can occur with or without reactive astrocytosis. The type of neuronal degeneration varies among the disorders.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Inflammatory demyelination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Inflammatory demyelination typically occurs in ALD, resulting in confluent and bilaterally symmetric loss of myelin in the cerebral and cerebellar white matter [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/30\">",
"     30",
"    </a>",
"    ]. The parieto-occipital regions are usually affected first, with asymmetric progression of the lesions toward the frontal or temporal lobes. In general, arcuate fibers are spared, except in chronic cases. Axonal loss may be considerable, but myelin loss is usually greater. Lesions may sometimes involve the brainstem, especially the pons. The spinal cord is usually spared, except for bilateral corticospinal tract degeneration. In mice engineered to be deficient in peroxisomal function, axonal degeneration, progressive demyelination, and an inflammatory response with both B and T cells was noted, suggesting a critical role for peroxisomes in neuroprotection [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When peripheral nerves are affected in X-ALD, characteristic lamellar and lamellar-lipid inclusions are seen in Schwann cell cytoplasm or within endoneurial macrophages. The neuropathology of X-ALD is discussed in greater detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other conditions in which inflammatory demyelination lesions occur include AMN [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/30\">",
"     30",
"    </a>",
"    ], NALD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/21\">",
"     21",
"    </a>",
"    ], and some cases of D-bifunctional enzyme deficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Non-inflammatory dysmyelination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninflammatory dysmyelination is seen in the early stages of AMN. The myelin appears pale, with scant interstitial macrophages that stain positive with periodic acid Schiff (PAS). No lymphocytes or reactive astrocytes are seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other changes in myelin",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other changes in myelin include nonspecific reductions in volume or staining, with or without reactive astrocytes. Three categories of lesions are seen.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major postdevelopmental noninflammatory abnormalities may occur in specific neurons or myelinated fiber tracts. These may affect specialized sensory neurons, resulting in sensorineural hearing loss (in ZWS, NALD, IRD, AMACR deficiency, RCDP, and acyl CoA oxidase deficiency) or retinal pigmentary degeneration (in ZWS, NALD, IRD and AMACR deficiency). In another lesion of this type, neurons of the dorsal nuclei of Clarke and the lateral cuneate nuclei accumulate lamellar lipids that contain VLCFA. This lesion occurs only in ZWS.",
"     </li>",
"     <li>",
"      In AMN, a degenerative axonopathy involves the ascending and descending tracts of the spinal cord, especially in fasciculus gracilis and the lateral corticospinal tracts. The histologic pattern is Wallerian degeneration [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/32\">",
"       32",
"      </a>",
"      ]. Mitochondrial pathology [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/33\">",
"       33",
"      </a>",
"      ] and oxidative stress [",
"      <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/34\">",
"       34",
"      </a>",
"      ] also contribute to pathogenesis.",
"     </li>",
"     <li>",
"      Cerebellar atrophy occurs in RCDP and probably IRD. This appears to result from loss of Purkinje and granule cells, with focal depletion of basket cells.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The features that should prompt consideration of a peroxisomal disorder in the differential diagnosis are discussed in this section. The clinical features of individual peroxisomal disorders are discussed in greater detail below.",
"   </p>",
"   <p>",
"    The clinical presentation of peroxisomal disorders varies with age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/10,35\">",
"     10,35",
"    </a>",
"    ]. In one review of 27 children with peroxisomal disorders, the following clinical features suggested the diagnosis at various ages [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/10\">",
"     10",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neonates: hypotonia, decreased activity, encephalopathy, seizures, craniofacial dysmorphism, skeletal abnormalities (calcific stippling, shortened proximal limbs)",
"     </li>",
"     <li>",
"      Children less than six months of age: Craniofacial dysmorphism, failure to thrive, hepatomegaly, prolonged jaundice, neurologic dysfunction, visual abnormalities (retinopathy, cataract, optic nerve dysplasia, abnormal electroretinography [ERG] or visual evoked potential), liver failure, hypocholesterolemia, osteoporosis",
"     </li>",
"     <li>",
"      Children six months to four years: Psychomotor retardation, neurologic dysfunction, hearing loss, abnormal brain auditory evoked potential, visual abnormalities (visual impairment, retinopathy, cataract, abnormal ERG), osteoporosis",
"     </li>",
"     <li>",
"      Children more than four years: Behavioral changes, intellectual deterioration, visual abnormalities, hearing impairment, peripheral neuropathy, gait abnormalities, white matter demyelination",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another review of 40 patients, the combination of certain clinical features suggested the diagnosis (&ge;3 features present in more than 75 percent of patients",
"    <strong>",
"     and",
"    </strong>",
"    at least one feature present in 50 to 75 percent of patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/35\">",
"     35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Features present in more than 75 percent of patients: Psychomotor retardation, hypotonia, impaired hearing,",
"      <span class=\"nowrap\">",
"       low/broad",
"      </span>",
"      nasal bridge, abnormal electroretinogram, hepatomegaly in the first year",
"     </li>",
"     <li>",
"      Features present in 50 to 75 percent of patients: Large fontanelle, shallow orbital ridges, epicanthus, anteverted nostrils, retinitis pigmentosa",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     APPROACH TO DIAGNOSIS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H747827\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Before addressing the individual disorders, considering a common approach to diagnosis is useful. If a peroxisomal disorder is suspected, plasma concentration of VLCFA should be measured. VLCFA levels are elevated in nearly all peroxisomal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Disorders of peroxisome biogenesis can be distinguished from peroxisomal beta-oxidation defects by additional measurements [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/36\">",
"     36",
"    </a>",
"    ]. The tests are available in specialized laboratories, including the Peroxisomal Disease Laboratory at the Kennedy Krieger Institute (707 North Broadway, Baltimore, MD 21205) and the Genetic Metabolic Diseases Laboratory at the Academic Medical Center of the University of Amsterdam.",
"   </p>",
"   <p>",
"    The following plasma concentrations should be measured:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dihydroxy and trihydroxy cholestanoic acid (increased in most disorders of peroxisome biogenesis, as well as DBP deficiency, AMACR deficiency, and SCPx deficiency)",
"     </li>",
"     <li>",
"      Phytanic acid (increased in many disorders of peroxisome biogenesis and in Refsum disease)",
"     </li>",
"     <li>",
"      Pristanic acid (increased in many disorders of peroxisome biogenesis, and in DBP, AMACR deficiency, and SCPx deficiency)",
"     </li>",
"     <li>",
"      Pipecolic acid (increased in many disorders of peroxisome biogenesis)",
"     </li>",
"     <li>",
"      Docosahexaenoic acid (moderately diminished in many disorders of peroxisome biogenesis)",
"     </li>",
"     <li>",
"      Plasmalogens (decreased in many disorders of peroxisome biogenesis and in the three genetic forms of RCDP)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Of note, these tests are not always abnormal early in the course of disorders of peroxisome biogenesis (eg, Zellweger spectrum disorders). One report described six patients with clinical features and MRI findings suggestive of relatively mild infantile peroxisomal defects, in whom plasma VLCFAs and other tests of peroxisomal dysfunction were normal or only mildly elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/37\">",
"     37",
"    </a>",
"    ]. The initial MRI abnormalities were in the hilus of the dentate nucleus, and gradually progressed to demyelination of the cerebral hemispheric white matter. A peroxisomal disorder was ultimately diagnosed through tests of catalase immunofluorescence in cultured skin fibroblasts, which are described in the paragraph below.",
"   </p>",
"   <p>",
"    Assays of the following processes in cultured skin fibroblasts may be necessary to confirm the diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      De novo plasmalogen biosynthesis",
"     </li>",
"     <li>",
"      Fatty acid beta-oxidation",
"     </li>",
"     <li>",
"      Phytanic acid alpha-oxidation",
"     </li>",
"     <li>",
"      Catalase-immunofluorescence",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    DNA analysis is available for all peroxisomal diseases including X-ALD [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/38\">",
"     38",
"    </a>",
"    ] and is the preferred method for the identification of women who are heterozygous for X-ALD, because it avoids the false negative results that may occur with the VLCFA assay in heterozygotes. DNA is required for the definition of the molecular defect in the disorders of peroxisome biogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/39,40\">",
"     39,40",
"    </a>",
"    ], and bifunctional enzyme deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal testing for all of the peroxisomal disorders is available for subsequent pregnancies of women with affected children or other positive family history. Prenatal diagnostic methods have shifted from biochemical to DNA-based methods, especially for X-ALD, for which previous (biochemical) diagnostic methods were notoriously difficult. Preimplantation diagnosis has been achieved in embryos from a couple at-risk for X-ALD using multiple displacement amplification (MDA) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Antenatal diagnosis is sometimes made by ultrasonography. In one report, increased nuchal translucency and decreased fetal movements suggested the diagnosis of ZWS in a fetus at risk [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/43\">",
"     43",
"    </a>",
"    ]. The diagnosis was confirmed by metabolic studies on cells obtained by chorionic villus sampling. In another report, RCDP was identified in a fetus with no family history based on the findings of severe limb shortening, premature ossification, and stippling of multiple epiphyses [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of liquid chromatography and tandem mass spectrometry",
"    <span class=\"nowrap\">",
"     (LC-MS/MS)",
"    </span>",
"    using newborn blood cards has been validated preliminarily as a diagnostic approach at birth. It is conceivable that this approach will be applicable to the full range of peroxisomal disorders, as well. For X-ALD, the implications of newborn screening include potential early treatment for affected males and counseling for carrier females, and the costs and risks of false-positive results. These and other issues will require careful consideration and the development of consensus guidelines before newborn screening can be widely implemented [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A survey of X-ALD and AMN families revealed strong endorsement of prenatal testing and newborn screening. Approximately 90 percent of respondents endorsed prenatal or newborn testing for at-risk males, and 51 percent endorsed testing for at-risk females. Newborn screening for",
"    <span class=\"nowrap\">",
"     X-ALD/AMN",
"    </span>",
"    was endorsed by 90 percent of respondents [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/47\">",
"     47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ZELLWEGER SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZWS (MIM #214100), also known as cerebrohepatorenal syndrome, is the prototype of peroxisome biosynthesis disorders. It is characterized by craniofacial dysmorphism and profound neurologic abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Epidemiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;ZWS is the most common peroxisomal disorder to present in early infancy. The incidence is 1 in 50,000 to 100,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peroxisome biogenesis disorders, including ZWS, NALD, and IRD, are inherited in an autosomal recessive manner. They are caused by mutations in at least 12 different genes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/48\">",
"     48",
"    </a>",
"    ]. The majority of infants with these conditions have mutations in either the PEX1 or PEX6 genes that encode ATPases needed to import protein from the cytosol into peroxisomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/49\">",
"     49",
"    </a>",
"    ]. One child with ZWS resulted from uniparental disomy, the result of maternal isodisomy for chromosome 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected individuals present at birth with a typical craniofacial dysmorphism. The appearance is characterized by the following features (",
"    <a class=\"graphic graphic_picture graphicRef72662 \" href=\"UTD.htm?19/62/20454\">",
"     picture 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      High forehead",
"     </li>",
"     <li>",
"      Large anterior fontanelle",
"     </li>",
"     <li>",
"      Markedly separated cranial sutures",
"     </li>",
"     <li>",
"      Hypoplastic supraorbital ridges",
"     </li>",
"     <li>",
"      Upward slant of the eyes",
"     </li>",
"     <li>",
"      Epicanthal folds",
"     </li>",
"     <li>",
"      Low and broad nasal bridge",
"     </li>",
"     <li>",
"      High arched palate",
"     </li>",
"     <li>",
"      Deformed ear lobes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Infants typically have hepatomegaly, which is associated with cirrhosis and biliary dysgenesis. Calcific stippling of the patellae, hips, and other epiphyses (chondrodysplasia punctata) is present in 50 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ]. Other features are glomerulocystic kidney disease, cataracts, and pigmentary retinopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/51\">",
"     51",
"    </a>",
"    ]. These abnormalities are already present at birth. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic abnormalities include profound hypotonia and weakness with absent reflexes, severe impairment of hearing and vision, and neonatal seizures. Developmental delay is profound. Infants rarely survive beyond six months of age [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Findings on cranial MRI include cortical and white matter abnormalities. In a study of six infants with ZWS, all had impaired myelination and diffusely abnormal cortical gyral patterns, consisting of microgyria and pachygyria [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/52\">",
"     52",
"    </a>",
"    ]. All had germinolytic cysts in the caudothalamic groove.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical findings in the disorders of peroxisomal biogenesis are due to deficient VLCFA beta-oxidation, phytanic acid oxidation, and plasmalogen synthesis. This results in the following abnormalities:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Increased plasma VLCFA concentration",
"     </li>",
"     <li>",
"      Increased concentrations of phytanic acid, pristanic acid, and pipecolic acid in plasma and fibroblasts",
"     </li>",
"     <li>",
"      Reduced erythrocyte concentration of plasmalogen",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The \"Pex Gene Screen\" provides an algorithm that permits the identification of the molecular defect in the Zellweger spectrum peroxisomal disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/40\">",
"     40",
"    </a>",
"    ]. The Pex Gene Screen is available at the Peroxisomal Disease Laboratory at the Kennedy Krieger Institute (707 North Broadway, Baltimore, MD 21205) and at the Academic Medical Center at the University of Amsterdam (Laboratory of Genetic Metabolic Diseases, Room F0-224, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;No effective treatment is available for ZWS. Appropriate counseling and support should be provided for the family.",
"   </p>",
"   <p>",
"    One approach under investigation is to normalize the concentration of docosahexaenoic acid (DHA). DHA concentration is low in brain, retina, and other tissues in this disorder, and may contribute to abnormalities in neurologic function. In one report, 20 individuals with Zellweger spectrum peroxisome biogenesis disorders were treated with DHA ethyl ester [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/53\">",
"     53",
"    </a>",
"    ]. Beneficial effects included normalization of DHA levels and liver function, improved vision in approximately one-half of those treated, and increased muscle tone. Myelination improved on MRI in nine patients. Clinical improvement was greatest in those who started treatment before age six months. Nevertheless, whether DHA treatment is really beneficial or not is still very much in debate [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another potential approach is pharmacologic induction of peroxisome proliferation. In one study, treatment of cultured fibroblasts from individuals with peroxisome biogenesis disorders with sodium 4-phenylbutyrate increased peroxisome number and increased transcription of ALD-related gene and the peroxin gene, PEX11alpha [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/55\">",
"     55",
"    </a>",
"    ]. Treatment decreased VLCFA concentration and increased VLCFA beta-oxidation and plasmalogen concentrations in NALD and IRD fibroblasts, but not in ZWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     NEONATAL ADRENOLEUKODYSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;NALD (MIM #202370) is another disorder of peroxisomal biogenesis. Some features are similar to ZWS, but NALD is less severe.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;NALD is inherited in an autosomal recessive manner. The majority of patients have mutations in either the PEX1 or PEX6 genes that encode ATPases needed to import proteins into peroxisomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presentation of NALD is at birth. The craniofacial appearance is dysmorphic, but less marked than ZWS, and consists primarily of mid-face hypoplasia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ]. Patients typically have hepatomegaly, but do not have renal microcysts or chondrodysplasia punctata.",
"   </p>",
"   <p>",
"    Affected children rarely have clinically significant adrenal insufficiency, although they typically have adrenal cortical atrophy. The response to ACTH stimulation is reduced. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=see_link\">",
"     \"Causes and clinical manifestations of primary adrenal insufficiency in children\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=see_link\">",
"     \"Diagnosis of adrenal insufficiency in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Neurologic features include weakness and hypotonia, optic atrophy, and seizures. Tremor, hyperreflexia, ataxia, sensory deficits, and progressive visual and auditory dysfunction develop during infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2,56\">",
"     2,56",
"    </a>",
"    ]. Some individuals walk, but cognitive function is poor.",
"   </p>",
"   <p>",
"    Neurologic regression typically occurs in early childhood. Most children die before three to five years of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Neuroimaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cranial MRI shows severe white matter deficiency. Cerebral cortical heterotopias and polymicrogyria are seen.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical findings in the disorders of peroxisomal biogenesis are due to deficient VLCFA beta-oxidation, phytanic acid oxidation, and plasmalogen synthesis. In NALD, this results in the same biochemical abnormalities seen in ZWS.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     INFANTILE REFSUM DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;IRD (MIM #266510) is the third disorder of peroxisomal biogenesis in which multiple peroxisomal functions are lost. It is less severe than ZWS or NALD.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;IRD is inherited in an autosomal recessive manner. The majority of patients have mutations in either the PEX1 or PEX6 genes that encode ATPases needed to import proteins into peroxisomes [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;IRD typically presents at one to six months of age with severe developmental delay [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ]. Because dysmorphic features are mild or absent, the diagnosis is often delayed. Dysmorphic features, when present, are mild to moderate and include a flat nasal bridge, epicanthal folds, and low set ears. Affected infants typically have hypotonia, abnormalities of the optic nerve and disc, retinitis pigmentosa, and sensorineural hearing loss.",
"   </p>",
"   <p>",
"    Some infants present with gastrointestinal abnormalities, including vomiting, diarrhea, and malabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/57\">",
"     57",
"    </a>",
"    ]. Most have hepatomegaly with cirrhosis.",
"   </p>",
"   <p>",
"    Neurologic deterioration is slower than in ZWS or NALD. Most affected individuals can walk, although they have ataxia. Many survive into adolescence.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The biochemical findings in the disorders of peroxisomal biogenesis are due to deficient VLCFA beta-oxidation, phytanic acid oxidation, and plasmalogen synthesis. In IRD, this results in biochemical abnormalities similar to ZWS and NALD, although less pronounced.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h1\">",
"     PEROXISOME BIOGENESIS DISORDERS WITH PROLONGED SURVIVAL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some individuals with peroxisome biogenesis disorders survive to adulthood, in one instance to the fifth decade [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/58\">",
"     58",
"    </a>",
"    ]. In one series of 31 individuals with prolonged survival, diagnosis was often delayed because dysmorphic features were mild or absent. Clinical features included: retinopathy, sensorineural hearing impairment, moderate to severe psychomotor retardation, and postnatal growth failure. Mutations in the PEX 1 gene, particularly the G843D mutation was the most common cause.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     RHIZOMELIC CHONDRODYSPLASIA PUNCTATA TYPE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCDP type 1 (MIM #215100) is a rare disorder of peroxisome biogenesis. Unlike ZWS, NALD, and IRD, fewer peroxisomal enzymes are affected. In the majority of affected children, fibroblasts are deficient in dihydroxyacetonephosphate acyltransferase (DHAP-AT) and alkyldihydroxyacetonephosphate synthase (alkyl-DHAP synthase), the two enzymes needed for plasmalogen synthesis. The third enzyme deficient in RCDP type 1 is phytanoyl-CoA hydroxylase, a key enzyme involved in phytanic acid alpha-oxidation [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/59\">",
"     59",
"    </a>",
"    ]. They are also unable to import peroxisomal thiolase.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCDP type 1 is caused by mutations in the PEX7 gene, mapped to chromosome 6p22-q24 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/39,59-63\">",
"     39,59-63",
"    </a>",
"    ]. This gene encodes the peroxisomal type 2 targeting signal receptor that helps target cytosolic proteins to the peroxisome. Some of those with Refsum disease also have mutations in this gene [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCDP presents in early childhood with profound mental retardation and dysmorphic facies. The unique feature is severe short stature that primarily affects the proximal long bones. Congenital cataracts and ichthyosis affect approximately 72 and 27 percent of patients, respectively. Joint contractures are common. The natural history is uncertain. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=see_link\">",
"     \"Cataract in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H37\">",
"    <span class=\"h2\">",
"     Radiographic studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The characteristic radiographic finding is chondrodysplasia punctata, the stippled calcification present in long bones and vertebrae. Ossification of the humerus and femur is also abnormal. Lateral films of the spine demonstrate an unusual coronal cleft of the vertebral bodies, which is thought to represent an embryonic arrest of bony development.",
"   </p>",
"   <p>",
"    MR imaging and hydrogen-1 MR spectroscopy of the brain was reported in one child [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/65\">",
"     65",
"    </a>",
"    ]. Areas of abnormal signal intensity were seen in the subcortical white matter. Metabolic abnormalities consistent with the deficiency in plasmalogen biosynthesis were detected by spectroscopy in normal-appearing white matter. These included increased levels of mobile lipids and myo-inositol, decreased choline, and the presence of acetate. In a neonate, MR imaging revealed pachygyria-polymicrogyria, brainstem and spinal cord compression due to spinal stenosis, and tethering of the spinal cord [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In another report, MR imaging was performed and correlated with clinical and biochemical profiles in 10 individuals (age 0.4 to 20.7 years) with RCDP type 1, and 1 with RCDP type 3 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/67\">",
"     67",
"    </a>",
"    ]. MR imaging abnormalities (including ventricular enlargement, increased subarachnoid spaces, supratentorial myelin abnormalities, and progressive cerebellar atrophy) were present in those with severe RCDP (defined by inability to sit and deficient verbal and nonverbal communication), but not in those with mild RCDP (defined by ability to sit and possession of verbal communication skills). The severity of the clinical and MR imaging abnormalities correlated with the plasmalogen levels but was not related to the phytanic acid level.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H38\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma VLCFA concentration is not elevated in this disorder. Erythrocyte levels of plasmalogen are decreased. Plasma concentrations of phytanic acid are increased, and pristanic acid levels are normal. The diagnosis is confirmed by demonstration of deficiency in plasmalogen synthesis and phytanic acid oxidation in fibroblasts [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Methods for the molecular diagnosis and assessment of genotype-phenotype correlations of RCDP are available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/39,63\">",
"     39,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H39\">",
"    <span class=\"h1\">",
"     ADRENOLEUKODYSTROPHY",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALD (MIM #300100) is a peroxisomal disorder of beta-oxidation that results in accumulation of VLCFA in all tissues. ALD consists of a spectrum of phenotypes (including adrenomyeloneuropathy, AMN) that vary in the age and severity of clinical presentation (",
"    <a class=\"graphic graphic_table graphicRef70311 graphicRef80404 graphicRef59029 \" href=\"UTD.htm?41/61/42974\">",
"     table 1A-C",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. These conditions are known as the",
"    <span class=\"nowrap\">",
"     ALD/AMN",
"    </span>",
"    complex.",
"   </p>",
"   <p>",
"    Abnormalities primarily affect the central nervous system, adrenal cortex, and Leydig cells in the testis. Affected males have one of three main phenotypes (childhood cerebral forms, adrenomyeloneuropathy, and Addison disease) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/70\">",
"     70",
"    </a>",
"    ]. Neurologic signs that resemble AMN develop in up to 50 percent of carrier females [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/71\">",
"     71",
"    </a>",
"    ]. The clinical course in females is milder and the onset is later (after age 35 years) than in affected males. The disorder is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"     \"Adrenoleukodystrophy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     REFSUM DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refsum disease (MIM #266500) is also known as hereditary motor and sensory neuropathy IV, and heredopathia atactica polyneuritiformis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=see_link\">",
"     \"Hereditary neuropathies associated with generalized disorders\"",
"    </a>",
"    .) A major difference from other peroxisomal disorders is that this disorder responds to dietary treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Genetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Refsum disease (RD) is an autosomal recessive disorder. In most instances, RD is caused by mutations in the gene (PhyH) encoding the enzyme phytanoyl-CoA hydroxylase (PAHX), located on chromosome 10pter-p11.2 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/72-74\">",
"     72-74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Some individuals with Refsum disease without mutations in the PAHX gene have mutations in the PEX7 gene, mapped to chromosome 6p22-q24 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/64\">",
"     64",
"    </a>",
"    ]. This gene encodes the peroxisomal type 2 targeting signal receptor, which helps to direct certain peroxisomal proteins from the cytosol into peroxisomes. Mutations in PEX7 usually cause RCDP type 1 but occasionally cause Refsum disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h2\">",
"     Pathophysiology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Phytanic acid, a branched-chain fatty acid derived from the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38081?source=see_link\">",
"     chlorophyll",
"    </a>",
"    constituent phytol, is present in the typical human diet. Normally it is metabolized by activation to its CoA ester, phytanoyl-CoA, and then alpha-oxidation to pristanic acid. Patients with Refsum disease are unable to degrade phytanic acid because of deficient activity of PAHX, a peroxisomal enzyme that catalyzes the first step of phytanic acid alpha-oxidation. The mechanism of phytanic acid toxicity to neuronal and other tissues is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h2\">",
"     Clinical features",
"    </span>",
"    &nbsp;&mdash;&nbsp;Affected individuals typically present in adolescence, although onset may be later. Initial clinical features include deteriorating vision due to retinitis pigmentosa and anosmia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2,75\">",
"     2,75",
"    </a>",
"    ]. Sensorineural hearing loss, ataxia, peripheral polyneuropathy, ichthyosis, and cardiac conduction defects typically occur after 10 to 15 years in some [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/76\">",
"     76",
"    </a>",
"    ]. Cognitive function is normal.",
"   </p>",
"   <p>",
"    Laboratory features include elevated cerebrospinal fluid protein concentration (100 to 600",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    without an increase in cells [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/72\">",
"     72",
"    </a>",
"    ]. Nerve conduction studies typically show slowed conduction velocity. Peripheral nerve biopsy reveals hypertrophic changes with onion bulb formation and paracrystalline inclusions on electron microscopy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical course is variable. Exacerbations may occur with acute illness, fasting, rapid weight loss, surgery, or pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Laboratory studies",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis is usually made clinically and confirmed by elevated plasma concentration of phytanic acid and mutation analysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/78\">",
"     78",
"    </a>",
"    ]. Values are typically &gt;200",
"    <span class=\"nowrap\">",
"     micromol/L,",
"    </span>",
"    while normal values are usually &lt;15",
"    <span class=\"nowrap\">",
"     micromol/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/75,79\">",
"     75,79",
"    </a>",
"    ]. PAHX activity is reduced in fibroblasts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment consists of dietary restriction to eliminate phytol-containing foods, such as meat or fats from ruminating animals, baked goods containing animal fats, and dairy products [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/2,75\">",
"     2,75",
"    </a>",
"    ]. Management goals are to reduce dietary intake of phytanic acid to less than 10 mg daily and avoidance of rapid weight loss or fasting, conditions which stimulate lipolysis [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/80\">",
"     80",
"    </a>",
"    ]. The range of foods allowed has gradually broadened to include many green vegetables because the free phytol content is low [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Strict reduction in dietary phytanic acid intake may be associated with a significant improvement in both the peripheral neuropathy and ataxia [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/82\">",
"     82",
"    </a>",
"    ]. In a series of 13 adult patients with Refsum disease treated with dietary therapy for 10 years or more, phytanic acid levels declined by almost 90 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/80\">",
"     80",
"    </a>",
"    ]. Phytanic acid levels were normalized (&lt;30",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 30 percent of the participants, partially normalized (30 to 300",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 50 percent, and remained elevated (&gt;300",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    in 15 percent, to some extent reflecting compliance with dietary restriction. None of the participants required plasmapheresis or admission for acute symptoms of Refsum disease. &nbsp;",
"   </p>",
"   <p>",
"    Phytanic acid concentration can also be reduced by plasmapheresis, which can be performed serially if necessary [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/82,83\">",
"     82,83",
"    </a>",
"    ]. Plasmapheresis efficiently removes phytanic acid associated with lipoproteins but does not efficiently deplete phytanic acid in adipose and neural tissue. This approach halts progression of the disease, but does not completely reverse neurologic abnormalities. Ichthyosis, sensory neuropathy, and ataxia resolve in approximately that order, and ECG abnormalities may improve. However, treatment may not affect retinitis pigmentosa, hearing impairment, or anosmia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h1\">",
"     OTHER DISORDERS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders in which only one peroxisomal enzyme is deficient have each been described in a few children. These are phenotypically similar to the peroxisomal biogenesis disorders. All have autosomal recessive inheritance [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Acyl-CoA oxidase deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acyl-CoA oxidase deficiency (MIM #264470), also known as pseudo-NALD, is caused by mutations in the gene encoding the peroxisomal enzyme acyl-CoA oxidase (ACOX), which catalyzes the first step in the peroxisomal beta-oxidation of VLCFAs [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/84\">",
"     84",
"    </a>",
"    ]. Importantly, a different acyl-CoA oxidase catalyzes the first step in the oxidation of pristanic acid and di- and tri-hydroxycholestanoic acid. The gene is localized on chromosome 17q25.",
"   </p>",
"   <p>",
"    Patients with acyl-CoA oxidase deficiency show a variety of clinical symptoms including neonatal hypotonia (92 percent), seizures (91 percent), failure to thrive (38 percent), visual system failure (78 percent), impaired hearing (77 percent), loss of motor achievements (83 percent), hepatomegaly (50 percent), and external dysmorphism (50 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/85\">",
"     85",
"    </a>",
"    ]. White matter abnormalities are present in all patients. All patients had psychomotor retardation but acquired limited skills, such as sitting and standing unsupported for a few seconds, voluntary control of hand function, and the use of a few words with comprehension of their meaning. The mean age of death is 5 years, with the oldest patients surviving until 10 years of age.",
"   </p>",
"   <p>",
"    Deficiency of ACOX results in increased plasma concentration of VLCFAs and normal levels for pristanic acid and the bile acid intermediates. Methods for the enzymatic and molecular diagnosis of acyl-CoA oxidase deficiency are available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h2\">",
"     D-bifunctional protein deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;D-bifunctional protein (DBP) deficiency (MIM #261515) is caused by mutations in the gene encoding the peroxisomal enzyme D-bifunctional protein (DBP), which catalyzes the second and third steps in the beta-oxidation of VLCFAs, as well as pristanic acid and di- and tri-hydroxy cholestanoic acid [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/86\">",
"     86",
"    </a>",
"    ]. The gene is located on chromosome 5q2. The range of phenotypic expression varies widely. Some individuals resemble those with Zellweger syndrome, while others are more mildly affected [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/41,87\">",
"     41,87",
"    </a>",
"    ]. Survival is reportedly less than with acyl-CoA oxidase deficiency.",
"   </p>",
"   <p>",
"    Deficiency of this enzyme results in increased plasma concentrations of VLCFA, pristanic acid, and the bile acid intermediates, di- and tri-hydroxycholestanoic acid.",
"   </p>",
"   <p>",
"    Methods for the molecular diagnosis and assessment of genotype-phenotype correlations of D-bifunctional enzyme deficiency are available [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     RCDP types 2 and 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;RCDP types 2 (MIM #222765) and 3 (MIM #600121) have clinical features similar to type 1 (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55544 \" href=\"UTD.htm?25/43/26288\">",
"     image 1",
"    </a>",
"    ). Survival may be significantly limited. However, the biochemical defect is a deficiency of plasmalogen synthesis alone, rather than deficiency of both plasmalogen synthesis and phytanic acid oxidation, as occurs with type 1.",
"   </p>",
"   <p>",
"    The more common disorder is RCDP type 2, which is caused by mutations in the GNPAT gene encoding dihydroxyacetone phosphate acyltransferase (DHAP-AT), located on chromosome 1 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/88\">",
"     88",
"    </a>",
"    ]. RCDP type 3 is characterized by a deficiency of alkyldihydroxyacetone phosphate synthase (alkyl-DHAP synthase) [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/89\">",
"     89",
"    </a>",
"    ] resulting from mutations in the ADHAPS gene that is located on chromosome 2q31 [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/90\">",
"     90",
"    </a>",
"    ]. In both disorders, erythrocyte plasmalogen concentration is decreased and plasma phytanic acid concentration is normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Alpha-methylacyl-CoA racemase (AMACR) deficiency",
"    </span>",
"    &nbsp;&mdash;&nbsp;AMACR is also known as 2-methylacyl-CoA racemase deficiency. Although only four patients have been described so far, it is already clear that the clinical signs and symptoms of AMACR deficiency may differ markedly. Indeed, the first two patients were characterized by an adult-onset sensorimotor neuropathy, whereas another patient presented very early in life with fulminant liver failure. At this time, it is too early to tell what the dominant phenotype of AMACR deficiency will be [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Pseudo-ZWS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical presentation of pseudo-ZWS is similar to ZWS. The only reported case was originally thought to be due to a deficiency of the peroxisomal enzyme 3-oxoacyl-coenzyme A thiolase [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/91\">",
"     91",
"    </a>",
"    ] but was later shown to be due to a deficiency of D-bifunctional enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/92\">",
"     92",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h2\">",
"     Pseudo-IRD",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudo-IRD has the clinical features of IRD. In one report, oxidation of phytanic and pipecolic acids was severely reduced, while oxidation of VLCFA and plasmalogen synthesis were only partially reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?8/23/8570/abstract/93\">",
"     93",
"    </a>",
"    ]. Plasma concentrations of phytanic and pipecolic acids were increased.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Peroxisomes are subcellular organelles that are present in all cells except erythrocytes. They host numerous catabolic and anabolic pathways that are essential to normal cellular metabolism. Peroxisomal disorders are a heterogeneous group of inborn errors of metabolism that result in impairment of peroxisome function. In most cases, this results in neurologic dysfunction of varying extent. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disorders of peroxisome biogenesis include Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease, in which multiple peroxisomal functions are deficient and peroxisomes are reduced in number. Rhizomelic chondrodysplasia punctata type 1 is also a disorder of peroxisome biogenesis; in this disease, peroxisomes are normal, and only two peroxisomal functions are lost. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other peroxisomal disorders are caused by deficiency of a single peroxisomal enzyme. This group includes X-linked adrenoleukodystrophy (including adrenomyeloneuropathy), Refsum disease (phytanoyl CoA hydroxylase deficiency), acyl CoA oxidase deficiency (pseudo-neonatal adrenoleukodystrophy), D-bifunctional protein deficiency, and others. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In neonates and infants, peroxisomal disorders typically present with hypotonia, decreased activity, encephalopathy, seizures, craniofacial dysmorphism, skeletal abnormalities, failure to thrive, hepatomegaly, prolonged jaundice, neurologic dysfunction, visual abnormalities and hypocholesterolemia. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In children, peroxisomal disorders may present with behavioral changes, psychomotor retardation, intellectual deterioration, neurologic dysfunction, hearing loss, or visual abnormalities. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Plasma levels of very long chain fatty acids are elevated in nearly all peroxisomal disorders, and are the first step in establishing the diagnosis. Disorders of peroxisome biogenesis can be distinguished from peroxisomal beta-oxidation defects by additional measurements. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Zellweger syndrome is characterized by craniofacial dysmorphism (",
"      <a class=\"graphic graphic_picture graphicRef72662 \" href=\"UTD.htm?19/62/20454\">",
"       picture 1",
"      </a>",
"      ) and profound neurologic abnormalities, and is the most common peroxisomal disorder to present in early infancy. Affected infants also have hepatomegaly, glomerulocystic kidney disease, cataracts, and pigmentary retinopathy. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Zellweger syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      X-linked adrenoleukodystrophy is the most common peroxisomal disorder with a spectrum of phenotypes (including adrenomyeloneuropathy) that vary in the age and severity of clinical presentation (",
"      <a class=\"graphic graphic_table graphicRef70311 graphicRef80404 graphicRef59029 \" href=\"UTD.htm?41/61/42974\">",
"       table 1A-C",
"      </a>",
"      ). Many affected individuals have associated adrenal insufficiency. (See",
"      <a class=\"local\" href=\"#H39\">",
"       'Adrenoleukodystrophy'",
"      </a>",
"      above.) This disorder is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=see_link\">",
"       \"Adrenoleukodystrophy\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Thomas JA, Greene CL, Cohn RM. Lysosomal storage and peroxisomal disorders presenting in the newborn. In: Avery's Diseases of the Newborn, 7th ed, Taeusch HW, Ballard RA (Eds), WB Saunders, Philadelphia 1998. p.275.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/2\">",
"      Percy AK, Rutledge SL. Adrenoleukodystrophy and related disorders. Ment Retard Dev Disabil Res Rev 2001; 7:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/3\">",
"      Wanders RJ, Waterham HR. Biochemistry of mammalian peroxisomes revisited. Annu Rev Biochem 2006; 75:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/4\">",
"      Roth KS. Peroxisomal disease--common ground for pediatrician, cell biologist, biochemist, pathologist, and neurologist. Clin Pediatr (Phila) 1999; 38:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/5\">",
"      Powers JM, Tummons RC, Caviness VS Jr, et al. Structural and chemical alterations in the cerebral maldevelopment of fetal cerebro-hepato-renal (Zellweger) syndrome. J Neuropathol Exp Neurol 1989; 48:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/6\">",
"      Wanders RJ, Waterham HR. Peroxisomal disorders: the single peroxisomal enzyme deficiencies. Biochim Biophys Acta 2006; 1763:1707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/7\">",
"      Steinberg SJ, Dodt G, Raymond GV, et al. Peroxisome biogenesis disorders. Biochim Biophys Acta 2006; 1763:1733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/8\">",
"      Shimozawa N. Molecular and clinical aspects of peroxisomal diseases. J Inherit Metab Dis 2007; 30:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/9\">",
"      Furuki S, Tamura S, Matsumoto N, et al. Mutations in the peroxin Pex26p responsible for peroxisome biogenesis disorders of complementation group 8 impair its stability, peroxisomal localization, and interaction with the Pex1p x Pex6p complex. J Biol Chem 2006; 281:1317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/10\">",
"      Baumgartner MR, Poll-The BT, Verhoeven NM, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol 1998; 44:720.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/11\">",
"      Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001; 49:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/12\">",
"      Moser HW, Moser AB. Peroxisomal disorders: overview. Ann N Y Acad Sci 1996; 804:427.",
"     </a>",
"    </li>",
"    <li>",
"     Gilles L, Adams R, Kolony E. The neurology of neonatal hereditary metabolic diseases. In: Neurology of Hereditary Metabolic Diseases of Children, 2nd ed, McGraw Hill, New York 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/14\">",
"      Moser AB, Kreiter N, Bezman L, et al. Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls. Ann Neurol 1999; 45:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/15\">",
"      Powers JM, Moser HW. Peroxisomal disorders: genotype, phenotype, major neuropathologic lesions, and pathogenesis. Brain Pathol 1998; 8:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/16\">",
"      Knazek RA, Rizzo WB, Schulman JD, Dave JR. Membrane microviscosity is increased in the erythrocytes of patients with adrenoleukodystrophy and adrenomyeloneuropathy. J Clin Invest 1983; 72:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/17\">",
"      Ho JK, Moser H, Kishimoto Y, Hamilton JA. Interactions of a very long chain fatty acid with model membranes and serum albumin. Implications for the pathogenesis of adrenoleukodystrophy. J Clin Invest 1995; 96:1455.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/18\">",
"      Gressens P, Baes M, Leroux P, et al. Neuronal migration disorder in Zellweger mice is secondary to glutamate receptor dysfunction. Ann Neurol 2000; 48:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/19\">",
"      Powers JM. Normal and defective neuronal membranes: structure and function: neuronal lesions in peroxisomal disorders. J Mol Neurosci 2001; 16:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/20\">",
"      Volpe JJ, Adams RD. Cerebro-hepato-renal syndrome of Zellweger: an inherited disorder of neuronal migration. Acta Neuropathol 1972; 20:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/21\">",
"      Kelley RI, Datta NS, Dobyns WB, et al. Neonatal adrenoleukodystrophy: new cases, biochemical studies, and differentiation from Zellweger and related peroxisomal polydystrophy syndromes. Am J Med Genet 1986; 23:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/22\">",
"      Powers JM. The pathology of peroxisomal disorders with pathogenetic considerations. J Neuropathol Exp Neurol 1995; 54:710.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/23\">",
"      Kaufmann WE, Theda C, Naidu S, et al. Neuronal migration abnormality in peroxisomal bifunctional enzyme defect. Ann Neurol 1996; 39:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/24\">",
"      Dimmick JE, Applegarth DA. Pathology of peroxisomal disorders. Perspect Pediatr Pathol 1993; 17:45.",
"     </a>",
"    </li>",
"    <li>",
"     Powers J. Peroxisomal diseases. In: Pediatric Neuropathology, Williams and Wilkins, Baltimore, MD 1995.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/26\">",
"      YAKOVAC WC. Calcareous chondropathies in the newborn infant. AMA Arch Pathol 1954; 57:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/27\">",
"      Jaffe R, Crumrine P, Hashida Y, Moser HW. Neonatal adrenoleukodystrophy: clinical, pathologic, and biochemical delineation of a syndrome affecting both males and females. Am J Pathol 1982; 108:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/28\">",
"      Griffin DE, Moser HW, Mendoza Q, et al. Identification of the inflammatory cells in the central nervous system of patients with adrenoleukodystrophy. Ann Neurol 1985; 18:660.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/29\">",
"      Powers JM, Liu Y, Moser AB, Moser HW. The inflammatory myelinopathy of adreno-leukodystrophy: cells, effector molecules, and pathogenetic implications. J Neuropathol Exp Neurol 1992; 51:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/30\">",
"      Powers JM. Adreno-leukodystrophy (adreno-testiculo-leukomyelo-neuropathic-complex). Clin Neuropathol 1985; 4:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/31\">",
"      Kassmann CM, Lappe-Siefke C, Baes M, et al. Axonal loss and neuroinflammation caused by peroxisome-deficient oligodendrocytes. Nat Genet 2007; 39:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/32\">",
"      Powers JM, DeCiero DP, Ito M, et al. Adrenomyeloneuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropathol Exp Neurol 2000; 59:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/33\">",
"      Powers JM, DeCiero DP, Cox C, et al. The dorsal root ganglia in adrenomyeloneuropathy: neuronal atrophy and abnormal mitochondria. J Neuropathol Exp Neurol 2001; 60:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/34\">",
"      Powers JM, Pei Z, Heinzer AK, et al. Adreno-leukodystrophy: oxidative stress of mice and men. J Neuropathol Exp Neurol 2005; 64:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/35\">",
"      Theil AC, Schutgens RB, Wanders RJ, Heymans HS. Clinical recognition of patients affected by a peroxisomal disorder: a retrospective study in 40 patients. Eur J Pediatr 1992; 151:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/36\">",
"      Wanders RJ, Schutgens RB, Barth PG. Peroxisomal disorders: a review. J Neuropathol Exp Neurol 1995; 54:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/37\">",
"      van der Knaap MS, Wassmer E, Wolf NI, et al. MRI as diagnostic tool in early-onset peroxisomal disorders. Neurology 2012; 78:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/38\">",
"      Boehm CD, Cutting GR, Lachtermacher MB, et al. Accurate DNA-based diagnostic and carrier testing for X-linked adrenoleukodystrophy. Mol Genet Metab 1999; 66:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/39\">",
"      Braverman N, Chen L, Lin P, et al. Mutation analysis of PEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Hum Mutat 2002; 20:284.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/40\">",
"      Steinberg S, Chen L, Wei L, et al. The PEX Gene Screen: molecular diagnosis of peroxisome biogenesis disorders in the Zellweger syndrome spectrum. Mol Genet Metab 2004; 83:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/41\">",
"      Ferdinandusse S, Ylianttila MS, Gloerich J, et al. Mutational spectrum of D-bifunctional protein deficiency and structure-based genotype-phenotype analysis. Am J Hum Genet 2006; 78:112.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/42\">",
"      Lled&oacute; B, Bernabeu R, Ten J, et al. Preimplantation genetic diagnosis of X-linked adrenoleukodystrophy with gender determination using multiple displacement amplification. Fertil Steril 2007; 88:1327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/43\">",
"      Johnson JM, Babul-Hirji R, Chitayat D. First-trimester increased nuchal translucency and fetal hypokinesia associated with Zellweger syndrome. Ultrasound Obstet Gynecol 2001; 17:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/44\">",
"      Hertzberg BS, Kliewer MA, Decker M, et al. Antenatal ultrasonographic diagnosis of rhizomelic chondrodysplasia punctata. J Ultrasound Med 1999; 18:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/45\">",
"      Raymond GV, Jones RO, Moser AB. Newborn screening for adrenoleukodystrophy: implications for therapy. Mol Diagn Ther 2007; 11:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/46\">",
"      Hubbard WC, Moser AB, Liu AC, et al. Newborn screening for X-linked adrenoleukodystrophy (X-ALD): validation of a combined liquid chromatography-tandem mass spectrometric (LC-MS/MS) method. Mol Genet Metab 2009; 97:212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/47\">",
"      Schaller J, Moser H, Begleiter ML, Edwards J. Attitudes of families affected by adrenoleukodystrophy toward prenatal diagnosis, presymptomatic and carrier testing, and newborn screening. Genet Test 2007; 11:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/48\">",
"      Ebberink MS, Mooijer PA, Gootjes J, et al. Genetic classification and mutational spectrum of more than 600 patients with a Zellweger syndrome spectrum disorder. Hum Mutat 2011; 32:59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/49\">",
"      Geisbrecht BV, Collins CS, Reuber BE, Gould SJ. Disruption of a PEX1-PEX6 interaction is the most common cause of the neurologic disorders Zellweger syndrome, neonatal adrenoleukodystrophy, and infantile Refsum disease. Proc Natl Acad Sci U S A 1998; 95:8630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/50\">",
"      Turner CL, Bunyan DJ, Thomas NS, et al. Zellweger syndrome resulting from maternal isodisomy of chromosome 1. Am J Med Genet A 2007; 143A:2172.",
"     </a>",
"    </li>",
"    <li>",
"     Volpe JJ. Degenerative diseases of the newborn. In: Neurology of the Newborn, 4th ed, WB Saunders, Philadelphia 2001. p.599.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/52\">",
"      Barkovich AJ, Peck WW. MR of Zellweger syndrome. AJNR Am J Neuroradiol 1997; 18:1163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/53\">",
"      Martinez M. Restoring the DHA levels in the brains of Zellweger patients. J Mol Neurosci 2001; 16:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/54\">",
"      Paker AM, Sunness JS, Brereton NH, et al. Docosahexaenoic acid therapy in peroxisomal diseases: results of a double-blind, randomized trial. Neurology 2010; 75:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/55\">",
"      Wei H, Kemp S, McGuinness MC, et al. Pharmacological induction of peroxisomes in peroxisome biogenesis disorders. Ann Neurol 2000; 47:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/56\">",
"      Chang YC, Huang CC, Huang SC, Hung FC. Neonatal adrenoleukodystrophy presenting with seizure at birth: a case report and review of the literature. Pediatr Neurol 2008; 38:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/57\">",
"      Mandel H, Meiron D, Schutgens RB, et al. Infantile refsum disease: gastrointestinal presentation of a peroxisomal disorder. J Pediatr Gastroenterol Nutr 1992; 14:83.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/58\">",
"      Poll-The BT, Gootjes J, Duran M, et al. Peroxisome biogenesis disorders with prolonged survival: phenotypic expression in a cohort of 31 patients. Am J Med Genet A 2004; 126A:333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/59\">",
"      Motley AM, Hettema EH, Hogenhout EM, et al. Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor. Nat Genet 1997; 15:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/60\">",
"      Braverman N, Steel G, Obie C, et al. Human PEX7 encodes the peroxisomal PTS2 receptor and is responsible for rhizomelic chondrodysplasia punctata. Nat Genet 1997; 15:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/61\">",
"      Purdue PE, Zhang JW, Skoneczny M, Lazarow PB. Rhizomelic chondrodysplasia punctata is caused by deficiency of human PEX7, a homologue of the yeast PTS2 receptor. Nat Genet 1997; 15:381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/62\">",
"      Ofman R, Hettema EH, Hogenhout EM, et al. Acyl-CoA:dihydroxyacetonephosphate acyltransferase: cloning of the human cDNA and resolution of the molecular basis in rhizomelic chondrodysplasia punctata type 2. Hum Mol Genet 1998; 7:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/63\">",
"      Motley AM, Brites P, Gerez L, et al. Mutational spectrum in the PEX7 gene and functional analysis of mutant alleles in 78 patients with rhizomelic chondrodysplasia punctata type 1. Am J Hum Genet 2002; 70:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/64\">",
"      van den Brink DM, Brites P, Haasjes J, et al. Identification of PEX7 as the second gene involved in Refsum disease. Am J Hum Genet 2003; 72:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/65\">",
"      Viola A, Confort-Gouny S, Ranjeva JP, et al. MR imaging and MR spectroscopy in rhizomelic chondrodysplasia punctata. AJNR Am J Neuroradiol 2002; 23:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/66\">",
"      Goh S. Neuroimaging features in a neonate with rhizomelic chondrodysplasia punctata. Pediatr Neurol 2007; 37:382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/67\">",
"      Bams-Mengerink AM, Majoie CB, Duran M, et al. MRI of the brain and cervical spinal cord in rhizomelic chondrodysplasia punctata. Neurology 2006; 66:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/68\">",
"      Moser HW, Raymond GV, Dubey P. Adrenoleukodystrophy: new approaches to a neurodegenerative disease. JAMA 2005; 294:3131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/69\">",
"      Berger J, G&auml;rtner J. X-linked adrenoleukodystrophy: clinical, biochemical and pathogenetic aspects. Biochim Biophys Acta 2006; 1763:1721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/70\">",
"      Moser HW, Loes DJ, Melhem ER, et al. X-Linked adrenoleukodystrophy: overview and prognosis as a function of age and brain magnetic resonance imaging abnormality. A study involving 372 patients. Neuropediatrics 2000; 31:227.",
"     </a>",
"    </li>",
"    <li>",
"     Moser HW, Moser AB, Steinberg SJ. X-linked adrenoleukodystrophy. GeneReviews. Available at: genetests.org (Accessed on October 12, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/72\">",
"      Jansen GA, Ofman R, Ferdinandusse S, et al. Refsum disease is caused by mutations in the phytanoyl-CoA hydroxylase gene. Nat Genet 1997; 17:190.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/73\">",
"      Mihalik SJ, Morrell JC, Kim D, et al. Identification of PAHX, a Refsum disease gene. Nat Genet 1997; 17:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/74\">",
"      Jansen GA, Hogenhout EM, Ferdinandusse S, et al. Human phytanoyl-CoA hydroxylase: resolution of the gene structure and the molecular basis of Refsum's disease. Hum Mol Genet 2000; 9:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/75\">",
"      Wierzbicki AS, Lloyd MD, Schofield CJ, et al. Refsum's disease: a peroxisomal disorder affecting phytanic acid alpha-oxidation. J Neurochem 2002; 80:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/76\">",
"      Wierzbicki AS, Mitchell J, Lambert-Hammill M, et al. Identification of genetic heterogeneity in Refsum's disease. Eur J Hum Genet 2000; 8:649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/77\">",
"      CAMMERMEYER J. Neuropathological changes in hereditary neuropathies: manifestation of the syndrome heredopathia atactica polyneuritiformis in the presence of interstitial hypertrophic polyneuropathy. J Neuropathol Exp Neurol 1956; 15:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/78\">",
"      Jansen GA, Waterham HR, Wanders RJ. Molecular basis of Refsum disease: sequence variations in phytanoyl-CoA hydroxylase (PHYH) and the PTS2 receptor (PEX7). Hum Mutat 2004; 23:209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/79\">",
"      Verhoeven NM, Kulik W, van den Heuvel CM, Jakobs C. Pre- and postnatal diagnosis of peroxisomal disorders using stable-isotope dilution gas chromatography--mass spectrometry. J Inherit Metab Dis 1995; 18 Suppl 1:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/80\">",
"      Baldwin EJ, Gibberd FB, Harley C, et al. The effectiveness of long-term dietary therapy in the treatment of adult Refsum disease. J Neurol Neurosurg Psychiatry 2010; 81:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/81\">",
"      Brown PJ, Mei G, Gibberd FB. Diet and Refsum's disease: The determination of phytanic acid and phytol in certain foods and the application of this knowledge to the choice of suitable convenience foods for patients with Refsum's disease. J Hum Nutr Diet 1993; 6:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/82\">",
"      Hungerb&uuml;hler JP, Meier C, Rousselle L, et al. Refsum's disease: management by diet and plasmapheresis. Eur Neurol 1985; 24:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/83\">",
"      Harari D, Gibberd FB, Dick JP, Sidey MC. Plasma exchange in the treatment of Refsum's disease (heredopathia atactica polyneuritiformis). J Neurol Neurosurg Psychiatry 1991; 54:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/84\">",
"      Fournier B, Saudubray JM, Benichou B, et al. Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal adrenoleukodystrophy. J Clin Invest 1994; 94:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/85\">",
"      Ferdinandusse S, Denis S, Hogenhout EM, et al. Clinical, biochemical, and mutational spectrum of peroxisomal acyl-coenzyme A oxidase deficiency. Hum Mutat 2007; 28:904.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/86\">",
"      van Grunsven EG, van Berkel E, Mooijer PA, et al. Peroxisomal bifunctional protein deficiency revisited: resolution of its true enzymatic and molecular basis. Am J Hum Genet 1999; 64:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/87\">",
"      Ferdinandusse S, Denis S, Mooyer PA, et al. Clinical and biochemical spectrum of D-bifunctional protein deficiency. Ann Neurol 2006; 59:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/88\">",
"      Elias ER, Mobassaleh M, Hajra AK, Moser AB. Developmental delay and growth failure caused by a peroxisomal disorder, dihydroxyacetonephosphate acyltransferase (DHAP-AT) deficiency. Am J Med Genet 1998; 80:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/89\">",
"      Wanders RJ, Dekker C, Hovarth VA, et al. Human alkyldihydroxyacetonephosphate synthase deficiency: a new peroxisomal disorder. J Inherit Metab Dis 1994; 17:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/90\">",
"      de Vet EC, Ijlst L, Oostheim W, et al. Alkyl-dihydroxyacetonephosphate synthase. Fate in peroxisome biogenesis disorders and identification of the point mutation underlying a single enzyme deficiency. J Biol Chem 1998; 273:10296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/91\">",
"      Goldfischer S, Collins J, Rapin I, et al. Pseudo-Zellweger syndrome: deficiencies in several peroxisomal oxidative activities. J Pediatr 1986; 108:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/92\">",
"      Ferdinandusse S, van Grunsven EG, Oostheim W, et al. Reinvestigation of peroxisomal 3-ketoacyl-CoA thiolase deficiency: identification of the true defect at the level of d-bifunctional protein. Am J Hum Genet 2002; 70:1589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?8/23/8570/abstract/93\">",
"      Aubourg P, Kremser K, Roland MO, et al. Pseudo infantile Refsum's disease: catalase-deficient peroxisomal particles with partial deficiency of plasmalogen synthesis and oxidation of fatty acids. Pediatr Res 1993; 34:270.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6147 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-213.131.41.98-E13A3EE944-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8570=[""].join("\n");
var outline_f8_23_8570=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H53\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Disorders of peroxisome biogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Deficiency of a single peroxisomal enzyme",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      PATHOPHYSIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NEUROPATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Migration and differentiation defects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Myelination abnormalities",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Inflammatory demyelination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Non-inflammatory dysmyelination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other changes in myelin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      APPROACH TO DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H747827\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ZELLWEGER SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Epidemiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      NEONATAL ADRENOLEUKODYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Neuroimaging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      INFANTILE REFSUM DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      PEROXISOME BIOGENESIS DISORDERS WITH PROLONGED SURVIVAL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      RHIZOMELIC CHONDRODYSPLASIA PUNCTATA TYPE 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H37\">",
"      Radiographic studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H38\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H39\">",
"      ADRENOLEUKODYSTROPHY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      REFSUM DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Genetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      Pathophysiology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      Clinical features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Laboratory studies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      OTHER DISORDERS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Acyl-CoA oxidase deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      D-bifunctional protein deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      RCDP types 2 and 3",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Alpha-methylacyl-CoA racemase (AMACR) deficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Pseudo-ZWS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      Pseudo-IRD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6147\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6147|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/43/26288\" title=\"diagnostic image 1\">",
"      RCDP type 2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6147|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/62/20454\" title=\"picture 1\">",
"      Zellweger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6147|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/53/24413\" title=\"table 1A\">",
"      X-linked adrenoleukodystrophy A",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?42/40/43660\" title=\"table 1B\">",
"      X-linked adrenoleukodystrophy B",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?18/19/18748\" title=\"table 1C\">",
"      X-linked adrenoleukodystrophy C",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33673?source=related_link\">",
"      Adrenoleukodystrophy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/14/22761?source=related_link\">",
"      Cataract in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/52/23369?source=related_link\">",
"      Causes and clinical manifestations of primary adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/54/17255?source=related_link\">",
"      Diagnosis of adrenal insufficiency in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/37/602?source=related_link\">",
"      Hereditary neuropathies associated with generalized disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12154?source=related_link\">",
"      Primary hyperoxaluria",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f8_23_8571="Reflex exam score";
var content_f8_23_8571=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F82522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F82522&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Reflex examination score",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Score",
"       </td>",
"       <td class=\"subtitle1\">",
"        Description",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        Reflex absent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        Reflex slight, less than normal (includes a trace response or a response brought out only by reinforcement)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        Reflex in lower half of normal range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        Reflex in upper half of normal range",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        Reflex enhanced, more than normal (includes clonus if present)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Hallet M. NINDS myotatic reflex scale. Neurology 1993; 43:2723. Copyright &copy; 1993 Lippincott Williams &amp; Wilkins.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8571=[""].join("\n");
var outline_f8_23_8571=null;
var title_f8_23_8572="Disorders of carbohydrate metab";
var content_f8_23_8572=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56040&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Selected disorders of carbohydrate metabolism",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Carbohydrate intolerance disorders",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Galactosemia",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Galactokinase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        UPD galactose epimerase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary fructose intolerance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Disorders of carbohydrate production or utilization",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Disorders of glycogenolysis (glycogen storage diseases, GSD)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver glycogen synthase deficiency (GSD 0)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucose-6-phosphatase deficiency (GSD I; von Gierke disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Lysosomal acid maltase deficiency (GSD II; Pompe disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glycogen debrancher deficiency (GSD III; Cori/Forbes disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glycogen branching enzyme deficiency (GSD IV; Andersen disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle phosphorylase deficiency (GSD V; McArdle disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Liver phosphorylase deficiency (GSD VI; Hers disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Muscle phosphofructokinase deficiency (GSD VII; Tarui disease)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphoglycerate kinase and phosphoglycerate mutase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphorylase b kinase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_single\">",
"        Disorders of gluconeogenesis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Fructose 1,6-biphosphatase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyruvate carboxylase deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphoenolpyruvate carboxykinase (PEPCK) deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Pyruvate dehydrogenase deficiency",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8572=[""].join("\n");
var outline_f8_23_8572=null;
var title_f8_23_8573="Research criteria for minor depressive disorder";
var content_f8_23_8573=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PSYCH%2F87557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PSYCH%2F87557&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Research criteria for minor depressive disorder",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         A.",
"        </strong>",
"        A mood disturbance, defined as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2_start\">",
"        <strong>",
"         1.",
"        </strong>",
"        At least two (but less than five) of the following symptoms have been presenting during the same two-week period and represent a change from previous functioning; at least one of the symptoms is either (A) or (B):",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         A.",
"        </strong>",
"        Depressed mood most of the day, nearly every day, as indicated by either subjective report (eg, feels sad or empty) or observation made by others (eg, appears tearful).",
"        <strong>",
"         Note:",
"        </strong>",
"        In children and adolescents, can be irritable mood.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         B.",
"        </strong>",
"        Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation made by others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         C.",
"        </strong>",
"        Significant weight loss when not dieting or weight gain (eg, a change of more than 5 percent of body weight in a month), or decrease or increase in appetite nearly every day.",
"        <strong>",
"         Note:",
"        </strong>",
"        In children, consider failure to make expected weight gains.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         D.",
"        </strong>",
"        Insomnia or hypersomnia nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         E.",
"        </strong>",
"        Psychomotor agitation or retardation nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         F.",
"        </strong>",
"        Fatigue or loss of energy nearly every day",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         G.",
"        </strong>",
"        Feelings of worthlessness or excessive or inappropriate guilt (which may be delusional) nearly every day (not merely self-reproach or guilt about being sick)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         H.",
"        </strong>",
"        Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\">",
"        <strong>",
"         I.",
"        </strong>",
"        Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or a specific plan for committing suicide",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         2.",
"        </strong>",
"        The symptoms cause clinically significant distress or impairment in social, occupational, or other important areas of functioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         3.",
"        </strong>",
"        The symptoms are not due to the direct physiological effects of a substance (eg, a drug of abuse, a medication) or a general medical condition (eg, hypothyroidism)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <strong>",
"         4.",
"        </strong>",
"        The symptoms are not better accounted for by bereavement (ie, a normal reaction to the death of a loved one)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         B.",
"        </strong>",
"        There has never been a major depressive episode and criteria are not met for dysthymic disorder",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         C.",
"        </strong>",
"        There has never been a manic episode, a mixed episode, or a hypomanic episode, and criteria are not met for cyclothymic disorder.",
"        <strong>",
"         Note:",
"        </strong>",
"        This exclusion does not apply if all of the manic-, mixed-, or hypomanic-like episodes are substance or treatment induced.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D.",
"        </strong>",
"        The mood disturbance does not occur exclusively during schizophrenia, schizophreniform disorder, schizoaffective disorder, delusional disorder, or psychotic disorder not otherwise specified",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from: the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, (Copyright &copy; 2000). American Psychiatric Association.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8573=[""].join("\n");
var outline_f8_23_8573=null;
var title_f8_23_8574="Contents: Renal ureteral stones";
var content_f8_23_8574=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?0/41/670\">",
"       Nephrology and Hypertension",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Renal ureteral stones",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Renal ureteral stones",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Diagnosis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25577\">",
"           Cystine stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/50/20266\">",
"           Diagnosis and acute management of suspected nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/22/29033\">",
"           Evaluation of the adult patient with established nephrolithiasis and treatment if stone composition is unknown",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38340\">",
"           Nephrolithiasis during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/58/39847\">",
"           The first kidney stone and asymptomatic nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Etiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25577\">",
"           Cystine stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/45/38616\">",
"           Dent's disease (X-linked recessive nephrolithiasis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/21/37206\">",
"           Medullary sponge kidney",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40802\">",
"           Pathogenesis and clinical manifestations of struvite stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/53/33626\">",
"           Risk factors for calcium stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/18/39201\">",
"           Triamterene nephrotoxicity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/57/27541\">",
"           Uric acid renal diseases",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Prevention",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/2/38953\">",
"           Prevention of recurrent calcium stones in adults",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/2/30756\">",
"           Clinical significance of residual stone fragments following stone removal",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/62/25577\">",
"           Cystine stones",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/50/20266\">",
"           Diagnosis and acute management of suspected nephrolithiasis in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/18/40231\">",
"           Management of struvite or staghorn calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/28/27079\">",
"           Management of ureteral calculi",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/28/38340\">",
"           Nephrolithiasis during pregnancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/62/30695\">",
"           Options in the management of renal and ureteral stones in adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/10/27812\">",
"           Renal complications of extracorporeal shock wave lithotripsy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/62/3047\">",
"           Uric acid nephrolithiasis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-AE163B825E-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f8_23_8574=[""].join("\n");
var outline_f8_23_8574=null;
var title_f8_23_8575="Comminuted fracture of the great toe";
var content_f8_23_8575=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F50747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F50747&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Comminuted fracture of the distal phalanx of the great toe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 361px; height: 364px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Note the incidental finding of a benign exostosis at the medial base of the distal phalanx (black arrow). Such exostoses of the toes are relatively common. The halo-effect in the soft tissue is a common artifact that results from adjusting the brightness of radiographs when using certain digital radiographic systems.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Robert L Hatch, MD, MPH.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f8_23_8575=[""].join("\n");
var outline_f8_23_8575=null;
